2020 Q2 10-Q 19 taxonomy
FALSE --12-31 0000081362 3 2020 Q2 1 1 1 1 0000081362 2020-01-01 2020-06-30 0000081362 kwr:StockOptionsCompensationExpenseMember 2020-01-01 2020-06-30 0000081362 kwr:NonvestedStockAwardsCompensationExpenseMember 2020-01-01 2020-06-30 0000081362 kwr:EmployeeStockPurchasePlanCompensationExpenseMember 2020-01-01 2020-06-30 0000081362 kwr:MatchingStockContribution401KPlanCompensationExpenseMember 2020-01-01 2020-06-30 0000081362 kwr:DirectorsStockOwnershipPlanCompensationExpenseMember 2020-01-01 2020-06-30 0000081362 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-06-30 0000081362 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-06-30 0000081362 us-gaap:EMEAMember 2020-01-01 2020-06-30 0000081362 srt:AsiaPacificMember 2020-01-01 2020-06-30 0000081362 2020-06-30 0000081362 2020-04-01 2020-06-30 0000081362 2019-04-01 2019-06-30 0000081362 2019-01-01 2019-06-30 0000081362 2019-12-31 0000081362 2018-12-31 0000081362 2019-06-30 0000081362 kwr:EuroTermLoanMember 2020-06-30 0000081362 kwr:DebtinstrumentidrbMember 2020-06-30 0000081362 kwr:MulticurrencyRevolverMember 2019-12-31 0000081362 kwr:DebtinstrumentidrbMember 2019-12-31 0000081362 us-gaap:AssetsTotalMember 2020-01-01 2020-06-30 0000081362 us-gaap:SalesRevenueNetMember 2020-01-01 2020-06-30 0000081362 srt:AmericasMember 2020-01-01 2020-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 srt:AmericasMember 2019-01-01 2019-06-30 0000081362 us-gaap:EMEAMember 2019-01-01 2019-06-30 0000081362 srt:AsiaPacificMember 2019-01-01 2019-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 srt:AmericasMember 2020-04-01 2020-06-30 0000081362 us-gaap:EMEAMember 2020-04-01 2020-06-30 0000081362 srt:AsiaPacificMember 2020-04-01 2020-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 srt:AmericasMember 2019-04-01 2019-06-30 0000081362 us-gaap:EMEAMember 2019-04-01 2019-06-30 0000081362 srt:AsiaPacificMember 2019-04-01 2019-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 srt:AmericasMember us-gaap:IntersegmentEliminationMember 2020-04-01 2020-06-30 0000081362 us-gaap:EMEAMember us-gaap:IntersegmentEliminationMember 2020-04-01 2020-06-30 0000081362 srt:AsiaPacificMember us-gaap:IntersegmentEliminationMember 2020-04-01 2020-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember us-gaap:IntersegmentEliminationMember 2020-04-01 2020-06-30 0000081362 srt:AmericasMember us-gaap:IntersegmentEliminationMember 2019-04-01 2019-06-30 0000081362 us-gaap:EMEAMember us-gaap:IntersegmentEliminationMember 2019-04-01 2019-06-30 0000081362 srt:AsiaPacificMember us-gaap:IntersegmentEliminationMember 2019-04-01 2019-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember us-gaap:IntersegmentEliminationMember 2019-04-01 2019-06-30 0000081362 srt:AmericasMember us-gaap:IntersegmentEliminationMember 2020-01-01 2020-06-30 0000081362 us-gaap:EMEAMember us-gaap:IntersegmentEliminationMember 2020-01-01 2020-06-30 0000081362 srt:AsiaPacificMember us-gaap:IntersegmentEliminationMember 2020-01-01 2020-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember us-gaap:IntersegmentEliminationMember 2020-01-01 2020-06-30 0000081362 srt:AmericasMember us-gaap:IntersegmentEliminationMember 2019-01-01 2019-06-30 0000081362 us-gaap:EMEAMember us-gaap:IntersegmentEliminationMember 2019-01-01 2019-06-30 0000081362 srt:AsiaPacificMember us-gaap:IntersegmentEliminationMember 2019-01-01 2019-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember us-gaap:IntersegmentEliminationMember 2019-01-01 2019-06-30 0000081362 us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-06-30 0000081362 srt:AmericasMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-06-30 0000081362 us-gaap:EMEAMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-06-30 0000081362 srt:AsiaPacificMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-06-30 0000081362 us-gaap:TransferredOverTimeMember 2020-04-01 2020-06-30 0000081362 srt:AmericasMember us-gaap:TransferredOverTimeMember 2020-04-01 2020-06-30 0000081362 us-gaap:EMEAMember us-gaap:TransferredOverTimeMember 2020-04-01 2020-06-30 0000081362 srt:AsiaPacificMember us-gaap:TransferredOverTimeMember 2020-04-01 2020-06-30 0000081362 kwr:PrimarymetalsMember 2020-04-01 2020-06-30 0000081362 srt:AmericasMember kwr:PrimarymetalsMember 2020-04-01 2020-06-30 0000081362 us-gaap:EMEAMember kwr:PrimarymetalsMember 2020-04-01 2020-06-30 0000081362 srt:AsiaPacificMember kwr:PrimarymetalsMember 2020-04-01 2020-06-30 0000081362 kwr:MetalworkingandotherMember 2020-04-01 2020-06-30 0000081362 srt:AmericasMember kwr:MetalworkingandotherMember 2020-04-01 2020-06-30 0000081362 us-gaap:EMEAMember kwr:MetalworkingandotherMember 2020-04-01 2020-06-30 0000081362 srt:AsiaPacificMember kwr:MetalworkingandotherMember 2020-04-01 2020-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 srt:AmericasMember kwr:GlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 us-gaap:EMEAMember kwr:GlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 srt:AsiaPacificMember kwr:GlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 srt:AmericasMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 us-gaap:EMEAMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 srt:AsiaPacificMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 srt:AmericasMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 us-gaap:EMEAMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 srt:AsiaPacificMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2020-04-01 2020-06-30 0000081362 us-gaap:TransferredAtPointInTimeMember 2019-04-01 2019-06-30 0000081362 srt:AmericasMember us-gaap:TransferredAtPointInTimeMember 2019-04-01 2019-06-30 0000081362 us-gaap:EMEAMember us-gaap:TransferredAtPointInTimeMember 2019-04-01 2019-06-30 0000081362 srt:AsiaPacificMember us-gaap:TransferredAtPointInTimeMember 2019-04-01 2019-06-30 0000081362 us-gaap:TransferredOverTimeMember 2019-04-01 2019-06-30 0000081362 srt:AmericasMember us-gaap:TransferredOverTimeMember 2019-04-01 2019-06-30 0000081362 us-gaap:EMEAMember us-gaap:TransferredOverTimeMember 2019-04-01 2019-06-30 0000081362 srt:AsiaPacificMember us-gaap:TransferredOverTimeMember 2019-04-01 2019-06-30 0000081362 kwr:PrimarymetalsMember 2019-04-01 2019-06-30 0000081362 srt:AmericasMember kwr:PrimarymetalsMember 2019-04-01 2019-06-30 0000081362 us-gaap:EMEAMember kwr:PrimarymetalsMember 2019-04-01 2019-06-30 0000081362 srt:AsiaPacificMember kwr:PrimarymetalsMember 2019-04-01 2019-06-30 0000081362 kwr:MetalworkingandotherMember 2019-04-01 2019-06-30 0000081362 srt:AmericasMember kwr:MetalworkingandotherMember 2019-04-01 2019-06-30 0000081362 us-gaap:EMEAMember kwr:MetalworkingandotherMember 2019-04-01 2019-06-30 0000081362 srt:AsiaPacificMember kwr:MetalworkingandotherMember 2019-04-01 2019-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 srt:AmericasMember kwr:GlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 us-gaap:EMEAMember kwr:GlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 srt:AsiaPacificMember kwr:GlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 srt:AmericasMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 us-gaap:EMEAMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 srt:AsiaPacificMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 srt:AmericasMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 us-gaap:EMEAMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 srt:AsiaPacificMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2019-04-01 2019-06-30 0000081362 us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-06-30 0000081362 srt:AmericasMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-06-30 0000081362 us-gaap:EMEAMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-06-30 0000081362 srt:AsiaPacificMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-06-30 0000081362 us-gaap:TransferredOverTimeMember 2020-01-01 2020-06-30 0000081362 srt:AmericasMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-06-30 0000081362 us-gaap:EMEAMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-06-30 0000081362 srt:AsiaPacificMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-06-30 0000081362 kwr:PrimarymetalsMember 2020-01-01 2020-06-30 0000081362 srt:AmericasMember kwr:PrimarymetalsMember 2020-01-01 2020-06-30 0000081362 us-gaap:EMEAMember kwr:PrimarymetalsMember 2020-01-01 2020-06-30 0000081362 srt:AsiaPacificMember kwr:PrimarymetalsMember 2020-01-01 2020-06-30 0000081362 kwr:MetalworkingandotherMember 2020-01-01 2020-06-30 0000081362 srt:AmericasMember kwr:MetalworkingandotherMember 2020-01-01 2020-06-30 0000081362 us-gaap:EMEAMember kwr:MetalworkingandotherMember 2020-01-01 2020-06-30 0000081362 srt:AsiaPacificMember kwr:MetalworkingandotherMember 2020-01-01 2020-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 srt:AmericasMember kwr:GlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 us-gaap:EMEAMember kwr:GlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 srt:AsiaPacificMember kwr:GlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 srt:AmericasMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 us-gaap:EMEAMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 srt:AsiaPacificMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-06-30 0000081362 srt:AmericasMember us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-06-30 0000081362 us-gaap:EMEAMember us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-06-30 0000081362 srt:AsiaPacificMember us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-06-30 0000081362 us-gaap:TransferredOverTimeMember 2019-01-01 2019-06-30 0000081362 srt:AmericasMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-06-30 0000081362 us-gaap:EMEAMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-06-30 0000081362 srt:AsiaPacificMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-06-30 0000081362 kwr:PrimarymetalsMember 2019-01-01 2019-06-30 0000081362 srt:AmericasMember kwr:PrimarymetalsMember 2019-01-01 2019-06-30 0000081362 us-gaap:EMEAMember kwr:PrimarymetalsMember 2019-01-01 2019-06-30 0000081362 srt:AsiaPacificMember kwr:PrimarymetalsMember 2019-01-01 2019-06-30 0000081362 kwr:MetalworkingandotherMember 2019-01-01 2019-06-30 0000081362 srt:AmericasMember kwr:MetalworkingandotherMember 2019-01-01 2019-06-30 0000081362 us-gaap:EMEAMember kwr:MetalworkingandotherMember 2019-01-01 2019-06-30 0000081362 srt:AsiaPacificMember kwr:MetalworkingandotherMember 2019-01-01 2019-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 srt:AmericasMember kwr:GlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 us-gaap:EMEAMember kwr:GlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 srt:AsiaPacificMember kwr:GlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 srt:AmericasMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 us-gaap:EMEAMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 srt:AsiaPacificMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 srt:AmericasMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 us-gaap:EMEAMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 srt:AsiaPacificMember kwr:TotalSalesWithoutGlobalSpecialtyBusinessesMember 2019-01-01 2019-06-30 0000081362 us-gaap:LandMember 2020-06-30 0000081362 kwr:StockOptionsCompensationExpenseMember 2019-04-01 2019-06-30 0000081362 kwr:NonvestedStockAwardsCompensationExpenseMember 2019-04-01 2019-06-30 0000081362 kwr:EmployeeStockPurchasePlanCompensationExpenseMember 2019-04-01 2019-06-30 0000081362 kwr:DirectorsStockOwnershipPlanCompensationExpenseMember 2019-04-01 2019-06-30 0000081362 kwr:StockOptionsCompensationExpenseMember 2020-04-01 2020-06-30 0000081362 kwr:NonvestedStockAwardsCompensationExpenseMember 2020-04-01 2020-06-30 0000081362 kwr:EmployeeStockPurchasePlanCompensationExpenseMember 2020-04-01 2020-06-30 0000081362 kwr:DirectorsStockOwnershipPlanCompensationExpenseMember 2020-04-01 2020-06-30 0000081362 kwr:StockOptionsCompensationExpenseMember 2019-01-01 2019-06-30 0000081362 kwr:NonvestedStockAwardsCompensationExpenseMember 2019-01-01 2019-06-30 0000081362 kwr:EmployeeStockPurchasePlanCompensationExpenseMember 2019-01-01 2019-06-30 0000081362 kwr:DirectorsStockOwnershipPlanCompensationExpenseMember 2019-01-01 2019-06-30 0000081362 us-gaap:EmployeeStockOptionMember 2020-06-30 0000081362 us-gaap:RestrictedStockMember 2020-06-30 0000081362 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0000081362 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0000081362 us-gaap:RestrictedStockMember 2020-01-01 2020-06-30 0000081362 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000081362 us-gaap:PensionPlansDefinedBenefitMember 2019-04-01 2019-06-30 0000081362 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-04-01 2019-06-30 0000081362 us-gaap:PensionPlansDefinedBenefitMember 2020-04-01 2020-06-30 0000081362 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-04-01 2020-06-30 0000081362 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-06-30 0000081362 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-06-30 0000081362 srt:AmericasMember 2019-12-31 0000081362 us-gaap:EMEAMember 2019-12-31 0000081362 srt:AsiaPacificMember 2019-12-31 0000081362 kwr:GlobalSpecialtyBusinessesMember 2019-12-31 0000081362 srt:AmericasMember 2020-06-30 0000081362 us-gaap:EMEAMember 2020-06-30 0000081362 srt:AsiaPacificMember 2020-06-30 0000081362 kwr:GlobalSpecialtyBusinessesMember 2020-06-30 0000081362 us-gaap:CustomerListsMember 2019-12-31 0000081362 kwr:TrademarksFomrulationsAndProductTechnologyMember 2019-12-31 0000081362 us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000081362 us-gaap:CustomerListsMember 2020-06-30 0000081362 kwr:TrademarksFomrulationsAndProductTechnologyMember 2020-06-30 0000081362 us-gaap:OtherIntangibleAssetsMember 2020-06-30 0000081362 us-gaap:FairValueInputsLevel1Member 2020-06-30 0000081362 us-gaap:FairValueInputsLevel2Member 2020-06-30 0000081362 us-gaap:FairValueInputsLevel3Member 2020-06-30 0000081362 us-gaap:FairValueInputsLevel1Member 2019-12-31 0000081362 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000081362 us-gaap:FairValueInputsLevel3Member 2019-12-31 0000081362 srt:MinimumMember kwr:AcpMember 2020-06-30 0000081362 kwr:AcpMember srt:MaximumMember 2020-06-30 0000081362 kwr:SbDeckingMember 2020-06-30 0000081362 us-gaap:CommonStockMember 2019-12-31 0000081362 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000081362 us-gaap:RetainedEarningsMember 2019-12-31 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000081362 us-gaap:NoncontrollingInterestMember 2019-12-31 0000081362 2020-01-01 0000081362 us-gaap:CommonStockMember 2020-01-01 0000081362 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 0000081362 us-gaap:RetainedEarningsMember 2020-01-01 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 0000081362 us-gaap:NoncontrollingInterestMember 2020-01-01 0000081362 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0000081362 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0000081362 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-06-30 0000081362 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-06-30 0000081362 us-gaap:CommonStockMember 2020-06-30 0000081362 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000081362 us-gaap:RetainedEarningsMember 2020-06-30 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000081362 us-gaap:NoncontrollingInterestMember 2020-06-30 0000081362 us-gaap:CommonStockMember 2018-12-31 0000081362 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000081362 us-gaap:RetainedEarningsMember 2018-12-31 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000081362 us-gaap:NoncontrollingInterestMember 2018-12-31 0000081362 2019-01-01 0000081362 us-gaap:CommonStockMember 2019-01-01 0000081362 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 0000081362 us-gaap:RetainedEarningsMember 2019-01-01 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 0000081362 us-gaap:NoncontrollingInterestMember 2019-01-01 0000081362 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0000081362 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0000081362 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0000081362 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-06-30 0000081362 2019-03-31 0000081362 us-gaap:CommonStockMember 2019-03-31 0000081362 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000081362 us-gaap:RetainedEarningsMember 2019-03-31 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000081362 us-gaap:NoncontrollingInterestMember 2019-03-31 0000081362 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000081362 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000081362 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000081362 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0000081362 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000081362 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000081362 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000081362 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0000081362 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000081362 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-06-30 0000081362 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-06-30 0000081362 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000081362 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0000081362 us-gaap:AccumulatedTranslationAdjustmentMember 2019-04-01 2019-06-30 0000081362 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-04-01 2019-06-30 0000081362 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-04-01 2019-06-30 0000081362 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000081362 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000081362 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000081362 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000081362 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000081362 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000081362 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-06-30 0000081362 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-06-30 0000081362 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-06-30 0000081362 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-06-30 0000081362 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-06-30 0000081362 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-06-30 0000081362 us-gaap:AccumulatedTranslationAdjustmentMember 2020-04-01 2020-06-30 0000081362 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-04-01 2020-06-30 0000081362 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-04-01 2020-06-30 0000081362 kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 srt:AmericasMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 us-gaap:EMEAMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 srt:AsiaPacificMember kwr:TotalSalesWithGlobalSpecialtyBusinessesMember 2020-01-01 2020-06-30 0000081362 kwr:MulticurrencyRevolverMember 2020-06-30 0000081362 kwr:UsTermLoanMember 2020-06-30 0000081362 srt:MaximumMember kwr:HoughtonCombinationMember 2020-06-30 0000081362 srt:MinimumMember kwr:HoughtonCombinationMember 2020-06-30 0000081362 kwr:OtherLiabilitiesCurrentMember 2019-12-31 0000081362 kwr:OtherLiabilitiesCurrentMember 2020-06-30 0000081362 us-gaap:InterestExpenseMember 2019-04-01 2019-06-30 0000081362 us-gaap:InterestExpenseMember 2020-04-01 2020-06-30 0000081362 us-gaap:InterestExpenseMember 2019-01-01 2019-06-30 0000081362 us-gaap:InterestExpenseMember 2020-01-01 2020-06-30 0000081362 2019-01-01 2019-12-31 0000081362 kwr:HoughtonCombinationMember 2020-01-01 2020-06-30 0000081362 kwr:HoughtonCombinationMember 2019-08-01 0000081362 kwr:HoughtonCombinationMember 2019-08-01 0000081362 kwr:HoughtonCombinationMember 2020-05-31 0000081362 kwr:HoughtonCombinationMember 2020-06-30 0000081362 kwr:NormanhaymemberMember 2019-10-01 2019-12-31 0000081362 kwr:NormanhaymemberMember 2019-10-01 0000081362 kwr:NormanhaymemberMember 2020-05-31 0000081362 kwr:NormanhaymemberMember 2020-06-30 0000081362 kwr:NormanhaymemberMember 2020-01-01 2020-03-31 0000081362 kwr:TelnordicMember 2020-04-01 2020-06-30 0000081362 kwr:TelnordicMember 2020-06-30 0000081362 kwr:TelnordicMember 2020-01-01 2020-06-30 0000081362 country:ZA 2020-03-31 0000081362 country:ZA 2020-01-01 2020-03-31 0000081362 kwr:MiningNorthAmericaMember 2018-03-31 0000081362 kwr:MiningNorthAmericaMember 2018-01-01 2018-03-31 0000081362 kwr:MiningNorthAmericaMember 2019-01-01 2019-03-31 0000081362 us-gaap:AccountingStandardsUpdate201707Member 2020-06-30 0000081362 kwr:CustomerconcentrationrisktopfivemembermemberMember 2019-01-01 2019-12-31 0000081362 us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000081362 kwr:FacilitiesvehiclesandmachineryandequipmentMember 2020-06-30 0000081362 kwr:QhprogramMember 2019-12-31 0000081362 kwr:QhprogramMember 2020-06-30 0000081362 kwr:QhprogramMember 2020-01-01 2020-06-30 0000081362 us-gaap:SalesRevenueNetMember 2019-01-01 2019-06-30 0000081362 us-gaap:SalesRevenueNetMember 2020-04-01 2020-06-30 0000081362 us-gaap:SalesRevenueNetMember 2019-04-01 2019-06-30 0000081362 us-gaap:AssetsTotalMember 2020-04-01 2020-06-30 0000081362 2019-08-01 0000081362 kwr:MulticurrencyRevolverMember 2019-08-01 0000081362 kwr:UsTermLoanMember 2019-08-01 0000081362 kwr:EuroTermLoanMember 2019-08-01 0000081362 kwr:MatchingStockContribution401KPlanCompensationExpenseMember 2019-04-01 2019-06-30 0000081362 kwr:PerformanceincentivestockunitsMember 2019-04-01 2019-06-30 0000081362 kwr:RestrictedStockGaipPlanMember 2019-04-01 2019-06-30 0000081362 kwr:MatchingStockContribution401KPlanCompensationExpenseMember 2020-04-01 2020-06-30 0000081362 kwr:PerformanceincentivestockunitsMember 2020-04-01 2020-06-30 0000081362 kwr:RestrictedStockGaipPlanMember 2020-04-01 2020-06-30 0000081362 kwr:MatchingStockContribution401KPlanCompensationExpenseMember 2019-01-01 2019-06-30 0000081362 kwr:PerformanceincentivestockunitsMember 2019-01-01 2019-06-30 0000081362 kwr:RestrictedStockGaipPlanMember 2019-01-01 2019-06-30 0000081362 kwr:PerformanceincentivestockunitsMember 2020-01-01 2020-06-30 0000081362 kwr:RestrictedStockGaipPlanMember 2020-01-01 2020-06-30 0000081362 kwr:PerformanceincentivestockunitsMember 2020-06-30 0000081362 kwr:CombinationandotheracquisitionrelatedMember 2020-04-01 2020-06-30 0000081362 kwr:CombinationandotheracquisitionrelatedMember 2020-01-01 2020-06-30 0000081362 kwr:CombinationandotheracquisitionrelatedMember 2019-01-01 2019-06-30 0000081362 us-gaap:PensionPlansDefinedBenefitMember 2020-06-30 0000081362 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-06-30 0000081362 kwr:DefinedbenefitplansettlementMember 2020-01-01 2020-06-30 0000081362 kwr:HoughtonCombinationMember 2019-12-31 0000081362 kwr:HoughtonCombinationMember 2020-06-30 0000081362 kwr:HoughtonCombinationMember 2020-01-01 2020-06-30 0000081362 kwr:LegacyQuakerMember 2020-06-30 0000081362 kwr:LegacyQuakerMember 2019-12-31 0000081362 srt:MinimumMember kwr:HoughtonEnvironmentalMattersMember 2020-06-30 0000081362 srt:MaximumMember kwr:HoughtonEnvironmentalMattersMember 2020-06-30 0000081362 kwr:HoughtonCombinationMember 2020-06-30 0000081362 kwr:HoughtonCombinationMember 2019-12-31 0000081362 kwr:UsTermLoanMember 2019-12-31 0000081362 kwr:EuroTermLoanMember 2019-12-31 0000081362 us-gaap:CommonStockMember 2020-03-31 0000081362 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000081362 us-gaap:RetainedEarningsMember 2020-03-31 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000081362 us-gaap:NoncontrollingInterestMember 2020-03-31 0000081362 2020-03-31 0000081362 us-gaap:CommonStockMember 2019-06-30 0000081362 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000081362 us-gaap:RetainedEarningsMember 2019-06-30 0000081362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000081362 us-gaap:NoncontrollingInterestMember 2019-06-30 0000081362 us-gaap:ForeignCountryMember country:BR 2020-01-01 2020-06-30 0000081362 us-gaap:ForeignCountryMember country:IT 2020-01-01 2020-06-30 0000081362 us-gaap:ForeignCountryMember country:CN 2020-01-01 2020-06-30 0000081362 us-gaap:ForeignCountryMember country:CA 2020-01-01 2020-06-30 0000081362 us-gaap:ForeignCountryMember country:NL 2020-01-01 2020-06-30 0000081362 us-gaap:ForeignCountryMember country:GB 2020-01-01 2020-06-30 0000081362 us-gaap:ForeignCountryMember country:ES 2020-01-01 2020-06-30 0000081362 us-gaap:ForeignCountryMember country:MX 2020-01-01 2020-06-30 0000081362 us-gaap:ForeignCountryMember country:DE 2020-01-01 2020-06-30 0000081362 us-gaap:ForeignCountryMember country:IN 2020-01-01 2020-06-30 0000081362 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-06-30 0000081362 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-04-01 2020-06-30 0000081362 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000081362 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0000081362 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-03-31 0000081362 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-06-30 0000081362 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-04-01 2019-06-30 0000081362 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000081362 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-31 0000081362 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000081362 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-06-30 0000081362 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000081362 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-31 0000081362 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0000081362 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-12-31 0000081362 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-06-30 0000081362 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-06-30 0000081362 kwr:HoughtonCombinationMember 2019-07-01 2019-09-30 0000081362 2019-10-01 2019-12-31 0000081362 srt:MinimumMember 2020-01-01 2020-06-30 0000081362 srt:MaximumMember 2020-01-01 2020-06-30 0000081362 kwr:BankLinesOfCreditAndOtherDebtObligationsMember 2020-06-30 0000081362 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-31 0000081362 2019-07-01 2019-09-30 0000081362 us-gaap:InternalRevenueServiceIRSMember 2020-01-01 2020-06-30 0000081362 us-gaap:ForeignCountryMember 2019-12-31 0000081362 us-gaap:ForeignCountryMember 2020-06-30 0000081362 us-gaap:ForeignCountryMember 2019-01-01 2019-12-31 iso4217:DKK iso4217:GBP iso4217:USD iso4217:ZAR xbrli:pure xbrli:shares iso4217:USD xbrli:shares dummy:People
 
 
 
 
 
 
 
 
 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
 
 
 
 
 
 
FORM
10-Q
 
 
 
 
 
 
QUARTERLY
 
REPORT PURSUANT TO SECTION
 
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
 
OF 1934
For the quarterly period ended
June 30, 2020
 
OR
 
TRANSITION REPORT PURSUANT TO
 
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
 
ACT OF 1934
For the transition period from
 
to
 
 
Commission file number
001-12019
 
 
 
 
 
QUAKER CHEMICAL CORPORATION
(Exact name of Registrant as specified in its charter)
 
 
 
 
 
 
Pennsylvania
 
23-0993790
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
901 E. Hector Street
,
Conshohocken
,
Pennsylvania
 
19428 – 2380
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code:
610
-
832-4000
 
Not Applicable
Former name, former address and former fiscal year,
 
if changed since last report.
 
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $1 par value
KWR
New York Stock Exchange
 
Indicate by check mark whether the Registrant (1) has filed all reports
 
required to be filed by Section 13 or 15(d) of the Securities Exchange
 
Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
 
to file such reports), and (2) has been subject to such filing requirements
 
for the past 90
days.
 
Yes
 
 
No
 
 
 
Indicate by check mark whether the Registrant has submitted electronically, every Interactive Data File required
 
to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter
 
period that the registrant was required to submit such files) .
 
Yes
 
 
No
 
 
 
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company”
 
in Rule 12b-2 of
the Exchange Act.
 
Large accelerated filer
 
Accelerated filer
 
 
Non-accelerated filer
 
 
Smaller reporting
 
company
Emerging growth company
 
 
 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period
 
for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange
 
Act.
 
 
 
Indicate by check mark whether the Registrant is a shell company (as defined
 
in Rule 12b-2 of the Exchange Act).
 
Yes
 
 
No
 
 
Indicate the number of shares outstanding of each of the issuer’s classes of common
 
stock, as of the latest practicable date.
 
 
 
Number of Shares of Common Stock
Outstanding on June 30, 2020
 
17,799,606
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
PART
 
I
FINANCIAL INFORMATION
 
Item 1.
 
Financial Statements (Unaudited).
 
Quaker Chemical Corporation
Condensed Consolidated Statements of Operations
(Dollars in thousands, except per share data)
 
Unaudited
Three Months Ended
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
Net sales
$
286,040
$
205,869
$
664,601
$
417,079
Cost of goods sold (
excluding amortization expense - See note 14
)
 
188,654
 
130,708
 
433,364
 
266,151
Gross profit
 
97,386
 
75,161
 
231,237
 
150,928
Selling, general and administrative expenses
 
86,667
 
50,026
 
185,368
 
101,481
Indefinite-lived intangible asset impairment
38,000
Restructuring and related charges
486
2,202
Combination, integration and other acquisition-related
 
expenses
7,995
4,604
15,873
9,087
Operating income (loss)
 
2,238
20,531
 
(10,206)
 
40,360
Other (expense) income, net
 
(993)
 
43
 
(22,168)
 
(592)
Interest expense, net
(6,811)
(733)
(15,272)
(1,509)
(Loss) income before taxes and equity in net income of
associated companies
 
(5,566)
 
19,841
 
(47,646)
 
38,259
Taxes on (loss)
 
income before equity in net
 
income of associated
companies
 
3,222
 
4,800
 
(9,848)
 
9,729
(Loss) income before equity in net income of associated
companies
 
(8,788)
 
15,041
 
(37,798)
 
28,530
Equity in net income of associated companies
 
1,066
 
608
 
1,732
 
1,019
Net (loss) income
(7,722)
15,649
(36,066)
29,549
Less: Net income attributable to noncontrolling interest
13
58
50
114
Net (loss) income attributable to Quaker Chemical Corporation
$
(7,735)
$
15,591
$
(36,116)
$
29,435
Per share data:
 
 
 
 
Net (loss) income attributable to Quaker Chemical Corporation
common shareholders – basic
$
(0.43)
$
1.17
$
(2.03)
$
2.21
Net (loss) income attributable to Quaker Chemical Corporation
 
common shareholders – diluted
$
(0.43)
$
1.17
$
(2.03)
$
2.20
Dividends declared
$
0.385
$
0.385
$
0.770
$
0.755
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
Quaker Chemical Corporation
Condensed Consolidated Statements of Comprehensive (Loss) Income
(Dollars in thousands)
 
Unaudited
Three Months Ended
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
Net (loss) income
$
(7,722)
$
15,649
$
(36,066)
$
29,549
Other comprehensive income (loss), net of tax
Currency translation adjustments
10,551
(519)
(44,200)
(951)
Defined benefit retirement plans
213
522
17,170
1,228
Current period change in fair value of derivatives
(111)
(4,092)
Unrealized gain (loss) on available-for-sale securities
1,608
307
(103)
1,580
Other comprehensive income (loss)
12,261
310
(31,225)
1,857
Comprehensive income (loss)
4,539
15,959
(67,291)
31,406
Less: Comprehensive (income) loss attributable to
noncontrolling interest
(14)
(82)
81
(137)
Comprehensive income (loss) attributable to Quaker Chemical
Corporation
$
4,525
$
15,877
$
(67,210)
$
31,269
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4
Quaker Chemical Corporation
Condensed Consolidated Balance Sheets
(Dollars in thousands, except par value and share amounts)
 
Unaudited
June 30,
December 31,
2020
2019
ASSETS
 
 
 
 
Current assets
 
 
 
 
Cash and cash equivalents
$
322,497
$
123,524
Accounts receivable, net
 
300,027
 
375,982
Inventories
 
 
Raw materials and supplies
 
80,331
 
82,058
Work-in-process
 
and finished goods
 
93,536
 
92,892
Prepaid expenses and other current assets
 
52,847
 
41,516
Total current
 
assets
 
849,238
 
715,972
Property, plant and
 
equipment, at cost
 
384,960
 
398,834
Less accumulated depreciation
 
(196,547)
 
(185,365)
Property, plant and
 
equipment, net
 
188,413
 
213,469
Right of use lease assets
40,517
42,905
Goodwill
 
604,649
 
607,205
Other intangible assets, net
 
1,044,516
 
1,121,765
Investments in associated companies
 
87,865
 
93,822
Deferred tax assets
 
12,362
 
14,745
Other non-current assets
 
43,966
 
40,433
Total assets
$
2,871,526
$
2,850,316
LIABILITIES AND EQUITY
 
 
Current liabilities
 
 
Short-term borrowings and current portion of long-term debt
$
38,217
$
38,332
Accounts and other payables
 
130,334
 
170,929
Accrued compensation
 
22,689
 
45,620
Accrued restructuring
10,432
18,043
Other current liabilities
 
81,019
 
87,010
Total current
 
liabilities
 
282,691
 
359,934
Long-term debt
 
1,070,306
 
882,437
Long-term lease liabilities
28,908
31,273
Deferred tax liabilities
 
196,669
 
211,094
Other non-current liabilities
 
125,611
 
123,212
Total liabilities
 
1,704,185
 
1,607,950
Commitments and contingencies (Note 19)
Equity
 
 
Common stock $
1
 
par value; authorized
30,000,000
 
shares; issued and
 
 
outstanding 2020 –
17,799,606
 
shares; 2019 –
17,735,162
 
shares
17,800
17,735
Capital in excess of par value
 
896,108
 
888,218
Retained earnings
 
362,265
 
412,979
Accumulated other comprehensive loss
 
(109,264)
 
(78,170)
Total Quaker
 
shareholders’ equity
 
1,166,909
 
1,240,762
Noncontrolling interest
 
432
1,604
Total equity
1,167,341
1,242,366
Total liabilities and
 
equity
$
2,871,526
$
2,850,316
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5
Quaker Chemical Corporation
Condensed Consolidated Statements of Cash Flows
(Dollars in thousands)
 
Unaudited
Six Months Ended
June 30,
2020
2019
Cash flows from operating activities
 
 
 
 
 
Net (loss) income
 
$
(36,066)
$
29,549
Adjustments to reconcile net income to net cash provided
 
by operating activities:
 
 
Amortization of debt issuance costs
 
2,375
 
70
Depreciation and amortization
 
42,079
 
9,702
Equity in undistributed earnings of associated companies,
 
net of dividends
 
3,219
 
1,658
Acquisition-related fair value adjustments related to inventory
229
Deferred compensation, deferred taxes and other,
 
net
 
(22,033)
 
(7,141)
Share-based compensation
 
7,673
 
1,672
Loss (gain) on disposal of property,
 
plant, equipment and other assets
 
81
 
(39)
Insurance settlement realized
 
(542)
 
(306)
Indefinite-lived intangible asset impairment
38,000
Combination and other acquisition-related expenses, net of
 
payments
1,860
399
Restructuring and related charges
2,202
Pension and other postretirement benefits
 
18,784
 
(21)
Increase (decrease) in cash from changes in current assets and current
 
 
liabilities, net of acquisitions:
Accounts receivable
 
61,659
 
(7,893)
Inventories
 
(3,689)
 
(257)
Prepaid expenses and other current assets
 
(2,849)
 
(2,039)
Change in restructuring liabilities
(9,592)
Accounts payable and accrued liabilities
 
(58,728)
 
(2,945)
 
Net cash provided by operating activities
 
44,662
 
22,409
Cash flows from investing activities
 
 
Investments in property,
 
plant and equipment
 
(7,534)
 
(5,544)
Payments related to acquisitions, net of cash acquired
 
(3,132)
 
(500)
Proceeds from disposition of assets
11
70
Insurance settlement interest earned
 
37
 
131
 
Net cash used in investing activities
 
(10,618)
 
(5,843)
Cash flows from financing activities
 
 
Payments of long-term debt
(18,702)
Borrowings (repayments) on revolving credit facilities, net
 
205,500
 
(24,034)
Repayments on other debt, net
(684)
 
(6)
Dividends paid
 
(13,662)
 
(9,868)
Stock options exercised, other
 
(1,923)
 
(1,374)
Purchase of noncontrolling interest in affiliates
(1,047)
Distributions to noncontrolling affiliate shareholders
(751)
 
Net cash provided by (used in) financing activities
 
168,731
 
(35,282)
 
Effect of foreign exchange rate changes on
 
cash
 
(4,575)
 
749
Net increase (decrease) in cash, cash equivalents and restricted
 
cash
 
198,200
 
(17,967)
Cash, cash equivalents and restricted cash at the beginning
 
of the period
 
143,555
 
124,425
Cash, cash equivalents and restricted cash at the end of
 
the period
$
341,755
$
106,458
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
(Dollars in thousands, except per share amounts,
 
unless otherwise stated)
(Unaudited)
 
6
Note 1 – Condensed Financial Information
As used in these Notes to Condensed Consolidated
 
Financial Statements, the terms “Quaker”, “Quaker Houghton”,
 
the
“Company”, “we”, and “our” refer to Quaker Chemical
 
Corporation (doing business as Quaker Houghton), its subsidiaries, and
associated companies, unless the context otherwise requires.
 
As used in these Notes to Condensed Consolidated
 
Financial Statements,
the term Legacy Quaker refers to the Company prior
 
to the closing of its combination with Houghton International,
 
Inc. (“Houghton”)
(herein referred to as the “Combination”).
 
The condensed consolidated financial statements included herein
 
are unaudited and have
been prepared in accordance with generally accepted
 
accounting principles in the United States (“U.S. GAAP”) for
 
interim financial
reporting and the United States Securities and Exchange Commission
 
(“SEC”) regulations.
 
Certain information and footnote
disclosures normally included in financial statements prepared
 
in accordance with U.S. GAAP have been condensed or
 
omitted
pursuant to such rules and regulations.
 
In the opinion of management, the financial statements reflect all
 
adjustments which are
necessary for a fair statement of the financial position,
 
results of operations and cash flows for the interim periods.
 
The results for the
three and six months ended June 30, 2020 are not necessarily
 
indicative of the results to be expected for the full year.
 
These financial
statements should be read in conjunction with the Company’s
 
Annual Report filed on Form 10-K for the year
 
ended December 31,
2019 (the “2019 Form 10-K”).
 
Hyper-inflationary economies
Economies that have a cumulative three-year rate of inflation
 
exceeding
100
% are considered hyper-inflationary in accordance
with U.S. GAAP.
 
A legal entity that operates within an economy deemed
 
to be hyper-inflationary is required to remeasure its
monetary assets and liabilities to the applicable published
 
exchange rates and record the associated gains or losses resulting
 
from the
remeasurement directly to the Condensed Consolidated
 
Statements of Operations.
Based on various indices or index compilations currently
 
being used to monitor inflation in Argentina as well as
 
recent economic
instability, effective
 
July 1, 2018, Argentina’s
 
economy was considered hyper-inflationary under U.S. GAAP.
 
As a result, the
Company began applying hyper-inflationary accounting
 
with respect to the Company's wholly owned Argentine
 
subsidiary beginning
July 1, 2018.
 
In addition, Houghton has an Argentina subsidiary to
 
which hyper-inflationary accounting also is applied.
 
As of, and
for the three and six months ended June 30, 2020
 
and 2019, the Company's Argentine subsidiaries represented
 
less than
1
% of the
Company’s consolidated
 
total assets and net sales, respectively.
 
During the three and six months ended June 30, 2020, the Company
recorded less than $
0.1
 
million and $
0.1
 
million, respectively,
 
of remeasurement losses associated with the applicable
 
currency
conversions related to Argentina.
 
Comparatively, during
 
the three and six months ended June 30, 2019,
 
the Company recorded less
than $
0.1
 
million of remeasurement gains and $
0.2
 
million of remeasurement losses associated with the applicable
 
currency
conversion related to Argentina.
 
These losses were recorded within foreign exchange
 
(losses) gains, net, which is a component of
other (expense) income, net, in the Company’s
 
Condensed Consolidated Statements of Operations.
Note 2 – Business Combinations
 
Houghton
On
August 1, 2019
, the Company completed the Combination, whereby the Company
 
acquired all of the issued and outstanding
shares of
Houghton
 
from Gulf Houghton Lubricants, Ltd. and certain other selling
 
shareholders in exchange for a combination of cash
and shares of the Company’s
 
common stock in accordance with the Share Purchase Agreement,
 
dated April 4, 2017.
 
Houghton is a
leading global provider of specialty chemicals and technical
 
services for metalworking and other industrial applications.
 
The
Company believes that combining Quaker’s
 
and Houghton’s products
 
and service offerings will allow Quaker Houghton to
 
better
serve its customers in its various end markets.
 
The Combination was subject to certain regulatory
 
and shareholder approvals.
 
At a shareholder meeting held during 2017, the
Company’s shareholders
 
approved the issuance of new shares of the Company’s
 
common stock at closing of the Combination.
 
Also
in 2017, the Company received regulatory approvals for
 
the Combination from China and Australia.
 
The Company received
regulatory approvals from the European Commission
 
(“EC”) during the second quarter of 2019 and the U.S. Federal
 
Trade
Commission (“FTC”) in July 2019.
 
The approvals from the FTC and the EC required the concurrent
 
divestiture of certain steel and
aluminum related product lines of Houghton, which
 
were sold by Houghton on August 1, 2019 for approximately
 
$
37
 
million in cash.
 
The final remedy agreed with the EC and the FTC was consistent
 
with the Company’s
 
previous expectation that the total divested
product lines would be approximately
3
% of the combined company’s
 
net sales.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
7
The following table summarizes the fair value of consideration
 
transferred in the Combination:
Cash transferred to Houghton shareholders (a)
$
170,829
Cash paid to extinguish Houghton debt obligations
702,556
Fair value of common stock issued as consideration (b)
789,080
Total fair value
 
of consideration transferred
$
1,662,465
(
a)
 
A portion is held in escrow by a third party,
 
subject to indemnification rights that lapse upon the achievement
 
of certain
milestones.
(b)
 
Amount was determined based on approximately
4.3
 
million shares, comprising
24.5
% of the common stock of the Company
immediately after the closing, and the closing price per
 
share of Quaker Chemical Corporation common stock
 
of $
182.27
 
on
August 1, 2019.
The Company accounted for the Combination under the
 
acquisition method of accounting.
 
This method requires the recording of
acquired assets, including separately identifiable
 
intangible assets, at their fair value on the acquisition
 
date.
 
Any excess of the
purchase price over the estimated fair value of
 
the identifiable net assets acquired is recorded as goodwill.
 
The determination of the
estimated fair value of assets acquired,
 
including indefinite and definite-lived intangible assets,
 
requires management’s
 
judgment and
often involves the use of significant estimates and assumptions
 
,
 
including assumptions with respect to future cash inflows and
outflows, discount rates, customer attrition rates, royalty
 
rates, asset lives and market multiples, among other items.
 
Fair values were
determined by management using a variety of methodolog
 
ies and resources, including external independent valuation
 
experts.
 
The
valuation methods included physical appraisals, discounted
 
cash flow analyses, excess earnings, relief from
 
royalty, and other
appropriate valuation techniques to determine the fair value
 
of assets acquired and liabilities assumed.
The following table presents the current preliminary estimated
 
fair values of Houghton net assets acquired:
Measurement
August 1,
Period
August 1, 2019
2019 (1)
Adjustments
(as adjusted)
Cash and cash equivalents
$
75,821
$
$
75,821
Accounts receivable, net
178,922
178,922
Inventories, net
95,193
95,193
Prepaid expenses and other assets
10,652
314
10,966
Property, plant and
 
equipment
115,529
(66)
115,463
Right of use lease assets
10,673
10,673
Investments in associated companies
66,447
66,447
Other non-current assets
4,710
1,553
6,263
Intangible assets
1,028,400
1,028,400
Goodwill
494,915
7,737
502,652
Total assets purchased
2,081,262
9,538
2,090,800
Short-term borrowings, not refinanced at closing
9,297
9,297
Accounts payable, accrued expenses and other accrued
 
liabilities
150,078
853
150,931
Deferred tax liabilities
205,082
7,132
212,214
Long-term lease liabilities
6,607
6,607
Other non-current liabilities
47,733
1,553
49,286
Total liabilities assumed
418,797
9,538
428,335
Total consideration
 
paid for Houghton
1,662,465
1,662,465
Less: cash acquired
75,821
75,821
Less: fair value of common stock issued as consideration
789,080
789,080
Net cash paid for Houghton
$
797,564
$
-
$
797,564
(1) As
 
previously disclosed in the Company’s
 
2019 Form 10-K.
As of June 30, 2020, the allocation of the purchase price
 
for the Combination has not been finalized and the
one-year
measurement period has not ended.
 
While not currently expected, further adjustments may be necessary
 
as a result of the Company’s
on-going assessment of additional information related
 
to the fair value of assets acquired and liabilities assumed.
 
Houghton assets
acquired and liabilities assumed have been assigned
 
to each of the Company’s reportable
 
segments on a specific identification or
allocated basis, as applicable.
 
Measurement period adjustments recorded during the first
 
six months of 2020 related primarily to
increasing the valuation allowances against the deferred
 
tax assets associated with foreign tax credits acquired as part
 
of the
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
8
Combination as a result of additional information available
 
used to update the Company’s
 
initial estimates of expenses allocated to
foreign source income and expected creditable foreign
 
taxes.
 
In addition, measurement period adjustments include the recognition
 
of
additional other non-current assets and other non-current
 
liabilities based on additional information obtained regarding
 
certain tax
audits and associated rights to indemnification, and
 
certain non-income tax liabilities payable upon closing of
 
the Combination in
certain countries.
 
Combination, integration and other acquisition-related
 
expenses have been and are expected to continue to be significant.
 
The
Company incurred total costs of approximately $
8.3
 
million and $
16.5
 
million for the three and six months ended June 30, 2020,
respectively, primarily
 
for professional fees related to Houghton integration
 
activities.
 
Comparatively, the Company
 
incurred total
costs of $
5.5
 
million and $
10.8
 
million during the three and six months ended June 30,
 
2019, respectively, primarily
 
for various
professional fees and integration planning and regulatory
 
approval.
 
These costs also include $
0.3
 
million and $
0.8
 
million of
accelerated depreciation charges during the three
 
and six months ended June 30, 2020, respectively,
 
and $
0.9
 
million and $
1.7
 
million
of interest costs to maintain the bank commitment
 
(“ticking fees”) for the Combination during the three and six months
 
ended June 30,
2019,
 
respectively.
 
The Company had current liabilities related to the Combination,
 
integration and other acquisition-related activities
of $
8.6
 
million and $
6.6
 
million as of June 30, 2020, and December 31, 2019, respectively,
 
primarily recorded within other accrued
liabilities on its Condensed Consolidated Balance Sheets.
 
Norman Hay
On
October 1, 2019
, the Company completed its acquisition of the operating divisions
 
of
Norman Hay plc
 
(“Norman Hay”), a
private U.K. company that provides specialty chemicals, operating
 
equipment, and services to industrial end markets.
 
The acquisition
adds new technologies in automotive, original equipment
 
manufacturer (“OEM”), and aerospace, as well as engineering expertise
which is expected to strengthen the Company’s
 
existing equipment solutions platform.
 
The acquired Norman Hay assets and
liabilities were assigned to the Global Specialty Businesses reportable
 
segment.
 
The original purchase price was
80.0
 
million GBP,
 
on
a cash-free and debt-free basis, subject to routine and customary
 
post-closing adjustments related to working capital and net
indebtedness levels.
The following table presents the preliminary estimated fair
 
values of Norman Hay net assets acquired:
Measurement
October 1,
Period
October 1, 2019
2019 (1)
Adjustments
(as adjusted)
Cash and cash equivalents
$
18,981
$
$
18,981
Accounts receivable, net
15,471
15,471
Inventories, net
8,213
(49)
8,164
Prepaid expenses and other assets
4,203
4,203
Property, plant and
 
equipment
14,981
14,981
Right of use lease assets
10,608
10,608
Intangible assets
51,088
51,088
Goodwill
29,384
102
29,486
Total assets purchased
152,929
53
152,982
Long-term debt included current portions
485
485
Accounts payable, accrued expenses and other accrued liabilities
13,488
(708)
12,780
Deferred tax liabilities
12,746
927
13,673
Long-term lease liabilities
8,594
8,594
Total liabilities assumed
35,313
219
35,532
Total consideration
 
paid for Norman Hay
117,616
(166)
117,450
Less: estimated purchase price settlement (2)
3,287
(3,287)
Less: cash acquired
18,981
18,981
Net cash paid for Norman Hay
$
95,348
$
3,121
$
98,469
(1)
 
As previously disclosed in the Company’s
 
2019 Form 10-K.
(2)
 
The Company finalized its post-closing adjustments for the
 
Norman Hay acquisition and paid approximately
2.5
 
million GBP
during the first quarter of 2020 to settle such adjustments.
As of June 30, 2020, the allocation of the purchase price
 
for Norman Hay has not been finalized and the
one-year
 
measurement
period has not ended.
 
Further adjustments may be necessary as a result of the
 
Company’s on-going assessment of
 
additional
information related to the fair value of assets acquired
 
and liabilities assumed.
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
9
Other Acquisitions
In May 2020, the Company acquired Tel
 
Nordic ApS (“TEL”), a company that specializes in lubricants and engineering
 
primarily
in high pressure aluminum die casting for its Europe,
 
Middle East and Africa (“EMEA”) reportable segment.
 
Consideration paid was
in the form of a convertible promissory note in the amount
 
of
20.0
 
million DKK, or approximately $
2.9
 
million, which was
subsequently converted into shares of the Company’s
 
common stock.
 
An adjustment to the purchase price of approximately
0.4
million DKK, or less than $
0.1
 
million, was made as a result of finalizing a post-closing
 
settlement in the second quarter of 2020.
 
The
Company allocated approximately $
2.4
 
million of the purchase price to intangible assets to be amortized
 
over
17
 
years.
 
In addition,
the Company recorded approximately $
0.5
 
million of goodwill, related to expected value not allocated to
 
other acquired assets, none
of which will be tax deductible.
 
The allocation of the purchase price of TEL has not been
 
finalized and the
one-year
 
measurement
period has not ended.
 
Further adjustments may be necessary as a result of the
 
Company’s on-going assessment of
 
additional
information related to the fair value of assets acquired
 
and liabilities assumed.
In March 2020, the Company acquired the remaining
49
% ownership interest in one of its South African affiliates,
 
Quaker
Chemical South Africa Limited (“QSA”) for
16.7
 
million ZAR, or approximately $
1.0
 
million, from its joint venture partner PQ
Holdings South Africa.
 
QSA is a part of the Company’s
 
EMEA reportable segment.
 
As this acquisition was a change in an existing
controlling ownership, the Company recorded $
0.7
 
million of excess purchase price over the carrying value of
 
the non-controlling
interest in Capital in excess of par value.
 
In 2018 the Company purchased certain formulations and product
 
technology for the mining
industry for $
1.0
 
million, with $
0.5
 
million of the purchase price paid at signing and the remaining
 
$
0.5
 
million of the purchase price
paid during the first quarter of 2019.
Note 3 – Recently Issued Accounting Standards
Recently Issued Accounting Standards
 
Adopted
The Financial Accounting Standards Board (“FASB”)
 
issued Account Standards Update (“ASU”)
 
2020-04,
Reference Rate
Reform (Topic
 
848): Facilitation of the Effects of Reference
 
Rate Reform on Financial Reporting
 
in March 2020.
 
The amendments
provide temporary optional expedients and exceptions for
 
applying GAAP to contract modifications, hedging relationships
 
and other
transactions to ease the potential accounting and financial
 
reporting burden associated with transitioning away from
 
reference rates
that are expected to be discontinued, including the London
 
Interbank Offered Rate (“LIBOR”).
 
ASU 2020-04 is effective for the
Company as of March 12, 2020 and generally can be
 
applied through December 31, 2022.
 
As of June 30, 2020, the expedients
provided in ASU 2020-04 do not impact the Company;
 
however, the Company will continue to
 
monitor for potential impacts on its
consolidated financial statements.
The FASB issued
 
ASU 2018-15
, Customer’s
 
Accounting for Implementation Costs Incurred
 
in a Cloud Computing Arrangement
That
 
Is a Service Contract
 
in August 2018 that clarifies the accounting for implementation
 
costs incurred in a cloud computing
arrangement under a service contract.
 
This guidance generally aligns the requirements for capitalizing
 
implementation costs incurred
in a hosting arrangement under a service contract with the
 
requirements for capitalizing implementation costs related
 
to internal-use
software.
 
The guidance within this accounting standard update is effective
 
for annual periods beginning after December 15, 2019 and
should be applied either retrospectively or prospectively
 
to all implementation costs incurred after the date of
 
adoption.
 
Early
adoption was permitted.
 
The Company adopted this standard on a prospective basis, effective
 
January 1, 2020.
 
There was no
cumulative effect of adoption recorded within
 
retained earnings on January 1, 2020.
 
The FASB issued
 
ASU 2018-14,
Disclosure Framework — Changes to
 
the Disclosure Requirements
 
for Defined Benefit Plans
 
in
August 2018 that modifies certain disclosure requirements
 
for fair value measurements.
 
The guidance removes certain disclosure
requirements regarding transfers between levels of
 
the fair value hierarchy as well as certain disclosures related
 
to the valuation
processes for certain fair value measurements.
 
Further, the guidance added certain disclosure
 
requirements including unrealized gains
and losses and significant unobservable inputs used to
 
develop certain fair value measurements.
 
The guidance within this accounting
standard update is effective for annual and
 
interim periods beginning after December 15, 2019, and should
 
be applied prospectively in
the initial year of adoption or prospectively to all periods
 
presented, depending on the amended disclosure requirement.
 
Early
adoption was permitted.
 
The Company adopted this standard on a prospective basis, effective
 
January 1, 2020.
 
ASU 2018-14
addresses disclosures only and will not have an impact
 
on the Company’s consolidated
 
financial statements.
The FASB issued
 
ASU 2016-13,
Financial Instruments - Credit Losses (Topic
 
326): Measurement of Credit
 
Losses on Financial
Instruments
in June 2016 related to the accounting for and disclosure of
 
credit losses.
 
The FASB subsequently
 
issued several
additional accounting standard updates which amended
 
and clarified the guidance, but did not materially change
 
the guidance or its
applicability to the Company.
 
This accounting guidance introduces a new model for
 
recognizing credit losses on financial
instruments, including customer accounts receivable,
 
based on an estimate of current expected credit losses.
 
The guidance within this
accounting standard update is effective for annual
 
and interim periods beginning after December 15, 2019.
 
Early adoption was
permitted.
 
The Company did not early adopt, but did adopt the guidance in
 
this accounting standard update, including all applicable
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
10
subsequent updates to this accounting guidance, as required
 
,
 
on a modified retrospective basis, effective January
 
1, 2020.
 
Adoption
did not have a material impact to the Company’s
 
financial statements as expected.
 
However, as a result of this adoption, the Company
recorded a cumulative effect of accounting change
 
that resulted in an increase to its allowance for doubtful accounts
 
of approximately
$
1.1
 
million, a decrease to deferred tax liabilities of $
0.2
 
million and a decrease to retained earnings of $
0.9
 
million.
 
In accordance with this guidance, the Company recognizes
 
an allowance for credit losses reflecting the net amount expected to
 
be
collected from its financial assets, primarily trade accounts
 
receivable.
 
This allowance represents the portion of the receivable that the
Company does not expect to collect over its contractual
 
life, considering past events and reasonable and supportable forecasts of
 
future
economic conditions.
 
The Company’s allowance for
 
credit losses on its trade accounts receivable is based on
 
specific collectability
facts and circumstances for each outstanding receivable and
 
customer, the aging of outstanding
 
receivables and the associated
collection risk the Company estimates for certain past due
 
aging categories, and also, the general risk to all outstanding accounts
receivable based on historical amounts determined to
 
be uncollectible.
Recently Issued Accounting Standards
 
Not Yet Adopted
The FASB
 
issued ASU 2020-01,
 
Investments – Equity Securities (Topic
 
321), Investments – Equity Method and Joint Ventures
(Topic
 
323), and Derivatives and Hedging (Topic
 
815) –Clarifying the Interactions between Topic
 
321, Topic
 
323, and Topic
 
815
 
in
January 2020 clarifying the interaction among the
 
accounting standards related to equity securities, equity method investments,
 
and
certain derivatives.
 
The new guidance, among other things, states that a company
 
should consider observable transactions that require
a company to either apply or discontinue the equity method
 
of accounting, for the purposes of applying the fair value
 
measurement
alternative immediately before applying or upon discontinuing
 
the equity method.
 
The new guidance also addresses the measurement
of certain purchased options and forward contracts used
 
to acquire investments.
 
The guidance within this accounting standard update
is effective for annual and interim periods beginning
 
after December 15, 2020 and is to be applied prospectively.
 
Early adoption is
permitted.
 
The Company has not early adopted the guidance and is currently
 
evaluating its implementation.
The FASB issued
 
ASU 2019-12
, Income Taxes
 
(Topic
 
740): Simplifying the Accounting for Income Taxes
 
in December 2019 to
simplify the accounting for income taxes.
 
The guidance within this accounting standard update removes
 
certain exceptions, including
the exception to the incremental approach for certain
 
intra-period tax allocations, to the requirement to recognize or not
 
recognize
certain deferred tax liabilities for equity method investments
 
and foreign subsidiaries, and to the general methodology
 
for calculating
income taxes in an interim period when a year-to-date
 
loss exceeds the anticipated loss for the year.
 
Further, the guidance simplifies
the accounting related to franchise taxes, the step up in
 
tax basis for goodwill, current and deferred tax expense, and codification
improvements for income taxes related to employee
 
stock ownership plans.
 
The guidance is effective for annual and interim periods
beginning after December 15, 2020.
 
Early adoption is permitted.
 
The Company has not early adopted the guidance and
 
is currently
evaluating its implementation.
The FASB issued
 
ASU 2018-13
, Fair Value
 
Measurement (Topic
 
820):
 
Disclosure Framework – Changes to the
 
Disclosure
Requirements for Fair Value
 
Measurement
 
in August 2018 that modifies certain disclosure requirement
 
s
 
for employers that sponsor
defined benefit pension or other postretirement plans.
 
The amendments in this accounting standard update remove
 
disclosures that are
no longer considered cost beneficial, clarify the specific
 
requirements of certain disclosures, and add new disclosure requirements
 
as
relevant.
 
The guidance within this accounting standard update is effective
 
for annual periods beginning after December 15, 2020, and
should be applied retrospectively to all periods presented.
 
Early adoption is permitted.
 
The Company has not early adopted the
guidance and is currently evaluating its implementation.
Note 4 – Business Segments
The Company’s operating
 
segments, which are consistent with its reportable segments,
 
reflect the structure of the Company’s
internal organization, the method by which
 
the Company’s resources are allocated
 
and the manner by which the Company and the
chief operating decision maker assess its performance.
 
During the third quarter of 2019 and in connection with the Combination,
 
the
Company reorganized its executive management
 
team to align with its new business structure, which reflects the
 
method by which the
chief operating decision maker of the Company assesses its performance
 
and allocates its resources.
 
The Company’s current
reportable segment structure includes
four
 
segments: (i) Americas; (ii) EMEA; (iii) Asia/Pacific; and (iv)
 
Global Specialty Businesses.
 
The three geographic segments are composed of
 
the net sales and operations in each respective region, excluding
 
net sales and
operations managed globally by the Global Specialty
 
Businesses segment, which includes the Company’s
 
container, metal finishing,
mining, offshore, specialty coatings, specialty grease
 
and Norman Hay businesses.
 
All prior period information for Legacy Quaker
has been recast to reflect these four segments as the Company’s
 
new reportable segments.
 
Prior to the Company’s
 
re-segmentation
during the third quarter of 2019, the Company’s
 
historical reportable segments were four geographic regions: (i)
 
North America; (ii)
EMEA; (iii) Asia/Pacific; and (iv) South America.
Though the Company changed its reportable segments in
 
the third quarter of 2019, the calculation of the reportable segments’
measures of earnings remains otherwise generally
 
consistent with past practices.
 
Segment operating earnings for the Company’s
reportable segments are comprised of net sales less cost of goods
 
sold (“COGS”) and selling, general and administrative expenses
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
11
(“SG&A”) directly related to the respective segment’s
 
product sales.
 
Operating expenses not directly attributable to the
 
net sales of
each respective segment are not included in segment
 
operating earnings, such as certain corporate and administrative
 
costs,
Combination, integration and other acquisition-related
 
expenses, and restructuring and related charges.
 
Other items not specifically
identified with the Company’s
 
reportable segments include interest expense, net and
 
other (expense) income, net.
The following table presents information about the performance
 
of the Company’s reportable segments
 
for the three and six
months ended June 30, 2020 and 2019:
Three Months Ended
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
Net sales
 
 
 
 
 
 
 
 
 
 
Americas
$
80,576
$
71,747
$
210,472
$
143,972
EMEA
 
77,702
 
49,012
 
182,541
 
101,437
Asia/Pacific
 
68,421
 
44,801
 
141,973
 
90,968
Global Specialty Businesses
 
59,341
 
40,309
 
129,615
 
80,702
Total net sales
$
286,040
$
205,869
$
664,601
$
417,079
Segment operating earnings
Americas
$
10,303
$
13,965
$
39,491
$
28,304
EMEA
10,245
8,938
28,604
17,731
Asia/Pacific
19,261
12,159
38,802
24,971
Global Specialty Businesses
 
16,393
 
10,970
 
36,953
 
21,574
Total segment operating
 
earnings
 
56,202
 
46,032
 
143,850
 
92,580
Combination, integration and other acquisition-related
 
expenses
(7,995)
(4,604)
(15,873)
(9,087)
Restructuring and related charges
(486)
(2,202)
Indefinite-lived intangible asset impairment
(38,000)
Non-operating and administrative expenses
(32,045)
(19,070)
(70,496)
(39,418)
Depreciation of corporate assets and amortization
 
(13,438)
 
(1,827)
 
(27,485)
 
(3,715)
Operating income (loss)
 
2,238
20,531
(10,206)
40,360
Other (expense) income, net
(993)
43
(22,168)
(592)
Interest expense, net
 
(6,811)
 
(733)
 
(15,272)
 
(1,509)
(Loss) income before taxes and equity in net income of
associated companies
$
(5,566)
$
19,841
$
(47,646)
$
38,259
Inter-segment revenues for the three and six months
 
ended June 30, 2020 were $
2.4
 
million and $
5.3
 
million for Americas, $
5.3
million and $
10.8
 
million for EMEA, $
0.1
 
million and $
0.3
 
million for Asia/Pacific, and $
1.0
 
million and $
2.3
 
million for Global
Specialty Businesses, respectively.
 
Inter-segment revenues for the three and six months
 
ended June 30, 2019 were $
1.3
 
million and
$
2.7
 
million for Americas, $
4.8
 
million and $
10.1
 
million for EMEA, less than $
0.1
 
million and $
0.1
 
million for Asia/Pacific, and
$
1.3
 
million and $
2.8
 
million for Global Specialty Businesses, respectively.
 
However, all inter-segment
 
transactions have been
eliminated from each reportable segment’s
 
net sales and earnings for all periods presented in the above
 
tables.
Note 5 – Net Sales and Revenue Recognition
Business Description
The Company develops, produces, and markets a broad
 
range of formulated chemical specialty products and offers
 
chemical
management services (“Fluidcare”) for various heavy
 
industrial and manufacturing applications throughout its four
 
segments.
 
The
Combination increased the Company’s
 
addressable metalworking, metals and industrial end markets, including
 
steel, aluminum,
aerospace, defense, transportation-OEM, transportation
 
-components, offshore sub-sea energy,
 
architectural aluminum, construction,
tube and pipe, can and container,
 
mining, specialty coatings and specialty greases.
 
The Combination also strengthened the product
portfolio of the combined Company.
 
The major product lines of Quaker Houghton include metal remo
 
val fluids, cleaning fluids,
corrosion inhibitors, metal drawing and forming fluids, die
 
cast mold releases, heat treatment and quenchants, metal forging
 
fluids,
hydraulic fluids, specialty greases, offshore
 
sub-sea energy control fluids, rolling lubricants, rod
 
and wire drawing fluids and surface
treatment chemicals.
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
12
A substantial portion of the Company’s
 
sales worldwide are made directly through its own employees
 
and its Fluidcare programs,
with the balance being handled through distributors and
 
agents.
 
The Company’s employees typically
 
visit the plants of customers
regularly, work
 
on site, and, through training and experience, identify production
 
needs which can be resolved or otherwise addressed
either by adapting the Company’s
 
existing products or by applying new formulations developed
 
in its laboratories.
 
The specialty
chemical industry comprises many companies similar in
 
size to the Company,
 
as well as companies larger and smaller than Quaker
Houghton.
 
The offerings of many of the Company’s
 
competitors differ from those of Quaker Houghton;
 
some offer a broad portfolio
of fluids, including general lubricants, while others have
 
a more specialized product range.
 
All competitors provide different levels of
technical services to individual customers.
 
Competition in the industry is based primarily on the ability to
 
provide products that meet
the needs of the customer, render
 
technical services and laboratory assistance to the customer and,
 
to a lesser extent, on price.
 
As part of the Company’s
 
Fluidcare business, certain third-party product sales to customers are
 
managed by the Company.
 
Where
the Company acts as a principal, revenues are recognized
 
on a gross reporting basis at the selling price negotiated with
 
its customers.
 
Where the Company acts as an agent, revenue is recognized on
 
a net reporting basis at the amount of the administrative fee earned
 
by
the Company for ordering the goods.
 
In determining whether the Company is acting as a principal
 
or an agent in each arrangement,
the Company considers whether it is primarily responsible
 
for the obligation to provide the specified good, has inventory
 
risk before
the specified good has been transferred to the customer
 
and has discretion in establishing the prices for the specified
 
goods.
 
The
Company transferred third-party products under arrangements
 
recognized on a net reporting basis of $
6.2
 
million and $
18.7
 
million
for the three and six months ended June 30, 2020,
 
respectively, and $
10.4
 
million and $
20.8
 
million for the three and six months ended
June 30, 2019,
 
respectively.
A significant portion of the Company’s
 
revenues are realized from the sale of process fluids and services
 
to manufacturers of
steel, aluminum, automobiles, aircraft, industrial equipment,
 
and durable goods, and, therefore, the Company is subject
 
to the same
business cycles as those experienced by these manufacturers and
 
their customers.
 
The Company’s financial performance
 
is generally
correlated to the volume of global production within the
 
industries it serves, rather than discretely related to the financial performance
of such industries.
 
Furthermore, steel and aluminum customers typically have
 
limited manufacturing locations compared to
metalworking customers and generally use higher
 
volumes of products at a single location.
 
As previously disclosed in its 2019 Form
10-K, during
 
2019, the Company’s five
 
largest customers (each composed of multiple subsidiaries or
 
divisions with semiautonomous
purchasing authority) accounted for approximately
12
% of consolidated net sales, with its largest customer
 
accounting for
approximately
6
% of consolidated net sales.
Revenue Recognition Model
The Company applies the FASB’s
 
guidance on revenue recognition which requires the
 
Company to recognize revenue in an
amount that reflects the consideration to which the Company
 
expects to be entitled in exchange for goods or services transferred
 
to its
customers.
 
To do this, the Company
 
applies the five-step model in the FASB’s
 
guidance, which requires the Company to: (i) identify
the contract with a customer; (ii) identify the performance
 
obligations in the contract; (iii) determine the transaction price;
 
(iv) allocate
the transaction price to the performance obligations in the
 
contract; and (v) recognize revenue when, or as, the Company
 
satisfies a
performance obligation.
The Company identifies a contract with a customer when a
 
sales agreement indicates approval and commitment of the parties;
identifies the rights of the parties; identifies the payment
 
terms; has commercial substance; and it is probable
 
that the Company will
collect the consideration to which it will be entitled in
 
exchange for the goods or services that will be transferred to
 
the customer.
 
In
most instances, the Company’s
 
contract with a customer is the customer’s
 
purchase order.
 
For certain customers, the Company may
also enter into a sales agreement which outlines a
 
framework of terms and conditions which apply to all future
 
and subsequent
purchase orders for that customer.
 
In these situations, the Company’s
 
contract with the customer is both the sales agreement as well as
the specific customer purchase order.
 
Because the Company’s contract
 
with a customer is typically for a single transaction or
customer purchase order, the duration
 
of the contract is almost always one year or less.
 
As a result, the Company has elected to apply
certain practical expedients and omit certain disclosures of
 
remaining performance obligations for contracts that have an
 
initial term of
one year or less as permitted by the FASB.
The Company identifies a performance obligation in a
 
contract for each promised good or service that is separately identifiable
from other obligations in the contract and for which the
 
customer can benefit from the good or service either on its own or together
with other resources that are readily available to
 
the customer.
 
The Company determines the transaction price as the amount
 
of
consideration it expects to be entitled to in exchange
 
for fulfilling the performance obligations, including the
 
effects of any variable
consideration, significant financing elements, amounts
 
payable to the customer or noncash consideration.
 
For any contracts that have
more than one performance obligation, the Company
 
allocates the transaction price to each performance obligation
 
in an amount that
depicts the amount of consideration to which the Company
 
expects to be entitled in exchange for satisfying each performance
obligation.
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
13
In accordance with the last step of the FASB’s
 
guidance, the Company recognizes revenue when,
 
or as, it satisfies the
performance obligation in a contract by transferring control
 
of a promised good or providing the service to the customer.
 
The
Company recognizes revenue over time as the customer
 
receives and consumes the benefits provided by the Company’s
 
performance;
the Company’s performance
 
creates or enhances an asset that the customer controls as the
 
asset is created or enhanced; or the
Company’s performance
 
does not create an asset with an alternative use to the entity,
 
and the entity has an enforceable right to
payment, including a profit margin, for performance
 
completed to date.
 
For performance obligations not satisfied over time, the
Company determines the point in time at which a customer
 
obtains control of an asset and the Company satisfies a perf
 
ormance
obligation by considering when the Company has a right
 
to payment for the asset; the customer has legal title to the
 
asset; the
Company has transferred physical possession of the asset; the
 
customer has the significant risks and rewards of ownership
 
of the asset;
or the customer has accepted the asset.
The Company typically satisfies its performance obligations
 
and recognizes revenue at a point in time for product
 
sales, generally
when products are shipped or delivered to the customer,
 
depending on the terms underlying each arrangement.
 
In circumstances
where the Company’s
 
products are on consignment, revenue is generally recognized
 
upon usage or consumption by the customer.
 
For
any Fluidcare or other services provided by the Company
 
to the customer, the Company typically satisfies its
 
performance obligations
and recognizes revenue over time, as the promised services
 
are performed.
 
The Company uses input methods to recognize revenue
over time related to these services, including labor costs
 
and time incurred.
 
The Company believes that these input methods represent
the most indicative measure of the Fluidcare or other service
 
work performed by the Company.
Other Considerations
The Company does not have standard payment terms for
 
all customers;
 
however the Company’s general
 
payment terms require
customers to pay for products or services provided after
 
the performance obligation is satisfied.
 
The Company does not have
significant financing arrangements with its customers.
 
The Company does not have significant amounts of variable
 
consideration in
its contracts with customers and where applicable,
 
the Company’s estimates of variable
 
consideration are not constrained.
 
The
Company records certain third-party license fees in
 
other (expense) income, net, in its Condensed Consolidated
 
Statements of
Operations,
 
which generally include sales-based royalties in exchange for
 
the license of intellectual property.
 
These license fees are
recognized in accordance with their agreed-upon
 
terms and when performance obligations are satisfied, which
 
is generally when the
third party has a subsequent sale.
Practical Expedients and Accounting Policy Elections
The Company has made certain accounting policy
 
elections and elected to use certain practical expedients as permitted
 
by the
FASB in applying
 
the guidance on revenue recognition.
 
It is the Company’s policy
 
to not adjust the promised amount of
consideration for the effects of a significant
 
financing component as the Company expects, at contract
 
inception, that the period
between when the Company transfers a promised good or service
 
to the customer and when the customer pays for that good
 
or service
will be one year or less.
 
In addition, it is the Company’s
 
policy to expense costs to obtain a contract as incurred
 
when the expected
period of benefit, and therefore the amortization period,
 
is one year or less.
 
It is also the Company’s accounting
 
policy to exclude
from the measurement of the transaction price all
 
taxes assessed by a governmental authority that are both imposed
 
on and concurrent
with a specific revenue-producing transaction and
 
collected by the entity from a customer, including
 
sales, use, value added, excise
and various other taxes.
 
Lastly, the Company
 
has elected to account for shipping and handling activities that occur
 
after the customer
has obtained control of a good as a fulfilment cost rather than
 
an additional promised service.
Contract Assets and Liabilities
The Company recognizes a contract asset or receivable
 
on its Condensed Consolidated Balance Sheet when the Company
provides a good or service in advance of receiving consideration.
 
A receivable is the Company’s
 
right to consideration that is
unconditional and only the passage of time is required
 
before payment of that consideration is due.
 
A contract asset is the Company’s
right to consideration in exchange for goods or services
 
that the Company has transferred to a customer.
 
The Company had
no
material contract assets recorded on its Condensed Consolidated
 
Balance Sheets as of June 30, 2020 or December 31,
 
2019.
 
A contract liability is recognized when the Company
 
receives consideration, or if it has the unconditional right
 
to receive
consideration, in advance of performance.
 
A contract liability is the Company’s
 
obligation to transfer goods or services to a customer
for which the Company has received consideration,
 
or a specified amount of consideration is due, from the customer.
 
The Company’s
contract liabilities primarily represent deferred revenue
 
recorded for customer payments received by the Company
 
prior to the
Company satisfying the associated performance obligation.
 
Deferred revenues are presented within other current liabilities
 
in the
Company’s Condensed
 
Consolidated Balance Sheets.
 
The Company had approximately $
3.2
 
million and $
2.2
 
million of deferred
revenue as of June 30, 2020 and December 31, 2019,
 
respectively.
 
During the six months ended June 30, 2020,
 
the Company satisfied
all of the associated performance obligations and recognized
 
into revenue the advanced payments received and recorded
 
as of
December 31, 2019.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
14
Disaggregated Revenue
The Company sells its various industrial process fluids,
 
its specialty chemicals and its technical expertise as a global
 
product
portfolio.
 
The Company generally manages and evaluates its performance
 
by segment first, and then by customer industry,
 
rather than
by individual product lines.
 
The Company has provided annual net sales information by
 
major product lines that represent
approximately 10% or more of consolidated net sales in its 2019
 
Form 10-K, and those annual percentages are generally consistent
with the current quarter’s net sales by product
 
line.
 
Also, net sales of each of the Company’s
 
major product lines are generally spread
throughout all three of the Company’s
 
geographic regions, and in most cases, approximately proportionate
 
to the level of total sales in
each region.
 
The following tables disaggregate the Company’s
 
net sales by segment, geographic region, customer industry,
 
and timing of
revenue recognized for the three and six months ended
 
June 30, 2020 and 2019.
 
The Company has made certain reclassifications of
disaggregated customer industry disclosures for the
 
three and six months ended June 30, 2020 to conform with
 
the Company’s current
period customer industry segmentation.
Three Months Ended June 30, 2020
Consolidated
Americas
EMEA
Asia/Pacific
Total
Customer Industries
Metals
$
32,687
$
24,924
$
35,416
$
93,027
Metalworking and other
47,889
52,778
33,005
133,672
80,576
77,702
68,421
226,699
Global Specialty Businesses
32,294
15,569
11,478
59,341
$
112,870
$
93,271
$
79,899
$
286,040
Timing of Revenue Recognized
Product sales at a point in time
$
108,644
$
87,995
$
78,195
$
274,834
Services transferred over time
4,226
5,276
1,704
11,206
$
112,870
$
93,271
$
79,899
$
286,040
 
Three Months Ended June 30, 2019
Consolidated
Americas
EMEA
Asia/Pacific
Total
Customer Industries
Metals
$
39,506
$
24,485
$
28,391
$
92,382
Metalworking and other
32,241
24,527
16,410
73,178
71,747
49,012
44,801
165,560
Global Specialty Businesses
31,145
4,138
5,026
40,309
$
102,892
$
53,150
$
49,827
$
205,869
Timing of Revenue Recognized
Product sales at a point in time
$
100,053
$
53,098
$
48,406
$
201,557
Services transferred over time
2,839
52
1,421
4,312
$
102,892
$
53,150
$
49,827
$
205,869
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
15
Six Months Ended June 30, 2020
Consolidated
Americas
EMEA
Asia/Pacific
Total
Customer Industries
Metals
$
79,360
$
54,812
$
77,005
$
211,177
Metalworking and other
131,112
127,729
64,968
323,809
210,472
182,541
141,973
534,986
Global Specialty Businesses
76,525
32,174
20,916
129,615
$
286,997
$
214,715
$
162,889
$
664,601
Timing of Revenue Recognized
Product sales at a point in time
$
277,446
$
206,418
$
159,351
$
643,215
Services transferred over time
9,551
8,297
3,538
21,386
$
286,997
$
214,715
$
162,889
$
664,601
 
Six Months Ended June 30, 2019
Consolidated
Americas
EMEA
Asia/Pacific
Total
Customer Industries
Metals
$
80,431
$
49,201
$
57,604
$
187,236
Metalworking and other
63,541
52,236
33,364
149,141
143,972
101,437
90,968
336,377
Global Specialty Businesses
63,315
8,001
9,386
80,702
$
207,287
$
109,438
$
100,354
$
417,079
Timing of Revenue Recognized
Product sales at a point in time
$
201,600
$
109,332
$
97,057
$
407,989
Services transferred over time
5,687
106
3,297
9,090
$
207,287
$
109,438
$
100,354
$
417,079
Note 6 – Leases
The Company determines if an arrangement is a lease
 
at its inception.
 
This determination generally depends on whether the
arrangement conveys the right to control the use of an
 
identified fixed asset explicitly or implicitly for a period of
 
time in exchange for
consideration.
 
Control of an underlying asset is conveyed if the Company
 
obtains the rights to direct the use of, and obtains
substantially all of the economic benefits from the use
 
of, the underlying asset.
 
Lease expense for variable leases and short-term
leases is recognized when the obligation is incurred.
 
The Company has operating leases for certain facilities, vehicles
 
and machinery and equipment with remaining lease terms up
 
to
11
 
years.
 
In addition, the Company has certain land use leases with remaining
 
lease terms up to
95
 
years.
 
The lease term for all of the
Company’s leases includes
 
the non-cancellable period of the lease plus any additional periods
 
covered by an option to extend the lease
that the Company is reasonably
 
certain it will exercise.
 
Operating leases are included in right of use lease assets, other current
liabilities and long-term lease liabilities on the Condensed
 
Consolidated Balance Sheet.
 
Right of use lease assets and liabilities are
recognized at each lease’s
 
commencement date based on the present value of its lease payments
 
over its respective lease term.
 
The
Company uses the stated borrowing rate for a lease when
 
readily determinable.
 
When a stated borrowing rate is not available in a
lease agreement, the Company uses its incremental borrowing
 
rate based on information available at the lease’s
 
commencement date
to determine the present value of its lease payments.
 
In determining the incremental borrowing rate used to present
 
value each of its
leases, the Company considers certain information
 
including fully secured borrowing rates readily available to the Company
 
and its
subsidiaries.
 
The Company has immaterial finance leases, which are
 
included in property, plant
 
and equipment, current portion of
long-term debt and long-term debt on the Condensed Consolidated
 
Balance Sheet.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
16
Operating lease expense is recognized on a straight-line
 
basis over the lease term.
 
Operating lease expense for the three and six
months ended June 30, 2020 was $
3.5
 
million and $
6.9
 
million, respectively.
 
Comparatively, operating
 
lease expense for the three
and six months ended June 30, 2019 was $
1.7
 
million and $
3.5
 
million, respectively.
 
Short-term lease expense for the three and six
months ended June 30, 2020 was $
0.4
 
million and $
0.9
 
million, respectively.
 
Comparatively, short-term
 
lease expense for the three
and six months ended June 30, 2019 was $
0.2
 
million and $
0.3
 
million, respectively.
 
The Company has
no
 
material variable lease
costs or sublease income for the three or six months ended
 
June 30, 2020 and 2019.
 
Cash paid for operating leases during the six months ended
 
June 30, 2020 and 2019 was $
6.8
 
million and $
3.4
 
million,
respectively.
 
The Company recorded new right of use lease assets and associated lease liabilities
 
of $
4.1
 
million during the six
months ended June 30, 2020.
 
Supplemental balance sheet information related to the Company’s
 
leases is as follows:
June 30,
December 31,
2020
2019
Right of use lease assets
$
40,517
$
42,905
Other current liabilities
11,085
11,177
Long-term lease liabilities
28,908
31,273
Total operating
 
lease liabilities
$
39,993
$
42,450
Weighted average
 
remaining lease term (years)
6.0
6.2
Weighted average
 
discount rate
4.21%
4.21%
Maturities of operating lease liabilities as of June 30,
 
2020 were as follows:
June 30,
2020
For the remainder of 2020
$
6,598
For the year ended December 31, 2021
10,978
For the year ended December 31, 2022
7,435
For the year ended December 31, 2023
5,434
For the year ended December 31, 2024
4,232
For the year ended December 31, 2025 and beyond
11,356
Total lease payments
46,033
Less: imputed interest
(6,040)
Present value of lease liabilities
$
39,993
Note 7 – Restructuring and Related Activities
As previously disclosed in its 2019 Form 10-K, in the third quarter of 2019, the Company’s management approved a global
restructuring plan (the “QH Program”) as part of its plan to realize certain cost synergies associated with the Combination. The QH
Program includes restructuring and associated severance costs to reduce total headcount by approximately 325 people globally and
plans for the closure of certain manufacturing and non-manufacturing facilities. The exact timing and total costs associated with the
QH Program will depend on a number of factors and is subject to change; however, the Company currently expects reduction in
headcount and site closures to continue to occur during 2020 and 2021 under the QH Program and estimates that total costs related to
the QH Program will approximate one-times the anticipated cost synergies realized from the QH Program. Employee separation
benefits will vary depending on local regulations within certain foreign countries and will include severance and other benefits.
 
All costs incurred to date relate to severance costs to reduce
 
headcount as well as costs to close certain facilities and are
 
recorded
in restructuring and related charges in the
 
Company’s Condensed Statements
 
of Operations.
 
As described in Note 4 of Notes to
Condensed Consolidated Financial Statements, restructuring
 
and related charges are not included in
 
the Company’s calculation of
reportable segments’ measure of operating earnings
 
and therefore these costs are not reviewed by or recorded to
 
reportable segments.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
17
Activity in the Company’s
 
accrual for restructuring under the QH Program for the six months ended
 
June 30, 2020 is as follows:
QH Program
Accrued restructuring as of December 31, 2019
$
18,043
Restructuring and related charges
2,202
Cash payments
(9,592)
Currency translation adjustments
 
(221)
Accrued restructuring as of June 30, 2020
$
10,432
In connection with the plans for closure of certain
 
manufacturing and non-manufacturing facilities, the Company
 
made a decision
to make available for sale certain facilities during the second
 
quarter of 2020 resulting in the reclassification of approximately
 
$
11.7
million of buildings and land to other current assets as of June
 
30, 2020.
 
Note 8 – Share-Based Compensation
The Company recognized the following share-based compensation
 
expense in its Condensed Consolidated Statements of
Operations for the three and six months ended June 30, 2020
 
and 2019:
 
Three Months Ended
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
Stock options
$
353
$
173
$
785
$
433
Non-vested restricted stock awards and restricted stock
 
units
1,259
440
2,523
1,138
Non-elective and elective 401(k) matching contribution in
 
stock
1,162
1,162
Employee stock purchase plan
24
47
Director stock ownership plan
54
23
94
54
Performance stock units
280
280
Annual incentive plan
(117)
2,829
Total share-based
 
compensation expense
$
2,991
$
660
$
7,673
$
1,672
Share-based compensation expense is recorded in SG&A,
 
except for approximately $
0.3
 
million and $
0.8
 
million for the three
and six months ended June 30, 2020, respectively,
 
and less than $
0.1
 
million for the six months ended June 30, 2019, recorded within
Combination, integration and other acquisition-related
 
expenses.
 
The increase in total share-based compensation expense for
 
the six
months ended June 30, 2020 includes performance stock
 
units, annual incentive plan accruals,
 
and non-elective and elective 401(k)
matching contributions
 
in stock as components
 
of share-based compensation beginning in 2020, described
 
further below.
Stock Options
 
During the first quarter of 2020, the Company granted
 
stock options under its long-term incentive plan (“LTIP”)
 
that are subject
only to time-based vesting over a
three
-year period.
 
For the purposes of determining the fair value of stock option
 
awards, the
Company used a Black-Scholes option pricing model and
 
the assumptions set forth in the table below:
Number of options granted
49,115
Dividend yield
0.99
%
Expected volatility
31.57
%
Risk-free interest rate
0.36
%
Expected term (years)
4.0
The fair value of these options is amortized on a straight
 
-line basis over the vesting period.
 
As of June 30, 2020,
 
unrecognized
compensation expense related to all stock options
 
granted was $
2.2
 
million, to be recognized over a weighted average remaining
period of
2.2
 
years.
 
Restricted Stock Awards
 
and Restricted Stock Units
 
During the six months ended June 30, 2020, the Company
 
granted
27,137
 
non-vested restricted shares and
5,804
 
non-vested
restricted stock units under its LTIP
 
,
 
subject to time-based vesting, generally over a three-year
 
period. The fair value of these grants is
based on the trading price of the Company’s
 
common stock on the date of grant. The Company adjusts the grant
 
date fair value of
these awards for expected forfeitures based on historical
 
experience
 
As of June 30, 2020, unrecognized compensation expense
related to the non-vested restricted shares was $
6.7
 
million, to be recognized over a weighted average remaining period
 
of
1.9
 
years,
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
18
and unrecognized compensation expense related to non-vested
 
restricted stock units was $
1.1
 
million, to be recognized over a
weighted average remaining period of
2.3
 
years.
Performance Stock Units
In March 2020, the Company included performance
 
-dependent stock awards (“PSUs”) as a component of its LTIP,
 
which will be
settled in a certain number of shares subject to market
 
-based and time-based vesting conditions.
 
The number of fully vested shares
that may ultimately be issued as settlement for each
 
award may range from
0
% up to
200
% of the target award, subject to the
achievement of the Company’s
 
total shareholder return (“TSR”) relative to the performance
 
of the Company’s peer
 
group, the S&P
Midcap 400 Materials group.
 
The service period required for the PSUs is three years and
 
the TSR measurement period for the PSUs is
from January 1, 2020 through December 31, 2022.
 
Compensation expense for PSUs is measured based on
 
their grant date fair value and is recognized on a straight-line basis over
the three-year vesting period.
 
The grant-date fair value of the PSUs was estimated using a
 
Monte Carlo simulation on the grant date
and using the following assumptions: (i) a risk-free
 
rate of
0.28
%; (ii) an expected term of
3.0
 
years; and (iii) a three-year daily
historical volatility for each of the companies in the
 
peer group, including Quaker Houghton.
 
As of June 30, 2020, the Company estimates that it will issue
 
approximately
25,500
 
fully vested shares as of the settlement date of
the award based on the conditions of the PSUs and
 
Company’s closing stock price
 
on June 30, 2020.
 
As of June 30, 2020, there was
approximately $
3.1
 
million of total unrecognized compensation cost related to PSUs which
 
the Company expects to recognize over a
weighted-average period of
2.7
 
years.
Annual Incentive Plan
The Company maintains an Annual Incentive Plan
 
(“AIP”), which may be settled in cash or a certain number of
 
shares subject to
performance-based and time-based vesting conditions.
 
It is the Company’s current
 
intention to settle the 2020 AIP in shares, and
therefore, expense associated with the AIP in 2020 will
 
be recorded as a component of share-based compensation
 
expense.
 
The
number of fully vested shares that may ultimately
 
be issued as settlement for each award is subject to the achievement
 
of the
Company’s performance
 
against certain internal financial and non-financial metrics and
 
approval by the Company’s Compensation
Committee.
 
Compensation expense for the AIP is measured based on the estimated
 
total value of the award.
 
The number of shares that will
ultimately be issued under the AIP award will be equal
 
to final value of the award converted into a number of shares based
 
on the
trading price of the Company’s
 
common stock on the date of settlement.
 
As of June 30, 2020, the Company estimates that it will issue
approximately
39,000
 
fully vested shares as of the settlement date of the award
 
based on the conditions of the AIP,
 
the Company’s
projected performance against its performance metrics
 
and Company’s closing
 
stock price on June 30, 2020.
Defined Contribution Plan
 
The Company has a 401(k) plan with an employer
 
match covering a majority of its U.S. employees.
 
The Company matches
50
%
of the first
6
% of compensation that is contributed to the plan, with a maximum
 
matching contribution of
3
% of compensation.
 
Additionally, the
 
plan provides for non-elective nondiscretionary contributions
 
on behalf of participants who have completed one year
of service equal to
3
% of the eligible participant's compensation.
 
The Company’s matching contributions
 
and non-elective
contributions may be made in cash or in fully vested shares
 
of the Company’s common
 
stock.
 
Beginning in April 2020,
 
the Company
began matching both non-elective and elective 401(k)
 
contributions in fully vested shares of its common stock rather than
 
cash.
 
For
the three and six months ended June 30, 2020, total contributions
 
were $
1.2
 
million.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
19
Note 9 – Pension and Other Postretirement
 
Benefits
The components of net periodic benefit cost for the
 
three and six months ended June 30, 2020 and 2019 are as follows:
Three Months Ended June 30,
Six Months Ended June 30,
Other
Other
Postretirement
Postretirement
Pension Benefits
Benefits
Pension Benefits
Benefits
2020
2019
2020
2019
2020
2019
2020
2019
Service cost
$
1,164
$
978
$
1
$
2
$
2,338
$
1,963
$
3
$
4
Interest cost
1,486
1,105
26
36
3,255
2,216
52
71
Expected return on plan assets
(1,761)
(978)
(3,720)
(1,962)
Settlement charge
22,667
Actuarial loss amortization
615
773
16
1,662
1,549
31
Prior service cost amortization
(41)
(41)
(81)
(83)
Net periodic benefit cost
$
1,463
$
1,837
$
43
$
38
$
26,121
$
3,683
$
86
$
75
In the fourth quarter of 2018, the Company began the process of terminating its Legacy Quaker non-contributory U.S. pension
plan (“Legacy Quaker U.S. Pension Plan”). During the third quarter of 2019, the Company received a favorable termination
determination letter from the Internal Revenue Service (“I.R.S.”) and amended the Legacy Quaker U.S. Pension Plan to comply with
final regulations of the Internal Revenue Code. The Company completed the Legacy Quaker U.S. Pension Plan termination during the
first quarter of 2020. In order to terminate the Legacy Quaker U.S. Pension Plan in accordance with I.R.S. and Pension Benefit
Guaranty Corporation requirements, the Company was required to fully fund the Legacy Quaker U.S. Pension Plan on a termination
basis and the amount necessary to do so was approximately $1.8 million, subject to final true up adjustments. In July 2020, the
Company finalized the amount of the liability and related annuity payments and expects to receive a refund in premium of
approximately $2 million in August 2020. In addition, the Company recorded a non-cash pension settlement charge at plan
termination of approximately $22.7 million. This settlement charge included the immediate recognition into expense of the related
unrecognized losses within accumulated other comprehensive (loss) income (“AOCI”) on the balance sheet as of the plan termination
date.
 
Employer Contributions
The Company previously disclosed in its 2019 Form 10-K
 
that it expected to make minimum cash contributions of $
10.0
 
million
to its U.S. and foreign pension plans and approximately
 
$
0.4
 
million to its other postretirement benefit plans in 2020. As a result
 
of
certain current year pension plan funding relief provided
 
by the Coronavirus Aid, Relief, and Economic Security
 
Act (the “CARES
Act”) enacted into law on March 27, 2020, the Company
 
now expects to make minimum cash contributions of
 
$
8.0
 
million to its U.S.
and foreign pension plans in 2020.
 
As of June 30, 2020, $
4.9
 
million and $
0.2
 
million of contributions have been made to the
Company’s U.S. and foreign
 
pension plans and its other postretirement benefit plans, respectively.
 
This excludes the $
1.8
 
million of
additional funding made in the first quarter of 2020, as required,
 
to terminate the Legacy Quaker U.S. Pension Plan, noted above.
Note 10 – Other (Expense) Income, Net
 
The components of other (expense) income, net, for the
 
three and six months ended June 30, 2020 and 2019 are as follows:
Three Months Ended
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
Income from third party license fees
$
208
$
193
$
512
$
413
Foreign exchange losses, net
(2,004)
(144)
(1,183)
(381)
(Loss) gain on fixed asset disposals, net
(83)
30
(81)
39
Non-income tax refunds and other related credits
832
813
2,131
965
Pension and postretirement benefit costs,
 
non-service components
(341)
(895)
(23,866)
(1,791)
Other non-operating income, net
395
46
319
163
Total other
 
(expense) income, net
$
(993)
$
43
$
(22,168)
$
(592)
Pension and postretirement benefit costs, non-service components
 
during the six months ended June 30, 2020 includes
 
$
22.7
million related to the Legacy Quaker U.S. Pension
 
Plan non-cash settlement charge described in Note
 
9 of Notes to Condensed
Consolidated Financial Statements.
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
20
Note 11 – Income Taxes
 
and Uncertain Income Tax
 
Positions
The Company’s effective
 
tax rate for the three and six months ended June 30, 2020 was an expense
 
of
57.9
% and a benefit of
20.7
%, respectively, compared to
 
an expense of
24.2
% and
25.4
%, respectively, for the
 
three and six months ended June 30, 2019.
 
The Company’s effective
 
tax rate for the three and six months ended June 30, 2020 was impacted
 
by the tax effect of certain one-time
pre-tax costs as well as certain tax charges
 
and benefits in the current period including those related to changes
 
in foreign tax credit
valuation allowances, discussed below,
 
tax law changes in foreign jurisdictions, changes in uncertain
 
tax positions, and the tax impact
of the Company’s termination
 
of its legacy Quaker U.S. Pension Plan.
 
Comparatively, the
 
three and six months ended June 30, 2019
effective tax rates were impacted by certain
 
non-deductible costs associated with the Combination, partially
 
offset by a favorable shift
in earnings to entities with lower effective
 
tax rates.
On March 27, 2020, in response to COVID-19 and its detrimental
 
impact to the global economy,
 
the CARES Act was enacted
into law, providing
 
a stimulus to the U.S. economy in the form of various individual
 
and business assistance programs as well as
temporary changes to existing tax law.
 
The changes include a postponement of certain tax payments,
 
deferral of the employer’s
portion of the social security tax and certain other payroll
 
-related incentives, and an increase in the interest expense
 
limitation under
Section 163(j) of the Internal Revenue Code from
30
% to
50
% for the 2019 and 2020 tax years.
 
ASC 740 requires the tax effects of
changes in tax laws or rates to be recorded in the period
 
of enactment.
 
Under the CARES Act, the Company has the option to use
 
its
2019 adjusted taxable income in determining its interest expense
 
limitation under Section 163(j).
 
While the Company is still
considering whether to make this election for 2020, the
 
current year tax provision takes into account this potential election and
associated tax benefit, which offsets an inc
 
rease to the Company’s foreign
 
tax credit valuation allowance recognized during the
current quarter primarily driven by changes in current
 
year projected taxable income due to the negative impacts from
 
COVID-19.
 
In
addition, the Company reviewed its existing deferred tax
 
assets in light of COVID-19 and determined that, at this time,
 
no change in
valuation allowance is required except with regard to
 
its foreign tax credits as noted above.
 
While the ultimate impact of COVID-19
on the Company’s results
 
of operations is still uncertain, the Company will continue to
 
assess future changes in projected taxable
income to determine if they result in additional changes
 
to any of the Company’s valuation
 
allowances.
 
As previously disclosed in its 2019 Form 10-K, the Company
 
had a deferred tax liability of $
8.2
 
million at December 31, 2019,
which primarily represents the Company’s
 
estimate of non-U.S. taxes it will incur to repatriate certain foreign
 
earnings to the U.S.
 
During the first six months of 2020, the Company made
 
certain adjustments to the deferred tax liability to take into
 
account a tax law
change enacted in the first quarter in a certain foreign
 
jurisdiction, the inclusion of other earnings to be repatriated,
 
and the actual
repatriation of earnings, resulting in a deferred tax liability
 
of $
6.3
 
million as of June 30, 2020.
 
As previously disclosed in its 2019 Form 10-K, in conjunction
 
with the Combination, the Company acquired foreign tax credit
deferred tax assets of $
41.8
 
million expiring between
2019 and 2028
.
 
Foreign tax credits may be carried forward for 10 years.
 
The
Company analyzes the expected impact of the utilization
 
of foreign tax credits based on projected U.S. taxable income,
 
overall
domestic loss recapture, annual limitations due to the
 
ownership change limitations provided by the Internal
 
Revenue Code, and
enacted tax law amongst other factors.
 
As of December 31, 2019, the Company had net realizable foreign
 
tax credits of $
32.7
 
million
on its balance sheet expected to be utilized between
2020 and 2026
.
 
As of June 30, 2020, the Company had net realizable foreign tax
credits of $
21.9
 
million on its balance sheet expected to be utilized between
2020 and 2026
.
 
The change in net realizable foreign tax
credits during the first six months of 2020 was primarily
 
driven by the Company's update to its initial opening balance
 
sheet estimate
with respect to acquired Houghton foreign tax credit deferred
 
tax assets, described in Note 2 of Notes to Condensed Consolidated
Financial Statements, as well as approximately $
3.7
 
million of tax expense for the six months ended June 30,
 
2020 based on revised
taxable income projections and changes to the interest expense
 
limitation under the CARES Act amongst other factors.
The Company continues to recognize interest and penalties
 
associated with uncertain tax positions as a component of
 
taxes on
(loss) income before equity in net income of associated
 
companies in its Condensed Consolidated Statements of Operations.
 
The
Company recognized an expense for interest of $
0.6
 
million and $
0.6
 
million and an expense for penalties of $
0.6
 
million and $
0.5
million in its Condensed Consolidated Statement of Operations
 
for the three and six months ended June 30, 2020, respectively
 
.
 
Comparatively,
 
the Company recognized an expense for interest of $
0.1
 
million and $
0.2
 
million and an expense for penalties of less
than $
0.1
 
million for both the three and six months ended June 30, 2019,
 
respectively.
 
As of June 30, 2020, the Company had accrued
$
2.8
 
million for cumulative interest and $
4.0
 
million for cumulative penalties in its Condensed Consolidated Balance
 
Sheets,
compared to $
2.3
 
million for cumulative interest and $
3.1
 
million for cumulative penalties accrued at December 31, 2019.
As of June 30, 2020, the Company’s
 
cumulative liability for gross unrecognized tax benefits was $
21.1
 
million, an increase of
$
2.0
 
million from the $
19.1
 
million cumulative liability accrued as of December 31,
 
2019.
 
During the six months ended June 30, 2020 and 2019, the
 
Company recognized a decrease of $
1.5
 
million and less than $
0.1
million, respectively,
 
in its cumulative liability for gross unrecognized tax benefits due
 
to the expiration of the applicable statutes of
limitations for certain tax years.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
21
The Company estimates that during the year ending December
 
31, 2020 it will reduce its cumulative liability for gross
unrecognized tax benefits by approximately $
2.3
 
million due to the expiration of the statute of limitations with regard
 
to certain tax
positions.
 
This estimated reduction in the cumulative liability for unrecognized
 
tax benefits does not consider any increase in liability
for unrecognized tax benefits with regard to existing tax
 
positions or any increase in cumulative liability for unrecognized
 
tax benefits
with regard to new tax positions for the year ending December
 
31, 2020.
The Company and its subsidiaries are subject to U.S. Federal income
 
tax, as well as the income tax of various state and foreign
tax jurisdictions.
 
Tax years that remain
 
subject to examination by major tax jurisdictions include Brazil from
2000
, Italy from
2006
,
China from
2010
, Canada from
2011
, the Netherlands and the United Kingdom from
2014
, Spain from
2015
, Mexico, Germany,
 
and
the U.S. from
2016
, India from fiscal year beginning April 1, 2017 and ending
 
March 31,
2018
, and various U.S. state tax jurisdictions
from
2010
.
 
As previously reported, the Italian tax authorities have
 
assessed additional tax due from the Company’s
 
subsidiary, Quaker Italia
S.r.l., relating to the tax
 
years
2007 through 2015
.
 
The Company has filed for competent authority relief related to
 
these assessments
under the Mutual Agreement Procedures (“MAP”) of the
 
Organization for Economic Co-Operation and Development
 
(“OECD”) for
all years except 2007.
 
During the second quarter of 2020, the Company received notification
 
that the Italian and Dutch competent
authorities reached an agreement as part of the MAP involving
 
tax years 2008 through 2015.
 
The Company has tentatively agreed to
the reduced tax assessments and has recorded $
1.4
 
million of additional reserves for uncertain tax positions for the
 
open tax years that
is consistent with the tentative agreement reached involving
 
tax years 2008 through 2015.
 
As of June 30, 2020, the Company believes
it has adequate reserves for uncertain tax positions with
 
respect to this matter.
Houghton Italia, S.r.l
 
is also currently involved in a corporate income tax audit with the
 
Italian tax authorities covering tax years
2014 through 2018.
 
As part of the purchase accounting related to the Combination,
 
the Company has established a $
5.4
 
million
reserve for uncertain tax positions relating to this audit.
 
These amounts relate to the 2014 to 2018 audit periods
 
as well as the seven-
month period in 2019 prior to the Combination.
 
Since these amounts relate to tax periods prior to the Combination,
 
the Company has
submitted an indemnification claim against funds
 
held in escrow by Houghton’s former
 
owners for certain tax liabilities arising pre-
Combination.
 
As a result, a corresponding $
5.4
 
million indemnification receivable has also been established through
 
purchase
accounting that would offset the $
5.4
 
million in tax liabilities booked through purchase accounting.
 
As of June 30, 2020, the
Company believes it has adequate reserves for uncertain
 
tax positions.
Note 12 – Earnings Per Share
The following table summarizes earnings per share calculations
 
for the three and six months ended June 30, 2020 and 2019:
Three Months Ended
 
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
Basic (loss) earnings per common share
 
 
 
Net (loss) income attributable to Quaker Chemical Corporation
$
 
(7,735)
$
15,591
$
 
(36,116)
$
29,435
Less: loss (income) allocated to participating securities
 
37
 
(34)
 
146
 
(81)
Net (loss) income available to common shareholders
$
 
(7,698)
$
15,557
$
 
(35,970)
$
29,354
Basic weighted average common shares outstanding
17,697,496
13,304,248
17,685,010
13,297,953
Basic (loss) earnings per common share
$
(0.43)
$
1.17
$
(2.03)
$
2.21
Diluted (loss) earnings per common share
Net (loss) income attributable to Quaker Chemical Corporation
$
(7,735)
$
15,591
$
 
(36,116)
$
29,435
Less: loss (income) allocated to participating securities
37
 
(34)
 
146
 
(81)
Net (loss) income available to common shareholders
$
(7,698)
$
15,557
$
(35,970)
$
29,354
Basic weighted average common shares outstanding
17,697,496
13,304,248
17,685,010
13,297,953
Effect of dilutive securities
48,007
47,362
Diluted weighted average common shares outstanding
17,697,496
13,352,255
17,685,010
13,345,315
Diluted (loss) earnings per common share
$
(0.43)
$
1.17
$
(2.03)
$
2.20
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
22
During the third quarter of 2019, the Company issued
 
approximately
4.3
 
million shares of common stock, comprising
24.5
% of
the common stock of the Company immediately after
 
the closing, as a component of the consideration transferred in the Combination.
Certain stock options and restricted stock units are not included
 
in the diluted (loss) earnings per share calculation because the effect
would have been anti-dilutive.
 
All of the Company’s potentially
 
dilutive shares for the three and six months ended June
 
30, 2020 are
anti-dilutive and not included in the dilutive (loss) earnings
 
per share calculation because of the Company’s
 
net loss for the periods.
 
Comparatively,
 
there were
no
 
anti-dilutive shares for the three and six months ended
 
June 30, 2019.
 
Note 13 – Restricted Cash
The Company has restricted cash recorded in other assets related to proceeds from an inactive subsidiary of the Company which
previously executed separate settlement and release agreements with two of its insurance carriers for an original total value of $35.0
million.
 
The proceeds of both settlements are restricted and can only be
 
used to pay claims and costs of defense associated with the
subsidiary’s asbestos litigation.
 
The proceeds of the settlement and release agreements
 
have been deposited into interest bearing
accounts that earned less than $
0.1
 
million in the six months ended June 30, 2020, compared to $
0.1
 
in the six months ended June 30,
2019.
 
The interest was offset by $
0.5
 
million of payments during the six months ended June 30,
 
2020, compared to $
0.3
 
million of
payments in the six months ended June 30, 2019.
 
Due to the restricted nature of the proceeds, a corresponding
 
deferred credit was
established in other non-current liabilities for an equal
 
and offsetting amount, and will remain until the restrictions
 
lapse or the funds
are exhausted via payments of claims and costs of defense.
The following table provides a reconciliation of cash,
 
cash equivalents and restricted cash as of June 30, 2020 and 2019
 
,
 
and
December 31, 2019 and 2018:
June 30,
December 31,
2020
2019
2019
2018
Cash and cash equivalents
$
322,497
$
86,355
$
123,524
$
104,147
Restricted cash included in other current assets
85
353
Restricted cash included in other assets
19,173
20,103
19,678
20,278
Cash, cash equivalents and restricted cash
$
341,755
$
106,458
$
143,555
$
124,425
Note 14 – Goodwill and Other Intangible Assets
Changes in the carrying amount of goodwill for the
 
six months ended June 30, 2020 were as follows:
Global
Specialty
Americas
EMEA
Asia/Pacific
Businesses
Total
Balance as of December 31, 2019
$
216,385
$
133,018
$
141,727
$
116,075
 
$
607,205
Goodwill acquired
531
531
Currency translation and other adjustments
 
(4,569)
(3,256)
5,940
(1,202)
(3,087)
Balance as of June 30, 2020
$
211,816
$
130,293
$
147,667
$
114,873
 
$
604,649
Other adjustments in the table above include updates
 
to the Company’s allocation
 
of the Houghton purchase price and associated
goodwill to each of the Company’s
 
reportable segments during the first six months of 2020.
Gross carrying amounts and accumulated amortization
 
for definite-lived intangible assets as of June 30, 2020 and December
 
31,
2019 were as follows:
Gross Carrying
Accumulated
Amount
Amortization
2020
2019
2020
2019
Customer lists and rights to sell
$
781,188
 
$
792,362
 
$
72,803
 
$
49,932
Trademarks, formulations and product
 
technology
 
155,924
 
 
157,049
 
 
25,475
 
 
21,299
Other
 
6,266
 
 
6,261
 
 
5,684
 
 
5,776
Total definite
 
-lived intangible assets
$
943,378
 
$
955,672
 
$
103,962
 
$
77,007
The Company amortizes definite-lived intangible assets on
 
a straight-line basis over their useful lives.
 
The Company recorded
$
13.7
 
million and $
27.7
 
million of amortization expense for the three and six months
 
ended June 30, 2020, respectively.
 
Comparatively,
 
the Company recorded $
1.8
 
million and $
3.6
 
million of amortization expense for the three and six months
 
ended June
30, 2019, respectively.
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
23
Estimated annual aggregate amortization expense for
 
the current year and subsequent five years is as follows:
For the year ended December 31, 2020
$
55,145
For the year ended December 31, 2021
54,885
For the year ended December 31, 2022
54,732
For the year ended December 31, 2023
54,515
For the year ended December 31, 2024
54,089
For the year ended December 31, 2025
53,418
Goodwill and intangible assets that have indefinite lives are
 
not amortized and are required to be assessed at least annually
 
for
impairment.
 
The Company completes its annual goodwill and indefinite-lived
 
intangible asset impairment test during the fourth
quarter of each year.
 
The Company continuously evaluates if triggering events indicate
 
a possible impairment in one or more of its
reporting units or indefinite-lived or long-lived assets.
As of March 31, 2020, the Company evaluated the initial imp
 
act of COVID-19 on the Company’s
 
operations, and the volatility
and uncertainty in the economic outlook as a result of
 
COVID-19 to determine if they indicated it was more likely
 
than not that the
carrying value of any of the Company’s
 
reporting units or indefinite-lived or long-lived assets was not
 
recoverable.
 
The Company
concluded that the impact of COVID-19 did not represent
 
a triggering event as of March 31, 2020 with regards to the Company’s
reporting units or indefinite-lived and long-lived assets, except
 
for the Company’s Houghton
 
and Fluidcare trademark and tradename
indefinite-lived intangible assets.
 
The determination of estimated fair value of the Houghton
 
and Fluidcare trademark and tradename indefinite-lived assets was
based on a relief from royalty valuation method which
 
requires management’s
 
judgment and often involves the use of significant
estimates and assumptions, including assumptions with respect
 
to the weighted average cost of capital (“WACC”)
 
as well as projected
net sales.
 
In the first quarter of 2020, as a result of the impact of
 
COVID-19 driving a decrease in projected legacy Houghton
 
net sales
in the current year and the impact of the current year
 
decline on projected future legacy Houghton net sales as well as an increase
 
in
the WACC
 
assumption utilized in the quantitative impairment assessment, the
 
Company concluded that the estimated fair values of
the Houghton and Fluidcare trademark and tradename
 
intangible assets were less than their carrying values.
 
As a result, an
impairment charge of $
38.0
 
million to write down the carrying values of these intangible
 
assets to their estimated fair values was
recorded in the first quarter of 2020.
 
The Company’s estimate of fair
 
value and the carrying value of these Houghton and Fluidcare
trademark and tradename indefinite-lived intangible assets as of
 
June 30, 2020 was $
204.0
 
million.
 
Comparatively, these indefinite-
lived intangible assets totaled $
242.0
 
million as of December 31, 2019.
 
In addition, the Company has other indefinite-lived intangible
assets totaling $
1.1
 
million as of both June 30, 2020 and December 31, 2019.
 
As of June 30, 2020, the Company continued to evaluate the on
 
-going impact of COVID-19 on the Company’s
 
operations, and
the volatility and uncertainty in the economic outlook as a result of
 
COVID-19, to determine if this indicated it was more likely
 
than
not that the carrying value of any of the Company’s
 
reporting units or indefinite-lived or long-lived intangible assets were
 
not
recoverable.
 
The Company concluded that the impact of COVID-19 did not represent
 
a triggering event as of June 30, 2020 with
regards to any of the Company’s
 
reporting units or indefinite-lived and long-lived intangible
 
assets.
While the Company concluded that the impact of COVID-19
 
did not represent a triggering event as of June 30, 2020 for any
 
of its
other long-lived or indefinite-lived assets or reporting
 
units, the Company will continue to evaluate the impact of COVID-19
 
on the
Company’s current and
 
projected results.
 
If the current economic conditions worsen or projections of the
 
timeline for recovery are
significantly extended, then the Company may conclude
 
in the future that the impact from COVID-19 requires the need
 
to perform
further interim quantitative impairment tests, which could
 
result in additional impairment charges in the future.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
24
Note 15 – Debt
 
Debt as of June 30, 2020 and December 31, 2019
 
includes the following:
As of June 30, 2020
As of December 31, 2019
Interest
Outstanding
 
Interest
Outstanding
 
Rate
Balance
Rate
Balance
Credit Facilities:
Revolver
1.67%
$
376,676
3.20%
$
171,169
U.S. Term Loan
2.10%
585,000
3.20%
600,000
EURO Term Loan
1.50%
147,584
1.50%
151,188
Industrial development bonds
5.26%
10,000
5.26%
10,000
Bank lines of credit and other debt obligations
Various
1,910
Various
2,608
Total debt
$
1,121,170
$
934,965
Less: debt issuance costs
(12,647)
(14,196)
Less: short-term and current portion of long-term debts
(38,217)
(38,332)
Total long
 
-term debt
$
1,070,306
$
882,437
Credit facilities
The Company’s primary
 
credit facility (as amended, the “New Credit Facility”) is comprised
 
of a $
400.0
 
million multicurrency
revolver (the “Revolver”), a $
600.0
 
million term loan (the “U.S. Term
 
Loan”), each with the Company as borrower,
 
and a $
150.0
million (as of August 1, 2019) Euro equivalent term loan (the
 
“EURO Term Loan”
 
and together with the “U.S. Term
 
Loan”, the
“Term Loans”
 
)
 
with Quaker Chemical B.V.,
 
a Dutch subsidiary of the Company as borrower,
 
each with a five-year term maturing in
August 2024.
 
Subject to the consent of the administrative agent and certain
 
other conditions, the Company may designate additional
borrowers.
 
The maximum amount available under the New Credit Facility can be
 
increased by up to $
300.0
 
million at the Company’s
request if there are lenders who agree to accept additional
 
commitments and the Company has satisfied certain other
 
conditions.
 
Borrowings under the New Credit Facility bear interest at a
 
base rate or LIBOR plus an applicable margin
 
based upon the Company’s
consolidated net leverage ratio.
 
There are LIBOR replacement provisions that contemplate a further
 
amendment if and when LIBOR
ceases to be reported.
 
The interest rate incurred on the outstanding borrowings under
 
the New Credit Facility during the six months
ended June 30, 2020 was approximately
2.5
%.
 
In addition to paying interest on outstanding principal under
 
the New Credit Facility,
the Company is required to pay a commitment fee ranging
 
from
0.2
% to
0.3
% depending on the Company’s
 
leverage ratio to the
lenders under the Revolver in respect of the unutilized
 
commitments thereunder.
 
The Company has unused capacity under the
Revolver of approximately $
15
 
million, net of bank letters of credit of approximately
 
$
8
 
million, as of June 30, 2020, as the Company
drew down most of the available capacity under the Revolver
 
in the second half of March 2020 as a precautionary measure
 
due to the
uncertainty of the impact of COVID-19 on the Company
 
as well as on the U.S. capital markets and bank liquidity,
 
among other
potential effects.
 
The New Credit Facility is subject to certain financial
 
and other covenants.
 
The Company’s initial consolidated net debt to
consolidated adjusted EBITDA ratio cannot exceed 4.25 to 1, with step downs in the permitted ratio over the course of the New Credit
Facility. The Company’s consolidated adjusted EBITDA to interest expense ratio cannot be less than 3.0 to 1. The New Credit
Facility also prohibits the payment of cash dividends if the Company is in default or if the amount of the dividend paid annually
exceeds the greater of $50.0 million and 20% of consolidated adjusted EBITDA unless the ratio of consolidated net debt to
consolidated adjusted EBITDA is less than 2.0 to 1, in which case there is no such limitation on amount.
 
As of June 30, 2020 and
December 31, 2019, the Company was in compliance with all of the New Credit Facility covenants.
 
The Term Loans have
 
quarterly
principal amortization during their respective five-year
 
maturities, with
5.0
% amortization of the principal balance due in years 1 and
2,
7.5
% in year 3, and
10.0
% in years 4 and 5, with the remaining principal amount due at maturity.
 
During the six months ended June
30, 2020, the Company made two quarterly amortization payments
 
related to the Term
 
Loans totaling $
18.7
 
million.
 
The New Credit
Facility is guaranteed by certain of the Company’s
 
domestic subsidiaries and is secured by first priority liens
 
on substantially all of the
assets of the Company and the domestic subsidiary guarantors,
 
subject to certain customary exclusions.
 
The obligations of the Dutch
borrower are guaranteed only by certain foreign subsidiaries
 
on an unsecured basis.
The New Credit Facility requires the Company to deliver to
 
the administrative
 
agent and each lender the audited consolidated
financial statements of the Company for each fiscal year
 
in a prescribed period of time.
 
On March 17, 2020, the Company,
 
the
administrative agent, and all parties to the New Credit Facility
 
entered into an amendment (the “Amendment”) which allowed
 
the
Company to deliver the annual audited consolidated financial
 
statements for the year ended December 31, 2019
 
to the bank group no
later than April 16, 2020 as compared to the initial deadline
 
of March 17, 2020.
 
The Company delivered its 2019 audited consolidated
financial statements to the administrative agent and each
 
lender on March 20, 2020 in compliance with the Amendment.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
25
The New Credit Facility required the Company to fix its variable
 
interest rates on at least
20
% of its total Term
 
Loans.
 
In order to
satisfy this requirement as well as to manage the
 
Company’s exposure to variable
 
interest rate risk associated with the New Credit
Facility, in November
 
2019, the Company entered into $
170.0
 
million notional amounts of three-year interest rate swaps at a base
 
rate
of
1.64
% plus an applicable margin as provided in the
 
New Credit Facility, based on
 
the Company’s consolidated
 
net leverage ratio.
 
At the time the Company entered into the swaps, and
 
as of June 30, 2020, this aggregate rate was
3.1
%.
 
See Note 18 of Notes to
Condensed Consolidated Financial Statements.
The Company capitalized $
23.7
 
million of certain third-party debt issuance costs in connection
 
with executing the New Credit
Facility.
 
Approximately $
15.5
 
million of the capitalized costs were attributed to the Term
 
Loans and recorded as a direct reduction of
long-term debt on the Company’s
 
Condensed Consolidated Balance Sheet.
 
Approximately $
8.3
 
million of the capitalized costs were
attributed to the Revolver and recorded within other assets on
 
the Company’s Condensed Consolidated
 
Balance Sheet.
 
These
capitalized costs are being amortized into interest expense
 
over the five-year term of the New Credit Facility.
 
As of June 30, 2020 and
December 31, 2019, the Company had $
12.6
 
million and $
14.2
 
million, respectively,
 
of debt issuance costs recorded as a reduction of
long-term debt.
 
As of June 30, 2020 and December 31, 2019, the Company
 
had $
6.7
 
million and $
7.6
 
million, respectively, of
 
debt
issuance costs recorded within other assets.
 
Industrial development bonds
As of June 30, 2020 and December 31, 2019, the Company
 
had fixed rate, industrial development authority bonds totaling
 
$
10.0
million in principal amount due in 2028.
 
These bonds have similar covenants to the New Credit Facility noted
 
above.
Bank lines of credit and other
 
debt obligations
The Company has certain unsecured bank lines of credit
 
and discounting facilities in one of its foreign subsidiaries, which
 
are not
collateralized.
 
The Company’s other debt
 
obligations primarily consist of certain domestic and foreign
 
low interest rate or interest-
free municipality-related loans, local credit facilities of
 
certain foreign subsidiaries and capital lease obligations.
 
Total unused
capacity under these arrangements as of June 30, 2020
 
was approximately $
37
 
million.
In addition to the bank letters of credit described in the “Credit facilities” subsection above, the Company’s only other off-balance
sheet arrangements include certain financial and other guarantees. The Company’s total bank letters of credit and guarantees
outstanding as of June 30, 2020 were approximately $14 million.
For the three and six months ended June 30, 2020,
 
the Company incurred the following debt related expenses included
 
within
Interest expense, net, in the Condensed Consolidated Statements
 
of Operations:
Three Months Ended
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
Interest expense
$
5,951
$
1,255
$
13,663
$
2,427
Amortization of debt issuance costs
1,188
28
2,375
70
Total
$
7,139
$
1,283
$
16,038
$
2,497
Based on the variable interest rates associated with the New
 
Credit Facility, as of June
 
30, 2020 and December 31, 2019, the
amounts at which the Company’s
 
total debt were recorded are not materially different
 
from their fair market value.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
26
Note 16 – Equity
The following tables present the changes in equity,
 
net of tax, for the three and six months ended June 30, 2020
 
and 2019:
Accumulated
Capital in
Other
Common
Excess of
Retained
Comprehensive
Noncontrolling
Stock
Par Value
Earnings
Loss
Interest
Total
Balance at March 31, 2020
$
17,752
$
888,533
$
376,853
$
(121,524)
$
418
$
1,162,032
Net (loss) income
(7,735)
13
(7,722)
Amounts reported in other comprehensive
 
income
12,260
1
12,261
Dividends ($
0.385
 
per share)
(6,853)
(6,853)
Share issuance and equity-based
compensation plans
48
7,575
7,623
Balance at June 30, 2020
$
17,800
$
896,108
$
362,265
$
(109,264)
$
432
$
1,167,341
Balance at March 31, 2019
$
13,334
$
96,832
$
413,992
$
(79,167)
$
1,372
$
446,363
Net income
15,591
58
15,649
Amounts reported in other comprehensive
 
income
286
24
310
Dividends ($
0.385
 
per share)
(5,135)
(5,135)
Share issuance and equity-based
compensation plans
4
770
774
Balance at June 30, 2019
$
13,338
$
97,602
$
424,448
$
(78,881)
$
1,454
$
457,961
The retained earnings and total equity amounts included
 
in the table above as of March 31, 2020 reflect certain immaterial
adjustments made in the second quarter of 2020 to the Company’s
 
cumulative effect of an accounting change effective
 
January 1,
2020.
 
See Note 3 of Notes to Condensed Financial Statements.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
27
Accumulated
Capital in
Other
Common
Excess of
Retained
Comprehensive
Noncontrolling
Stock
Par Value
Earnings
Loss
Interest
Total
Balance at December 31, 2019
$
17,735
$
888,218
$
412,979
$
(78,170)
$
1,604
$
1,242,366
Cumulative effect of an accounting change
(911)
(911)
Balance at January 1, 2020
17,735
888,218
412,068
(78,170)
1,604
1,241,455
Net (loss) income
(36,116)
50
(36,066)
Amounts reported in other comprehensive
 
loss
(31,094)
(131)
(31,225)
Dividends ($
0.770
 
per share)
(13,687)
(13,687)
Acquisition of noncontrolling interest
(707)
(340)
(1,047)
Distribution to noncontrolling interest
affiliate shareholders
(751)
(751)
Share issuance and equity-based
compensation plans
65
8,597
8,662
Balance at June 30, 2020
$
17,800
$
896,108
$
362,265
$
(109,264)
$
432
$
1,167,341
Balance at December 31, 2018
$
13,338
$
97,304
$
405,125
$
(80,715)
$
1,317
$
436,369
Cumulative effect of an accounting change
(44)
(44)
Balance at January 1, 2019
13,338
97,304
405,081
(80,715)
1,317
436,325
Net income
29,435
114
29,549
Amounts reported in other comprehensive
 
income
1,834
23
1,857
Dividends ($
0.755
 
per share)
(10,068)
(10,068)
Share issuance and equity-based
compensation plans
298
298
Balance at June 30, 2019
$
13,338
$
97,602
$
424,448
$
(78,881)
$
1,454
$
457,961
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
28
The following tables show the reclassifications from and
 
resulting balances of AOCI for the three and six months ended
 
June 30,
2020 and 2019:
Defined
Unrealized
Currency
Benefit
(Loss) Gain in
 
Translation
Pension
Available-for
 
-
Derivative
Adjustments
Plans
Sale Securities
Instruments
Total
Balance at March 31, 2020
$
(99,187)
$
(17,576)
$
(460)
$
(4,301)
$
(121,524)
Other comprehensive income (loss) before
 
reclassifications
10,550
(336)
2,128
(144)
12,198
Amounts reclassified from AOCI
600
(93)
507
Current period other comprehensive income (loss)
10,550
264
2,035
(144)
12,705
Related tax amounts
(51)
(427)
33
(445)
Net current period other comprehensive income (loss)
 
10,550
213
1,608
(111)
12,260
Balance at June 30, 2020
$
(88,637)
$
(17,363)
$
1,148
(4,412)
$
(109,264)
Balance at March 31, 2019
$
(49,753)
$
(29,845)
$
431
$
$
(79,167)
Other comprehensive (loss) income before
reclassifications
(543)
(79)
432
(190)
Amounts reclassified from AOCI
732
(43)
689
Current period other comprehensive (loss) income
(543)
653
389
499
Related tax amounts
(131)
(82)
(213)
Net current period other comprehensive (loss) income
(543)
522
307
286
Balance at June 30, 2019
$
(50,296)
$
(29,323)
$
738
$
$
(78,881)
Defined
Unrealized
Currency
Benefit
Gain (Loss) in
 
Translation
Pension
Available-for
 
-
Derivative
Adjustments
Plans
Sale Securities
Instruments
Total
Balance at December 31, 2019
$
(44,568)
$
(34,533)
$
1,251
$
(320)
$
(78,170)
Other comprehensive (loss) income before
reclassifications
(44,069)
492
(8)
(5,315)
(48,900)
Amounts reclassified from AOCI
24,966
(125)
24,841
Current period other comprehensive (loss) income
(44,069)
25,458
(133)
(5,315)
(24,059)
Related tax amounts
(8,288)
30
1,223
(7,035)
Net current period other comprehensive (loss) income
(44,069)
17,170
(103)
(4,092)
(31,094)
Balance at June 30, 2020
$
(88,637)
$
(17,363)
$
1,148
$
(4,412)
$
(109,264)
Balance at December 31, 2018
$
(49,322)
$
(30,551)
$
(842)
$
$
(80,715)
Other comprehensive (loss) income before
 
reclassifications
(974)
81
2,139
1,246
Amounts reclassified from AOCI
1,465
(139)
1,326
Current period other comprehensive (loss) income
(974)
1,546
2,000
2,572
Related tax amounts
(318)
(420)
(738)
Net current period other comprehensive (loss) income
(974)
1,228
1,580
1,834
Balance at June 30, 2019
$
(50,296)
$
(29,323)
$
738
$
$
(78,881)
All reclassifications related to unrealized gain (loss) in
 
available-for-sale securities relate to the Company’s
 
equity interest in a
captive insurance company and are recorded in equity
 
in net income of associated companies.
 
The amounts reported in other
comprehensive income for non-controlling interest are
 
related to currency translation adjustments.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
29
Note 17 – Fair Value
 
Measurements
 
The Company has valued its company-owned life insurance
 
policies at fair value.
 
These assets are subject to fair value
measurement as follows:
 
Fair Value
 
Measurements at June 30, 2020
Total
Using Fair Value
 
Hierarchy
Assets
Fair Value
Level 1
Level 2
Level 3
Company-owned life insurance
$
1,711
$
$
1,711
$
Total
$
1,711
$
$
1,711
$
 
Fair Value
 
Measurements at December 31, 2019
Total
Using Fair Value
 
Hierarchy
Assets
Fair Value
Level 1
Level 2
Level 3
Company-owned life insurance
 
$
1,782
$
$
1,782
$
Total
$
1,782
$
$
1,782
$
The fair values of Company-owned life insurance assets are based
 
on quotes for like instruments with similar credit ratings and
terms.
 
The Company did not hold any Level 3 investments as of
 
June 30, 2020 or December 31, 2019, respectively,
 
so related
disclosures have not been included.
 
Note 18 – Hedging Activities
As previously disclosed in its 2019 Form 10-K, in order to
 
satisfy certain requirements of the New Credit Facility as well as to
manage the Company’s exposure
 
to variable interest rate risk associated with the New Credit Facility,
 
in November 2019, the
Company entered into $
170.0
 
million notional amounts of three-year interest rate swaps.
 
See Note 15 of Notes to Condensed
Consolidated Financial Statements.
 
These interest rate swaps are designated as cash flow
 
hedges and, as such, the contracts are
marked-to-market at each reporting date and any unrealized gains
 
or losses are included in AOCI to the extent effective
 
and
reclassified to interest expense in the period during
 
which the transaction affects earnings or it becomes
 
probable that the forecasted
transaction will not occur.
 
The Company has previously used derivative financial instruments primarily
 
for the purposes of hedging
exposures to fluctuations in interest rates.
 
The Company did not utilize derivatives designated as cash flow
 
hedges during the three
and six months ended June 30, 2019.
 
The balance sheet classification and fair values of the
 
Company’s derivative instruments,
 
which are Level 2 measurements, are as
follows:
Fair Value
Condensed Consolidated
June 30,
December 31,
Balance Sheet Location
2020
2019
Derivatives designated as cash flow hedges:
Interest rate swaps
Other non-current liabilities
$
5,730
$
415
$
5,730
$
415
The following table presents the net unrealized loss deferred to
 
AOCI:
June 30,
December 31,
2020
2019
Derivatives designated as cash flow hedges:
Interest rate swaps
AOCI
$
4,412
$
320
$
4,412
$
320
The following table presents the net gain reclassified from
 
AOCI to earnings:
Three Months Ended
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
Amount and location of expense reclassified
from AOCI into Expense (Effective Portion)
Interest expense, net
$
(483)
$
$
(465)
$
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
30
Interest rate swaps are entered into with a limited number
 
of counterparties, each of which allows for net settlement
 
of all
contracts through a single payment in a single currency
 
in the event of a default on or termination of any one
 
contract.
 
As such, in
accordance with the Company’s
 
accounting policy,
 
these derivative instruments are recorded on a net basis within
 
the Condensed
Consolidated Balance Sheets.
Note 19 – Commitments and Contingencies
The Company previously disclosed in its 2019 Form 10-K
 
that AC Products, Inc. (“ACP”), a wholly owned subsidiary,
 
has been
operating a groundwater treatment system to hydraulically
 
contain groundwater contamination emanating from ACP’s
 
site, the
principal contaminant of which is perchloroethylene.
 
As of June 30, 2020, ACP believes it is close to meeting the
 
conditions for
closure of the groundwater treatment system, but continues
 
to operate this system while in discussions with the relevant
 
authorities.
 
As of June 30, 2020, the Company believes that the range
 
of potential-known liabilities associated with the balance
 
of the ACP water
remediation program is approximately $
0.1
 
million to $
1.0
 
million.
 
The low and high ends of the range are based on the length of
operation of the treatment system as determined
 
by groundwater modeling.
 
Costs of operation include the operation and maintenance
of the extraction well, groundwater monitoring and progr
 
am management.
 
The Company previously disclosed in its 2019 Form 10-K
 
that an inactive subsidiary of the Company that was acquired
 
in 1978
sold certain products containing asbestos, primarily
 
on an installed basis, and is among the defendants in numerous
 
lawsuits alleging
injury due to exposure to asbestos.
 
During the three and six months ended June 30, 2020,
 
there have been no significant changes to
the facts or circumstances of this previously disclosed matter,
 
aside from on-going claims and routine payments associated with
 
this
litigation.
 
Based on a continued analysis of the existing and anticipated
 
future claims against this subsidiary,
 
it is currently projected
that the subsidiary’s total
 
liability over the next 50 years for these claims is approximately
 
$
0.5
 
million (excluding costs of defense).
The Company previously disclosed in its 2019 Form 10-K
 
that as a result of the closing of the Combination, the Company
 
is now
party to Houghton environmental matters related to certain
 
domestic and foreign properties currently or previously
 
owned.
 
These
environmental matters primarily require the Company
 
to perform long-term monitoring as well as operating and maintenance
 
at each
of the applicable sites.
 
During the three and six months ended June 30, 2020, there
 
have been no significant changes to the facts or
circumstances of these previously disclosed matters, aside from
 
on-going monitoring and maintenance activities and routine payments
associated with each of the sites.
 
The Company continually evaluates its obligations related
 
to such matters, and based on historical
costs incurred and projected costs to be incurred over
 
the next 28 years, has estimated the present value range of costs for
 
all of the
Houghton environmental matters, on a discounted
 
basis, to be between approximately $
5
 
million and $
6
 
million as of June 30, 2020,
for which $
5.8
 
million was accrued within other accrued liabilities and other
 
non-current liabilities on the Company’s
 
Condensed
Consolidated Balance Sheet as of June 30, 2020.
 
Comparatively, as of
 
December 31, 2019, the Company had $
6.6
 
million accrued for
with respect to these matters.
The Company believes, although there can be no assurance
 
regarding the outcome of other unrelated environmental matters, that
it has made adequate accruals for costs associated with other
 
environmental problems of which it is aware.
 
Approximately $
0.1
million and $
0.2
 
million were accrued as of June 30, 2020 and December
 
31, 2019, respectively,
 
to provide for such anticipated future
environmental assessments and remediation costs.
 
The Company is party to other litigation which management
 
currently believes will not have a material adverse
 
effect on the
Company’s results of
 
operations, cash flows or financial condition.
 
In addition, the Company has an immaterial amount of contractual
purchase obligations.
Note 20 – COVID-19 Global Pandemic
In early 2020, a global outbreak of COVID-19 occurred
 
initially in China and then across all locations where the Company does
business, and which is continuing into the second half of
 
the year.
 
In March 2020, the World
 
Health Organization formally identified
the COVID-19 outbreak as a pandemic.
 
In an effort to halt the outbreak of COVID-19, the governments
 
of impacted countries,
including but not limited to the United States, the European
 
Union, and China, have taken various actions to reduce
 
its spread,
including travel restrictions, shutdowns of businesses deemed
 
nonessential, and stay-at-home or similar orders.
 
This outbreak and
associated measures to reduce its spread have caused
 
significant disruptions
 
to the operations of the Company and its suppliers and
customers.
 
The disruptions and negative impact to the Company
 
include significant volume declines and lower net sales first at its
China subsidiaries in the first quarter of 2020 and
 
subsequently, particularly
 
beginning in the second half of March and into the second
quarter, at many of its other
 
sites globally as the global economy slowed significantly in response
 
to the pandemic.
 
Management
continues to monitor the impact that the COVID-19 pandemic
 
is having on the Company,
 
the overall specialty chemical industry,
 
and
the economies and markets in which the Company operates.
 
 
Quaker Chemical Corporation
Notes to Condensed Consolidated Financial Statements
 
- Continued
(Dollars in thousands, except share and per share amounts
 
,
 
unless otherwise stated)
(Unaudited)
 
31
Further, management continues to
 
evaluate how COVID-19-related circumstances, such as remote
 
work arrangements, have
affected financial reporting processes, internal control
 
over financial reporting, and disclosure controls and procedures.
 
While the
circumstances have presented and are expected to continue
 
to present challenges, at this time, management does not believe
 
that
COVID-19 has had a material impact on financial reporting
 
processes, internal controls over financial reporting, and
 
disclosure
controls and procedures.
 
The full extent of the COVID-19 pandemic related
 
business and travel restrictions and changes to business and
 
consumer
behavior intended to reduce its spread are uncertain as of
 
the date of this Report as COVID-19 and the responses of governmental
authorities continue to rapidly evolve globally.
 
The Company cannot reasonably estimate the magnitude of the effects
 
these
conditions will have on the Company’s
 
operations as they are subject to significant uncertainties relating to
 
the ultimate geographic
spread of the virus, the incidence and severity of
 
the disease, the duration or recurrence of the outbreak, the
 
length of the travel
restrictions and business closures imposed by governments
 
of impacted countries, and the economic response by governments
 
of
impacted countries.
 
To the extent
 
that the Company’s customers and
 
suppliers continue to be significantly and adversely impacted by
 
COVID-19, this
could reduce the availability,
 
or result in delays, of materials or supplies to or from
 
the Company, which in
 
turn could significantly
interrupt the Company’s
 
business operations.
 
Such impacts could grow and become more significant to the
 
Company’s operations
and the Company’s liquidity
 
or financial position.
 
Therefore, given the speed and frequency of continuously
 
evolving developments
with respect to this pandemic, the Company cannot reasonably
 
estimate the magnitude or the full extent to which COVID-19
 
may
impact the Company’s results
 
of operations, liquidity or financial position.
 
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
32
Item 2.
 
Management’s Discussion and Analysis
 
of Financial Condition and Results of Operations
.
As used in this Report, the terms “Quaker Houghton
 
”, the “Company”, “we” and “our” refer to Quaker Chemical
 
Corporation
(doing business as Quaker Houghton),
 
its subsidiaries, and associated companies, unless the context otherwise
 
requires.
 
As used in
this Report, the term Legacy Quaker refers to the Company
 
prior to closing its combination with Houghton International,
 
Inc.
(“Houghton”) (herein referred to as the “Combination”)
 
on August 1, 2019.
 
Throughout this Quarterly Report on Form 10-Q (the
“Report”),
 
all figures presented, unless otherwise stated, reflect the results of
 
operations of the combined company for the three and
six months ended June 30, 2020 and Legacy Quaker for the
 
three and six months ended June 30,
 
2019.
 
Executive Summary
Quaker Houghton is a global leader in industrial process
 
fluids.
 
With a presence around the world,
 
including operations in over 25
countries, our customers include thousands of the world’s
 
most advanced and specialized steel, aluminum, automotive, aerospace,
offshore, can, mining, and metalworking
 
companies.
 
Our high-performing, innovative and sustainable solutions are
 
backed by best-
in-class technology,
 
deep process knowledge, and customized services. Quaker
 
Houghton is headquartered in Conshohocken,
Pennsylvania, located near Philadelphia in the United States.
 
The Company’s second
 
quarter of 2020 performance was dramatically affected
 
by the COVID-19 pandemic and its impact on the
global economy,
 
including most of the Company’s
 
end customers.
 
However, the second quarter of 2020
 
performance was also
relatively consistent with the Company’s
 
guidance as of the end of the first quarter.
 
Net sales of $286.0 million in the second quarter
of 2020 increased 39% compared to $205.9 million
 
in the second quarter of 2019, due primarily to the inclusion of $142.5
 
million of
Houghton and Norman Hay plc (“Norman Hay”) net
 
sales.
 
Excluding Houghton and Norman Hay net sales, the Company’s
 
net sales
would have declined approximately 30% quarter-over-quarter,
 
primarily driven by a decrease in sales volumes of approximately
 
27%
due to the impacts of COVID-19 and a negative impact
 
from foreign exchange of 4%.
 
The Company’s gross profit and
 
selling,
general and administrative expenses (“SG&A”) also increased
 
due to the inclusion of Houghton and Norman Hay quarter-over-
quarter, but both were also negatively
 
impacted by foreign exchange and benefited by the realization of
 
cost savings associated with
the Combination as well as the impact of lower SG&A due
 
to the sales decline and further cost saving measures put in place to
 
help
offset the impacts of COVID-19.
 
The Company reported a second quarter of 2020
 
net loss of $7.7 million or $0.43 per diluted share compared
 
to second quarter of
2019 net income of $15.6 million or $1.17 per diluted share.
 
The second quarter of 2020 net loss was primarily driven
 
by the negative
impact of COVID-19.
 
Excluding costs associated with the Combination and other non-core
 
items in each period, the Company’s
 
non-
GAAP earnings per diluted share were $0.21 in the
 
second quarter of 2020 compared to $1.56 in the prior year second
 
quarter.
 
Prior
year second quarter earnings per share do not reflect the
 
additional 4.3 million shares issued as part of the consideration
 
for the
Combination.
 
The Company’s adjusted EBITDA increased
 
to $32.1 million in the second quarter of 2020 compared
 
to $31.4 million
in the prior year quarter primarily due to the Combination,
 
the inclusion of Norman Hay and the benefits of cost savings realized
 
from
the Combination,
 
which were largely offset
 
by the current quarter negative impacts of COVID-19 and foreign
 
exchange.
 
See the Non-
GAAP Measures section of this Item below,
 
as well as other items discussed in the Company’s
 
Consolidated Operations Review in the
Operations section of this Item, below.
 
During the third quarter of 2019 and in connection with the
 
Combination, the Company established a new reportable
 
segment
structure that consists of four segments: (i) Americas; (ii)
 
Europe, Middle East and Africa (“EMEA”); (iii) Asia/Pacific;
 
and (iv)
Global Specialty Businesses.
 
The Company’s 2020
 
operating performance by reportable segment reflected the
 
positive impact of
Houghton’s performance
 
in all of its segments and Norman Hay in its Global Specialty
 
Businesses segment.
 
Without the inclusion of
Houghton and Norman Hay,
 
net sales would have been lower in all segments compared
 
to the prior year, primarily driven by declines
in volume due to the negative impacts of COVID-19 on
 
the Company’s end markets and
 
negative foreign currency translation in all
segments due to a stronger U.S. dollar quarter-over-quart
 
er.
 
As reported, segment operating earnings were higher
 
in most segments
compared to 2019 which also reflects the inclusion of Houghton
 
and Norman Hay partially offset by the negative
 
impacts of COVID-
19 and the impact of fixed manufacturing
 
costs on dramatically lower volumes compared to the Company’s
 
normal production levels.
 
Additional details of each segment’s
 
operating performance are further discussed in the Company’s
 
reportable segments review,
 
in the
Operations section of this Item, below.
 
The Company had net operating cash flow of approximately
 
$24.5 million in the second quarter of 2020 compared $22.4
 
million in
the second quarter of 2019, resulting in an 99% increase
 
in its current year-to-date net operating cash flow
 
to $44.7 million compared
to $22.4 million in the first six months of 2019.
 
The increase in net operating cash flow year-over-year
 
was driven by the inclusion of
Houghton and Norman Hay earnings as well as changes
 
in cash flows related to working capital.
 
The key drivers of the Company’s
operating cash flow and working capital are further discussed
 
in the Company’s Liquidity
 
and Capital Resources section of this Item,
below.
Overall, the Company’s
 
second quarter results were significantly impacted by the global
 
economic slowdown due to COVID-19,
but the performance was largely consistent with
 
the Company’s expectations
 
in light of the COVID-19 pandemic.
 
The Company saw
significant volume declines across the globe due to the impact
 
of COVID-19, certain domestic volume weakness due
 
to the declines in
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
33
the aerospace industry and foreign exchange headwinds
 
due to a stronger U.S. dollar.
 
Despite these impacts, the Company was able to
generate significant cash flow,
 
continue to pay its regular dividends, pay down its debt and
 
continue to execute its integration plans for
the Combination.
 
The current global economic slowdown and other impacts
 
due to COVID-19 pose an unprecedented challenge, but the
 
Company
expects to successfully navigate this downturn
 
as the Company has demonstrated the ability,
 
now and in the past, to respond quickly
to changing market conditions.
 
The Company also expects to maintain sufficient
 
liquidity and compliance with debt covenants
despite these difficult economic times.
 
The Company expects that its integration synergies
 
and additional cost savings actions as well
as continuing share gain in the marketplace will help
 
the Company during these challenging times, and,
 
coupled with the benefit of a
projected gradual rebound in demand in the Company’s
 
end markets,
 
will help drive significant adjusted EBITDA growth in 2021
 
and
2022.
 
Impact of COVID-19
 
In early 2020, the global outbreak of COVID-19
 
negatively impacted all locations where the Company
 
does business.
 
Although
the Company has now experienced a full quarter reflecting
 
the impacts of COVID-19, the full extent of the outbreak
 
and related
business impacts still remain uncertain and, therefore,
 
the full extent to which COVID-19 may impact the Company’s
 
results of
operations or financial condition is uncertain.
 
This outbreak has significantly disrupted the operations of the
 
Company and its
suppliers and customers.
 
The Company has experienced significant volume declines and
 
lower net sales as further described in this
section, first at its China subsidiaries in the first quarter
 
of 2020 and subsequently,
 
particularly beginning in the second half of March
and into the second quarter, throughout
 
the rest of the business due to the global economic slowdown brought
 
on by COVID-19.
 
Management continues to monitor the impact that the COVID-19
 
pandemic is having on the Company,
 
the overall specialty chemical
industry and the economies and markets in which the
 
Company operates.
 
 
Given the speed and frequency of the continuously evolving developments
 
with respect to this pandemic, the Company cannot, as
of the date of this Report, reasonably estimate the
 
magnitude or the full extent of the impact to its future results of
 
operations or to the
ability of it or its customers to resume more normal
 
operations, even as certain restrictions are lifted.
 
A prolonged outbreak or
resurgence and period of continued restrictions
 
on day-to-day life and business operations would likely result
 
in volume declines and
lower net sales for the later periods of 2020, as compared
 
to the prior year.
 
To the extent that the
 
Company’s customers and suppliers
continue to be significantly and adversely impacted by
 
COVID-19, this could reduce the availability,
 
or result in delays, of materials
or supplies to or from the Company,
 
which in turn could significantly interrupt the Company’s
 
business operations.
 
Given this
ongoing uncertainty,
 
the Company anticipates that its future results of operations, including the
 
results for the remainder of 2020,
could be significantly adversely impacted by COVID-19.
 
Further, management continues to
 
evaluate how COVID-19-related circumstances, such as remote
 
work arrangements, have
affected financial reporting processes and systems, internal
 
control over financial reporting, and disclosure controls and
 
procedures.
 
While the circumstances have presented and are expected
 
to continue to present challenges, at this time, management
 
does not believe
that COVID-19 has had a material impact on financial
 
reporting processes, internal controls over financial reporting,
 
and disclosure
controls and procedures.
 
For additional information regarding the potential impact of COVID-19,
 
see Item 1A of Part II of this
Report.
 
The Company’s top
 
priority is, and especially during this pandemic remains, to protect the health
 
and safety of its employees and
customers, while working to ensure business continuity
 
to meet customers’ needs:
 
 
Our People
 
– The Company has taken steps to protect the health and wellbeing
 
of its people in affected areas through various
actions, including enabling work at home where needed and
 
possible, and employing social distancing standards,
implementing travel restrictions where applicable, enhancing
 
onsite hygiene practices, and instituting visitation restrictions
 
at
the Company’s facilities.
 
The Company does not expect that it will incur material
 
expenses implementing health and safety
policies for employees, contractors, and customers.
 
 
 
Our Operations
 
– Currently, all of
 
the Company’s 34 production
 
facilities worldwide are open and operating and are deemed
as essential businesses in the jurisdictions where they are
 
operating.
 
The Company believes it has been able to meet the
needs of all its customers across the globe despite the
 
current economic challenges.
 
 
 
Our Business Conditions
 
– The Company’s second
 
quarter of 2020 results were consistent with expectations.
 
Demand
decreased as many customers reduced production levels, and in
 
some cases, temporarily shut down their facilities during the
second quarter of 2020.
 
All four of the Company’s reportable
 
segments showed significant declines in volumes and
 
net sales
due to COVID-19 with the Americas being the most impacted and
 
Asia/Pacific being the least impacted.
 
April and May
were the worst months of the quarter as many customers
 
globally were shut down or operating at reduced rates, especially
 
in
the automotive sector.
 
In June, the Company began to see net sales increase in all reportable
 
segments.
 
The Company
currently expects that the impact from COVID-19 in the second
 
quarter of 2020 will be the most severe and expects a gradual
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
34
quarterly improvement sequentially throughout the remainder of
 
the year, subject to the effective containment
 
of the virus
and its effects.
 
However, it remains highly uncertain
 
as to how long the global pandemic and related economic challenges
will last and when and to what extent our customers’ businesses will recover.
 
 
 
Our Actions
 
– The Company has taken actions to conserve cash and
 
reduce costs.
 
Some of the actions taken include
eliminating all discretionary expenditures, delaying or
 
freezing salary increases where legally permitted, reducing executives’
salaries, lowering targeted capital expenditures
 
by approximately 30%, and accelerating and fine-tuning the Company’s
integration plan.
 
These initiatives have been designed and implemented so that
 
the Company can successfully manage
through this challenging situation while continuing
 
to protect the health of its employees, meet customers’ needs,
 
maintain
the Company’s long
 
-term competitive advantages and above-market growth,
 
and enable it to continue to effectively integrate
with Houghton.
 
While the Company has taken a number of actions to protect our
 
workforce, to continue to serve our
customers with excellence and to conserve cash and
 
reduce costs, which have been effective thus far,
 
further actions to
respond to the pandemic and its effects may be
 
necessary as conditions continue to evolve.
 
Liquidity and Capital Resources
At June 30, 2020, the Company had cash, cash equivalents and
 
restricted cash of $341.8 million, including $19.3 million of
restricted cash.
 
Total cash, cash equivalents
 
and restricted cash was $143.6 million at December 31, 2019, which
 
included $20.0
million of restricted cash.
 
The $198.2 million increase in cash, cash equivalents and
 
restricted cash was the net result of $168.7
million of cash provided by financing activities and $44.7
 
million of cash provided by operating activities, partially
 
offset by $10.6
million of cash used in investing activities and a $4.6
 
million negative impact due to the effect of
 
foreign currency translation on cash.
 
Net cash flows provided by operating activities were $44.7
 
million in the first six months of 2020 compared to $22.4
 
million in
the first six months of 2019.
 
The Company’s current
 
year operating cash flow increase was largely due to the
 
inclusion of Houghton
and Norman Hay earnings, which were not included
 
in the prior year, as well as slightly lower outflows
 
related to working capital in
the current quarter largely due to the decline
 
in sales due to the impact of COVID-19 including its impact on working
 
capital levels.
 
The Company had higher cash dividends received from
 
its associated companies year-over-year,
 
including $5.0 million received from
the Company’s joint venture
 
in Korea in the first quarter of 2020.
 
Net cash flows used in investing activities were $10.6
 
million in the first six months of 2020 compared to $5.8 million
 
in the first
six months of 2019.
 
This increase in cash outflows was driven by higher investments in
 
property, plant and equipment
 
due to the
inclusion of Houghton and Norman Hay expenditures in
 
2020 including higher capital expenditures related to integrating
 
the
companies during the six months ended June 30,
 
2020.
 
Also, in the current year, the Company finalized
 
its post-closing adjustment
related to Norman Hay for approximately $3.2 million,
 
whereas the Company had a prior year payment of $0.5 million
 
to finalize the
acquisition of certain formulations and product technology
 
in the mining industry.
 
Net cash flows provided by financing activities were $168.7 million
 
in the first six months of 2020 compared to cash used in
financing activities of $35.3 million in the first six months
 
of 2019.
 
The $204.0 million increase in net cash flows was due primarily
to additional borrowings of $205.5 million on the Company’s
 
revolving credit facility in the current year compared to
 
payments of
$24.0 million in the prior year.
 
As a precautionary measure in response to the economic uncertainty
 
related to COVID-19, the
Company drew down most of the available liquidity
 
on its revolving credit facility during the second half of March
 
2020, which drove
the large change in borrowings compared
 
to the prior year.
 
This increase in borrowings was partially offset
 
by $18.7 million of
scheduled repayments under the Company’s
 
term loan agreement.
 
In addition, the Company paid $13.7 million of cash dividends
during the first six months of 2020, a $3.8 million or
 
38% increase in cash dividends compared to the prior year,
 
primarily due to the
approximately 4.3 million shares issued at closing of
 
the Combination, as well as the prior year cash dividend per
 
share increase
initiated in May 2019.
 
Finally, during the
 
first six months of 2020, the Company used $1.0 million to
 
purchase the remaining
noncontrolling interest in its South Africa affiliate.
 
Prior to this buyout, the Company’s
 
South Africa affiliate made a distribution to
the prior noncontrolling affiliate shareholder
 
of approximately $0.8 million in the first six months of
 
2020.
 
There were no similar
noncontrolling interest activities in the first six months
 
of 2019.
 
As previously disclosed in its Annual Report on Form 10
 
-K for the year ended December 31, 2019 (the “2019 Form
 
10-K”), on
August 1, 2019, the Company completed the Combination,
 
whereby the Company acquired all of the issued
 
and outstanding shares of
Houghton from Gulf Houghton Lubricants, Ltd. in accordance with
 
the Share Purchase Agreement dated April 4, 2017.
 
The final
purchase consideration was comprised of: (i) $170.8 million
 
in cash; (ii) the issuance of approximately 4.3 million shares of
 
common
stock of the Company with par value of $1.00, comprising
 
24.5% of the common stock of the Company at closing; and
 
(iii) the
Company’s refinancing
 
of $702.6 million of Houghton’s
 
indebtedness at closing.
 
Cash acquired in the Combination was $75.8
million. Prior to the Combination, the Company secured
 
commitments from certain banks for a new credit facility
 
(as amended, the
“New Credit Facility”).
 
Concurrent with the closing of the Combination on August
 
1, 2019, the New Credit Facility became effective
 
,
replacing the Company’s
 
previous credit facility.
 
See Note 2 and Note 15 of Notes to Condensed Consolidated
 
Financial Statements.
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
35
As of June 30, 2020, the Company had New Credit Facility borrowings
 
outstanding of $1,109.3 million.
 
As of December 31,
2019, the Company had New Credit Facility borrowings
 
outstanding of $922.4 million.
 
The Company has unused capacity under the
Revolver of approximately $15 million, net of bank
 
letters of credit of approximately $8 million, as of June 30
 
,
 
2020.
 
As mentioned
above, the Company drew down most of the available
 
capacity on the Revolver in the second half of March 2020
 
as a precautionary
measure in response to the economic uncertainty
 
related to COVID-19.
 
The Company’s other debt obligations
 
are primarily industrial
development bonds, bank lines of credit and municipality
 
-related loans, which totaled $11.9 million
 
as of June 30, 2020 and $12.6
million as of December 31, 2019, respectively.
 
Total unused capacity
 
under these arrangements as of June 30, 2020 was
approximately $37 million.
 
The Company’s total net debt
 
as of June 30, 2020 was $798.7 million.
 
As of June 30,
 
2020 and
December 31, 2019, the Company was in compliance with
 
all of the New Credit Facility covenants.
 
The New Credit Facility required the Company to fix its variable
 
interest rates on at least 20% of its total Term
 
Loans. In order to
satisfy this requirement as well as to manage the
 
Company’s exposure to variable
 
interest rate risk associated with the New Credit
Facility, in November
 
2019, the Company entered into $170.0 million notional
 
amounts of three-year interest rate swaps at a base rate
of 1.64% plus an applicable margin as provided
 
in the New Credit Facility, based
 
on the Company’s consolidated
 
net leverage ratio.
At the time the Company entered into the swaps, and
 
as of June 30, 2020, this aggregate rate was 3.1%.
 
The Company expects to realize Combination cost
 
synergies on a pro forma combined company
 
basis of $53 million in 2020, $65
million in 2021 and $75 million in 2022.
 
The Company estimates that it realized approximately $22 million
 
of cost savings during the
first six months of 2020 on a combined company pro
 
forma basis, increasing its cumulative synergies
 
realized in the eleven months
since closing of the Combination to approximately $29
 
million.
 
The Company expects to incur additional costs and
 
make associated cash payments to integrate Quaker
 
and Houghton and
continue realizing the Combination’s
 
total anticipated cost synergies.
 
The Company expects cash payments,
including those pursuant
to the QH Program, described below,
 
but excluding incremental capital expenditures related to the
 
Combination, will generally
approximate one-times its total anticipated cost synergies.
 
The Company expects to incur these costs over a three-year
 
period post-
close, with a significant portion of these costs incurred
 
or expected to be incurred in 2019 and the current year.
 
The Company
incurred $16.5 million of total Combination,
 
integration and other acquisition-related expenses in the first six months
 
of 2020,
including $0.8 million of accelerated depreciation, described in
 
the Non-GAAP measures of this Item below.
 
The Company had
aggregate net cash outflows of approximately $13.8 million
 
related to the Combination,
 
integration and other acquisition-related
expenses during the first six months of 2020.
 
Comparatively, during the
 
first six months of 2019, the Company incurred $10.8 million
of total Combination,
 
integration and other acquisition-related expenses, including
 
$1.7 million of ticking fees, described in the Non-
GAAP Measures of this Item below,
 
and aggregate net cash outflows related to these costs were $10.4
 
million.
 
Quaker Houghton’s management
 
approved, and the Company initiated, a global restructuring
 
plan (the “QH Program”) in the
third quarter of 2019 as part of its planned cost synergies
 
associated with the Combination.
 
The QH Program includes restructuring
and associated severance costs to reduce total headcount
 
by approximately 325 people globally and plans for the closure
 
of certain
manufacturing and non-manufacturing facilities.
 
In connection with the plans for closure of certain manufacturing
 
and non-
manufacturing facilities, the Company made a decision
 
to make available for sale certain facilities during the second
 
quarter of 2020
resulting in the reclassification of approximately $11.7
 
million of buildings and land to other current assets as of June 30,
 
2020.
 
The
Company expects to receive amounts in excess of
 
net book value for the properties held for sale.
 
Additionally, as a result
 
of the QH
Program, the Company recognized $2.2 million of restructuring
 
and related charges in the first six months of 2020.
 
The exact timing
and total costs associated with the QH Program will depend
 
on a number of factors and is subject to change;
 
however, the Company
currently expects reduction in headcount and site closures
 
will continue to occur during 2020 and 2021 under the QH Program
 
and
estimates that total costs related to the QH Program will approximate
 
one-times the anticipated cost synergies realized
 
under this
program.
 
The Company made cash payments related to the settlement of
 
restructuring liabilities under the QH Program during the
first six months of 2020 of approximately $9.6 million.
 
In the fourth quarter of 2018, the Company began the
 
process of terminating its non-contributory U.S. pension plan (“the Legacy
Quaker U.S. Pension Plan”).
 
The Company completed the Legacy Quaker U.S. Pension
 
Plan termination during the first quarter of
2020.
 
In order to terminate the Legacy Quaker U.S. Pension Plan in accordance
 
with I.R.S. and Pension Benefit Guaranty
Corporation requirements, the Company was required
 
to fully fund the Legacy Quaker U.S. Pension Plan on a termination
 
basis and
the amount necessary to do so was approximately
 
$1.8 million, subject to final true up adjustments.
 
In July 2020, the Company
finalized the amount of liability and related annuity
 
payments and expects to receive a refund in premium of approximately
 
$2 million
in August 2020.
 
In addition, the Company recorded a non-cash pension settlement
 
charge at plan termination of approximately $22.7
million.
 
As of June 30, 2020, the Company’s
 
gross liability for uncertain tax positions, including interest and
 
penalties, was $28.0 million.
The Company cannot determine a reliable estimate of
 
the timing of cash flows by period related to its uncertain tax
 
position liability.
However, should the entire liability
 
be paid, the amount of the payment may be reduced by up
 
to $8.0 million as a result of offsetting
benefits in other tax jurisdictions.
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
36
The Company believes that its existing cash, anticipated
 
cash flows from operations and available additional liquidity
 
will be
sufficient to support its operating requirements
 
and fund its business objectives for at least the next twelve months,
 
including but not
limited to, payments of dividends to shareholders, costs related
 
to the Combination and integration, pension plan contributions,
 
capital
expenditures, other business opportunities and other
 
potential contingencies.
 
The Company’s liquidity is affected
 
by many factors,
some based on normal operations of our business and
 
others related to the impact of the pandemic on our business
 
and on global
economic conditions as well as industry uncertainties, which we cannot
 
predict.
 
We also cannot predict
 
economic conditions and
industry downturns or the timing, strength or duration
 
of recoveries.
 
We may seek,
 
as we believe appropriate, additional debt or
equity financing which would provide capital for corporate
 
purposes, working capital funding, additional liquidity needs
 
or to fund
future growth opportunities, including possible acquisitions
 
and investments.
 
The timing and amount of potential capital requirements
cannot be determined at this time and will depend
 
on a number of factors, including the actual and projected
 
demand for our products,
specialty chemical industry conditions, competitive factors,
 
and the condition of financial markets, among others.
 
Critical Accounting Policies and Estimates
The Company’s critical accounting
 
policies and estimates, as set forth in its 2019 Form 10-K remain
 
materially consistent.
 
However, due to the current impact
 
as well as the volatility and uncertainty in the economic outlook
 
as a result of COVID-19, the
Company re-evaluated certain of its estimates, most notably
 
its estimates and assumptions with regards to goodwill and
 
other
intangible assets during the first quarter of 2020.
 
Goodwill and other intangible assets:
The Company accounts for business combinations under
 
the acquisition method of
accounting.
 
This method requires the recording of acquired assets, including
 
separately identifiable intangible assets, at their
acquisition date fair values.
 
Any excess of the purchase price over the estimated fair value of
 
the identifiable net assets acquired is
recorded as goodwill.
 
The determination of the estimated fair value of assets acquired
 
requires management’s judgment
 
and often
involves the use of significant estimates and assumptions,
 
including assumptions with respect to future cash inflows
 
and outflows,
discount rates, royalty rates, asset lives and market multiples, among
 
other items.
 
When necessary, the Company
 
consults with
external advisors to help determine fair value.
 
For non-observable market values, the Company may determine
 
fair value using
acceptable valuation principles, including the excess earnings,
 
relief from royalty,
 
lost profit or cost methods.
The Company amortizes definite-lived intangible assets on
 
a straight-line basis over their useful lives.
 
Goodwill and intangible
assets that have indefinite lives are not amortized and are
 
required to be assessed at least annually for impairment.
 
The Company
completes its annual goodwill and indefinite-lived intangible asset impairment
 
test during the fourth quarter of each year.
 
The
Company continuously evaluates if triggering events indicate
 
a possible impairment in one or more of its indefinite
 
-lived or long-lived
assets.
 
As of March 31, 2020, the Company evaluated the initial impact
 
of COVID-19 on the Company’s
 
operations, as well as the
volatility and uncertainty in the economic outlook as a
 
result of COVID-19,
 
to determine if this indicated it was more likely than not
that the carrying value of any of the Company’s
 
indefinite-lived or long-lived assets was not recoverable.
 
While the impact of
COVID-19 has already had a negative effect
 
on the Company’s operations
 
and was expected to significantly impact the Company’s
full year 2020 results, in evaluating if a triggering
 
event was present for one or more of the Company indefinite-lived
 
or long-lived
assets, the Company also considered the carrying value
 
and estimated fair value for each asset, as well as the Company’s
 
expected
impact from COVID-19 on each specific asset.
 
The Company concluded that the impact of COVID-19
 
did not represent a triggering
event as of March 31, 2020 with regards to the Company’s
 
indefinite-lived and long-lived assets, except for the Company’s
 
Houghton
and Fluidcare trademark and tradename indefinite
 
-lived intangible assets.
 
Given the relatively short period of time between the
 
fair value determination for the acquired Houghton and
 
Fluidcare trademark
and tradename indefinite-lived intangible assets as of the
 
closing of the Combination on August 1, 2019, and the 2019 annual
impairment testing date of October 1, the Company’s
 
2019 annual impairment assessment concluded that the $242.0
 
million carrying
value of acquired Houghton and Fluidcare indefinite-lived
 
intangible assets generally approximated fair value, with excess fair value
of less than 5%.
 
Because of the previously concluded relatively narrow gap
 
between fair value and carrying value, the Company
concluded in the first quarter of 2020 that the expected
 
current year impact from COVID-19 on the Company’s
 
net sales represented a
triggering event.
 
As a result of the conclusion, the Company completed an interim
 
quantitative indefinite-lived intangible asset
impairment assessment as of March 31, 2020.
 
The determination of estimated fair value of the Houghton
 
and Fluidcare trademark and tradename indefinite-lived assets was
based on a relief from royalty valuation method which
 
requires management’s
 
judgment and often involves the use of significant
estimates and assumptions, including assumptions with respect
 
to the weighted average cost of capital (“WACC”)
 
as well as projected
net sales.
 
In completing the interim quantitative impairment
 
assessment as of March 31, 2020, the Company used a WACC
assumption of approximately 10% as well as current year
 
forecasted net sales and management’s
 
estimates with respect to future net
sales growth rates specific to legacy Houghton’s
 
net sales.
 
As a result of an increase in the WACC
 
assumption as of March 31, 2020,
compared to the prior year fourth quarter annual impairment
 
assessment, and the significant current year decline in projected
 
legacy
Houghton net sales due to the impact of COVID-19,
 
the Company concluded that the estimated fair values of these intangib
 
le assets
were less than their carrying values and that an
 
impairment charge to write down their carrying values
 
to their estimated fair values
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
37
was warranted.
 
This resulted in a first quarter of 2020 non-cash impairment
 
charge of $38.0 million for these indefinite-lived
intangible assets.
 
The Company performed a qualitative assessment over these
 
indefinite-lived intangible assets as of June 30, 2020
and concluded that no further impairment indicators existed.
 
The book value of these assets as of June 30, 2020 was $204.0
 
million.
 
As of June 30, 2020, the Company continued to evaluate the on
 
-going impact of COVID-19 on the Company’s
 
operations, and
the volatility and uncertainty in the economic outlook as a result of
 
COVID-19 to determine if again this indicated it was more
 
likely
than not that the carrying value of any of the Company’s
 
reporting units or indefinite-lived or long-lived assets was not recoverable.
 
The Company concluded that the impact of COVID-19 did
 
not represent a triggering event as of June 30, 2020
 
with regards to any of
the Company’s repor
 
ting units or indefinite-lived and long-lived assets.
 
If the current economic conditions worsen or projections of
the timeline for recovery are significantly extended, then
 
the Company may conclude in the future that the impact from
 
COVID-19
requires
 
the need to perform further interim quantitative impairment
 
tests, which could result in additional impairment charges
 
in the
future.
Non-GAAP Measures
The information in this Report includes non-GAAP (unaudited)
 
financial information that includes EBITDA, adjusted EBITDA,
adjusted EBITDA margin, non-GAAP operating
 
income, non-GAAP operating margin, non-GAAP net income
 
and non-GAAP
earnings per diluted share.
 
The Company believes these non-GAAP financial measures
 
provide meaningful supplemental information
as they enhance a reader’s understanding of the
 
financial performance of the Company,
 
are indicative of future operating performance
of the Company,
 
and facilitate a comparison among fiscal periods, as the non-GAAP financial
 
measures exclude items that are not
considered indicative of future operating performance
 
or not considered core to the Company’s
 
operations.
 
Non-GAAP results are
presented for supplemental informational purposes only
 
and should not be considered a substitute for the financial information
presented in accordance with GAAP.
 
The Company presents EBITDA which is calculated as net (loss)
 
income attributable to the Company before depreciation
 
and
amortization, interest expense, net, and taxes on (loss) income
 
before equity in net income of associated companies.
 
The Company
also presents adjusted EBITDA which is calculated as EBITDA
 
plus or minus certain items that are not considered indicative of
 
future
operating performance or not considered core to the Company’s
 
operations.
 
In addition, the Company presents non-GAAP operating
income which is calculated as operating income (loss) plus
 
or minus certain items that are not considered indicative of future operating
performance or not considered core to the Company’s
 
operations.
 
Adjusted EBITDA margin and non-GAAP operating
 
margin are
calculated as the percentage of adjusted EBITDA and
 
non-GAAP operating income to consolidated net sales, respectively.
 
The
Company believes these non-GAAP measures provide
 
transparent and useful information and are widely used by analysts, investors,
and competitors in our industry as well as by management
 
in assessing the operating performance of the Company on
 
a consistent
basis.
Additionally, the
 
Company presents non-GAAP net income and non-GAAP earnings
 
per diluted share as additional performance
measures.
 
Non-GAAP net income is calculated as adjusted EBITDA, defined
 
above, less depreciation and amortization, interest
expense, net, and taxes on (loss) income before equity
 
in net income of associated companies, in each cash adjusted,
 
as applicable, for
any depreciation, amortization, interest or tax impacts resulting
 
from the non-core items identified in the reconciliation
 
of net (loss)
income attributable to the Company to adjusted EBITDA.
 
Non-GAAP earnings per diluted share is calculated as non-GAAP net
income per diluted share as accounted for under the
 
“two-class share method.”
 
The Company believes that non-GAAP net income
and non-GAAP earnings
 
per diluted share provide transparent and useful information
 
and are widely used by analysts, investors, and
competitors in our industry as well as by management in
 
assessing the operating performance of the Company on a consistent
 
basis.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
38
The following tables reconcile the Company’s
 
non-GAAP financial measures (unaudited) to their most
 
directly comparable
GAAP (unaudited) financial measures (dollars in thousands unless
 
otherwise noted, except per share amounts):
Non-GAAP Operating Income and Margin Reconciliations
Three Months Ended
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
Operating income (loss)
$
2,238
$
20,531
$
(10,206)
$
40,360
Fair value step up of inventory sold (a)
226
226
Houghton combination, integration and other
 
 
acquisition-related expenses (b)
8,253
4,604
16,529
9,087
Restructuring and related charges (c)
486
2,202
Customer bankruptcy costs (d)
463
Charges related to the settlement of a non-core
 
equipment sale (e)
384
384
Indefinite-lived intangible asset impairment (f)
38,000
Non-GAAP operating income
$
11,203
$
25,519
$
47,214
$
49,831
Non-GAAP operating margin (%) (m)
3.9%
12.4%
7.1%
11.9%
 
EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin
and Non-GAAP Net Income Reconciliations
Three Months Ended
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
Net (loss) income attributable to Quaker Chemical Corporation
$
(7,735)
$
15,591
$
(36,116)
$
29,435
Depreciation and amortization (b)(k)
21,158
4,843
42,742
9,702
Interest expense, net (b)
6,811
733
15,272
1,509
Taxes on (loss)
 
income before equity in net income
 
of associated companies (l)
3,222
4,800
(9,848)
9,729
EBITDA
23,456
25,967
12,050
50,375
Equity income in a captive insurance company (g)
(482)
(390)
(155)
(736)
Fair value step up of inventory sold (a)
226
226
Houghton combination, integration and other
 
acquisition-related expenses (b)
7,963
4,604
15,766
9,087
Restructuring and related charges (c)
486
2,202
Customer bankruptcy costs (d)
463
Charges related to the settlement of a non-core
 
equipment sale (e)
384
384
Indefinite-lived intangible asset impairment (f)
38,000
Pension and postretirement benefit costs,
 
non-service components (h)
341
895
23,866
1,791
Currency conversion impacts of hyper-inflationary economies (i)
73
(31)
124
163
Adjusted EBITDA
$
32,063
$
31,429
$
92,542
$
61,064
Adjusted EBITDA margin (%) (m)
11.2%
15.3%
13.9%
14.6%
Adjusted EBITDA
$
32,063
$
31,429
$
92,542
$
61,064
Less: Depreciation and amortization (b)
20,869
4,843
41,980
9,702
Less: Interest expense, net - adjusted (b)
6,811
(130)
15,272
(216)
Less: Taxes on (loss)
 
income before equity in net income
 
of associated companies - adjusted (j)(l)
673
5,787
7,136
11,827
Non-GAAP net income
$
3,710
$
20,929
$
28,154
$
39,751
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
39
Non-GAAP Earnings per Diluted Share Reconciliations
Three Months Ended
Six Months Ended
June 30,
June 30,
2020
2019
2020
2019
GAAP (loss) earnings per diluted share attributable to
Quaker Chemical Corporation common shareholders
$
(0.43)
$
1.17
$
(2.03)
$
2.20
Equity income in a captive insurance company
 
per diluted share (g)
(0.03)
(0.03)
(0.01)
(0.06)
Fair value step up of inventory sold per diluted share (a)
0.01
0.01
Houghton combination, integration and other
 
 
acquisition-related expenses per diluted share (b)
0.37
0.34
0.73
0.69
Restructuring and related charges per diluted
 
share (c)
0.02
0.09
Customer bankruptcy costs per diluted share (d)
0.02
Charges related to the settlement of a non-core
 
equipment
 
sale per diluted share (e)
0.02
0.02
Indefinite-lived intangible asset impairment per diluted
 
share
(f)
1.65
Pension and postretirement benefit costs,
 
non-service components per diluted share (h)
0.01
0.06
0.89
0.11
Currency conversion impacts of hyper-inflationary
 
 
economies per diluted share (i)
0.01
0.01
0.01
Impact of certain discrete tax items per diluted share (j)
0.25
0.23
Non-GAAP earnings per diluted share (n)
$
0.21
$
1.56
$
1.59
$
2.97
(a)
 
Fair value step up of inventory sold relates to an
 
expense associated with selling inventory of acquired businesses during
 
the
second quarter of 2020,
 
which was adjusted to fair value as a part of purchase accounting.
 
This increase to COGS is not
indicative of the future operating performance of the
 
Company.
 
(b)
 
Houghton combination,
 
integration and other acquisition-related expenses include certain
 
legal, financial, and other advisory and
consultant costs incurred in connection with due diligence,
 
regulatory approvals, integration planning, as well as certain
 
one-time
labor costs associated with the Company’s
 
acquisition-related activities.
 
These costs are not indicative of the future operating
performance of the Company.
 
Approximately $2.3 million and $3.5 million in the
 
three and six months ended June 30, 2019,
respectively, of
 
these pre-tax costs were considered non-deductible for the purpose of
 
determining the Company’s effective
 
tax
rate, and, therefore, taxes on (loss) income before equity
 
in net income of associated companies - adjusted reflects the
 
impact of
these items.
 
During the three and six months
 
ended June 30, 2020, the Company recorded $0.3 million and
 
$0.8 million of
accelerated depreciation related to certain of the Company’s
 
facilities, which is included in the caption “Houghton
 
combination,
integration and other acquisition-related expenses” in the
 
reconciliation of operating income (loss) to non-GAAP operating
income and included in the caption “Depreciation and
 
amortization” in the reconciliation of net (loss) income attributable
 
to the
Company to EBITDA, but excluded from the caption
 
“Depreciation and amortization” in the reconciliation of adjusted
 
EBITDA
to non-GAAP net income attributable to the Company.
 
During the three and six months ended June 30,
 
2019, the Company
incurred $0.9 million and $1.7 million, respectively,
 
of ticking fees to maintain the bank commitment related
 
to the Combination.
 
These interest costs are included in the caption “Interest expense,
 
net” in the reconciliation of net (loss) income attributable
 
to the
Company to EBITDA, but are excluded from the caption
 
“Interest expense, net – adjusted” in the reconciliation of adjusted
EBITDA to non-GAAP net income.
 
See Note 2 of Notes to Condensed Consolidated Financial Statements,
 
which appears in Item
1 of this Report.
(c)
 
Restructuring and related charges represent
 
the costs incurred by the Company associated with the QH restructuring
 
program
which was initiated in the third quarter of 2019 as part
 
of the Company’s plan
 
to realize cost synergies associated with the
Combination.
 
These costs are not indicative of the future operating performance
 
of the Company.
 
See Note 7 of Notes to
Condensed Consolidated Financial Statements, which appears
 
in Item 1 of this Report.
 
(d)
 
Customer bankruptcy costs represent the cost associated
 
with a specific reserve for trade accounts receivable related
 
to a customer
who filed for bankruptcy protection.
 
These expenses are not indicative of the future operating
 
performance of the Company.
(e)
 
Charges related to the settlement of a non-core
 
equipment sale represent the pre-tax charge related to
 
a one-time, uncommon,
customer settlement associated with a prior sale of non
 
-core equipment.
 
These charges are not indicative of the future operating
performance of the Company.
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
40
(f)
 
Indefinite-lived intangible asset impairment represents the
 
non-cash charge taken to write down the value
 
of certain indefinite-
lived intangible assets associated with the Houghton
 
Combination.
 
The Company has no prior history of goodwill or intangible
asset impairments and this charge is not indicative
 
of the future operating performance of the Company.
 
See Note 14 of Notes to
Condensed Consolidated Financial Statements, which app
 
ears in Item 1 of this Report.
(g)
 
Equity income in a captive insurance company represents the
 
after-tax income attributable to the Company’s
 
interest in Primex,
Ltd. (“Primex”), a captive insurance company.
 
The Company holds a 33% investment in and has significant
 
influence over
Primex, and therefore accounts for this interest under the
 
equity method of accounting.
 
The income attributable to Primex is not
indicative of the future operating performance of the
 
Company and is not considered core to the Company’s
 
operations.
(h)
 
Pension and postretirement benefit costs, non-service components
 
represent the pre-tax, non-service component of the Company’s
pension and postretirement net periodic benefit cost in
 
each period.
 
These costs are not indicative of the future operating
performance of the Company.
 
The six months ended June 30, 2020 includes the $22.7
 
million settlement charge for the
Company’s termination
 
of the Legacy Quaker U.S. Pension Plan.
 
See Note 9 of Notes to Condensed Consolidated Financial
Statements, which appears in Item 1 of this Report.
(i)
 
Currency conversion impacts of hyper-inflationary economies represents
 
the foreign currency remeasurement impacts associated
with the Company’s affiliates
 
whose local economies are designated as hyper-inflationary
 
under U.S. GAAP.
 
During the three
and six months ended June 30, 2020 and 2019, the
 
Company incurred non-deductible, pre-tax charges related
 
to the Company’s
Argentine affiliates.
 
These charges related to the immediate recognition
 
of foreign currency remeasurement in the Condensed
Consolidated Statements of Operations associated with
 
these entities are not indicative of the future operating
 
performance of the
Company.
 
See Note 1 of Notes to Condensed Consolidated Financial Statements, which
 
appears in Item 1 of this Report.
(j)
 
The impacts of certain discrete tax items included the impact of
 
changes in the valuation allowance for foreign tax credits
acquired with the Combination, changes in withholding
 
tax rates and the associated impact on previously accrued
 
for distributions
at certain of the Company’s
 
Asia/Pacific subsidiaries, additional reserves for uncertain
 
tax positions related to tax audits at certain
of the Company’s EMEA
 
subsidiaries, as well as the offsetting impact and
 
amortization of a deferred tax benefit the Company
recorded in the fourth quarter of 2019 related to an intercompany
 
intangible asset transfer.
 
See Note 11 of Notes to Condensed
Consolidated Financial Statements, which appears in Item
 
1 of this Report.
 
(k)
 
Depreciation and amortization for the three and six
 
months ended June 30, 2020 includes $0.3 million and $0.7
 
million,
respectively, of
 
amortization expense recorded within equity in net income of
 
associated companies in the Company’s
 
Condensed
Consolidated Statements of Operations, which is attributable
 
to the amortization of the fair value step up for the Company’s
 
50%
interest in a Houghton joint venture in Korea as a result
 
of required purchase accounting.
(l)
 
Taxes on (loss)
 
income before equity in net income of associated companies – adjusted
 
presents the impact of any current and
deferred income tax expense (benefit), as applicable, of the
 
reconciling items presented in the reconciliation of net (loss) income
attributable to Quaker Chemical Corporation to adjusted
 
EBITDA, and was determined utilizing the applicable rates in the taxing
jurisdictions in which these adjustments occurred, subject
 
to deductibility.
 
Fair value step up of inventory sold described in (a)
resulted in incremental taxes of less than $0.1 million during
 
both the three and six months ended June 30, 2020
 
.
 
Houghton
combination,
 
integration and other acquisition-related expenses described
 
in (b) resulted in incremental taxes of $1.5 million and
$3.4
 
million for the three and six months ended June 30, 2020,
 
respectively, and $0.7 million
 
and $1.6 million for the three and
six months ended June 30, 2019,
 
respectively.
 
Restructuring and related charges described in (c) resulted
 
in incremental taxes of
$0.1 million and $0.5 million for the three and six months
 
ended June 30, 2020.
 
Customer bankruptcy costs described in (d)
resulted in incremental taxes of $0.1 million during the
 
six months ended June 30, 2020.
 
Charges related to the settlement of a
non-core equipment sale described in (e)
 
resulted in incremental taxes of $0.1 million for both the three
 
and six months ended
June 30, 2019.
 
Indefinite-lived intangible asset impairment described in (f) resulted
 
in incremental taxes of $8.7 million during
the six months ended June 30, 2020.
 
Pension and postretirement benefit costs, non-service components
 
described in (h) resulted
in incremental taxes of $0.1 million and $8.0 million
 
for the three and six months ended June 30, 2020, respectively,
 
and $0.2
million and $0.4 million for the three and six months ended
 
June 30, 2019, respectively.
 
Tax impact of certain
 
discrete items
described in (j) resulted in incremental taxes of $4.4 million
 
and $4.0 million for the three and six months ended
 
June 30, 2020.
 
(m)
 
The Company calculates adjusted EBITDA margin
 
and non-GAAP operating margin as the percentage
 
of adjusted EBITDA and
non-GAAP operating income to consolidated net sales.
(n)
 
The Company calculates non-GAAP earnings per diluted share
 
as non-GAAP net income attributable to the Company
 
per
weighted average diluted shares outstanding using the “two-class share
 
method” to calculate such in each given period.
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
41
Off-Balance Sheet Arrangements
The Company had no material off-balance
 
sheet items, as defined under Item 303(a)(4) of Regulation S-K as of
 
June 30, 2020.
 
The Company’s only
 
off-balance sheet items outstanding as of June 30,
 
2020 represented approximately $14 million of total bank
letters of credit and guarantees.
 
The bank letters of credit and guarantees are not significant to
 
the Company’s liquidity
 
or capital
resources.
 
See also Note 15 of Notes to Condensed Consolidated Financial
 
Statements, which appears in Item 1 of this Report.
 
Operations
Consolidated Operations Review – Comparison of the Second
 
Quarter of 2020 with the Second Quarter of 2019
Net sales were $286.0 million in the second quarter of
 
2020 compared to $205.9 million in the second quarter
 
of 2019.
 
The net
sales increase of 39%
 
quarter-over-quarter includes net sales from Houghton
 
and Norman Hay of $142.5 million.
 
Without Houghton
 
and Norman Hay net sales, the Company’s
 
current quarter net sales would have declined approximately
 
30%, which reflects a
decrease in sales volumes of approximately 27
 
%
 
and a negative impact from foreign currency translation of 4%
 
partially offset by an
increase from selling price and product mix of 1%.
 
The primary driver of the volume decline in the current quarter
 
was the negative
impact of COVID-19 on global production levels.
COGS were $188.7 million in the second quarter of 2020
 
compared to $130.7 million in the second quarter of 2019
 
.
 
The increase
in COGS of 44%
 
was primarily due to the inclusion of Houghton and Norman
 
Hay sales and associated COGS, as well as $0.3 million
of accelerated depreciation charges and $0.2
 
million of an inventory fair value step up charge
 
described in the Non-GAAP Measures
section of this Item above, partially offset by
 
lower COGS on the decline in legacy Quaker net sales, described
 
above.
Gross profit in the second quarter of 2020 of $97.4 million
 
increased $22.2 million or 30% from the second quarter
 
of 2019,
 
due
primarily to Houghton and Norman Hay net sales, noted
 
above.
 
The Company’s reported gross margin
 
in the current quarter was
34.0%
 
compared to 36.5% in the second quarter of 2019.
 
The decrease in gross margin quarter-over-quarter
 
was primarily due to the
significantly lower volumes in the current quarter and the
 
related impact from fixed manufacturing costs, as well as price
 
and product
mix largely due to lower gross margins
 
in the legacy Houghton business, partially offset by
 
certain COGS decreases as a result of the
Company’s progression
 
on Combination-related logistics and procurement cost savings
 
initiatives.
 
SG&A in the second quarter of 2020 increased $36.6 million
 
compared to the second quarter of 2019 due primarily to
 
additional
SG&A from Houghton and Norman Hay.
 
This increase was partially offset by lower SG&A due
 
to foreign currency translation, the
impact of the sales decline on direct selling costs, lower incentive
 
compensation on reduced Company performance, the impact
COVID-19 cost savings actions,
 
including lower travel expenses, and the benefits of realized
 
cost savings associated with the
Combination.
During the second quarter of 2020,
 
the Company incurred $8.0 million of Combination,
 
integration and other acquisition-related
expenses, primarily for professional fees related to Houghton
 
integration activities.
 
Comparatively, the Company
 
incurred $4.6
million of expenses in the prior year second quarter,
 
primarily for integration planning and regulatory approvals.
 
See the Non-GAAP
Measures section of this Item, above.
The Company initiated a restructuring program during
 
the third quarter of 2019 as part of its global plan to realize cost
 
synergies
associated with the Combination.
 
The Company expects reductions in headcount and site closures under
 
this program to continue
during 2020 and 2021.
 
The Company recorded additional restructuring and related
 
charges of $0.5 million related to this program
during the second quarter of 2020 and there were no similar
 
restructuring charges recorded during the second
 
quarter of 2019.
 
See the
Non-GAAP Measures section of this Item, above.
Operating income in the second quarter of 2020 was $2.2
 
million compared to $20.5 million in the second quarter of 2019.
 
Excluding the Combination,
 
integration and other acquisition-related charges, restructuring
 
and related charges and other non-core
items, the Company’s
 
current quarter non-GAAP operating income decreased to $11.2
 
million compared to $25.5 million in the prior
year quarter, primarily due to
 
the negative impact of COVID-19, which more than offset
 
the added net sales and operating income
from Houghton and Norman Hay and the benefits from
 
cost savings related to the Combination.
The Company had other expense, net, of $1.0 million
 
in the second quarter of 2020 compared to other income, net, of
 
less than
$0.1 million in the second quarter of 2019.
 
The quarter-over-quarter change was primarily driven
 
by higher foreign currency
transaction losses in the second quarter of 2020 as compared to
 
the prior year second quarter, partially
 
offset by lower non-service
components of pension and postretirement benefit costs.
 
Interest expense,
 
net, increased $6.1
 
million compared to
 
the second quarter
 
of 2019, as
 
a result of
 
additional borrowings
 
under
the Company’s term loans
 
and revolving credit facility to finance the closing of the Combination
 
on August 1, 2019.
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
42
The Company’s effective
 
tax rates for the second quarters of 2020 and 2019 were an expense of
 
57.9% and 24.2%, respectively.
 
The Company’s current
 
quarter effective tax rate was driven by the impact
 
of certain tax charges in the current period
 
relating to
changes in the valuation allowance for foreign tax
 
credits acquired with the Combination and additional charges
 
for uncertain tax
positions resulting from certain foreign tax audits combined
 
with pre-tax losses as a result of the negative impacts
 
of COVID-19.
 
Excluding the impact of these items as well as all other non-core
 
items in each quarter, described in
 
the Non-GAAP Measures section
of this Item, above, the Company estimates that its second
 
quarters of 2020 and 2019 effective tax rates would
 
have been
approximately 18% and 22%, respectively.
 
The Company may experience continued volatility in its effectiv
 
e
 
tax rates due to several
factors, including the timing of tax audits and the expiration
 
of applicable statutes of limitations as they relate to uncertain
 
tax
positions, the unpredictability of the timing and
 
amount of certain incentives in various tax jurisdictions, the treatment
 
of certain
acquisition-related costs and the timing and amount
 
of certain share-based compensation-related tax benefits, among
 
other factors.
 
In
addition, the foreign tax credit valuation allowance is based
 
on a number of variables, including forecasted earnings,
 
which may vary.
 
Equity in net income of associated companies increased $0.5 million
 
in the second quarter of 2020 compared to the second
quarter of 2019, primarily due to additional earnings
 
from the Company’s 50% interest in
 
a joint venture in Korea and higher earnings
from the Company’s interest
 
in a captive insurance company.
 
See the Non-GAAP Measures section of this Item, above.
Net income attributable to non-controlling interest was consistent
 
at less than $0.1 million in both the second quarters of
 
2020 and
2019.
Foreign exchange negatively impacted the Company’s
 
second quarter results by approximately $0.11
 
per diluted share, primarily
due to approximately $1.9 million of higher foreign
 
exchange transaction losses quarter-over-quarter as well
 
as the negative impact
from foreign currency translation on earnings due to the
 
strengthening of the U.S. dollar against certain major foreign currencies
 
in the
current quarter.
Consolidated Operations Review – Comparison of the First Six
 
Months of 2020 with the First Six Months of 2019
Net sales were $664.6 million in the first six months of
 
2020 compared to $417.1 million in the first six months of
 
2019.
 
The net
sales increase of 59% year-over-year includes
 
net sales from Houghton and Norman Hay of $332.8 million.
 
Without Houghton and
Norman Hay net sales, the Company’s
 
current year net sales would have declined approximately 20%,
 
which reflects a decrease in
sales volumes of approximately 16%, a negative impact
 
from foreign currency translation of 3% and a decrease from
 
selling price and
product mix of 1%.
 
Consistent with the second quarter of 2020 description above,
 
the primary driver of the volume decline in the
current year was the negative impact of COVID-19 on
 
global production levels.
COGS were $433.4 million in the first six months of 2020
 
compared to $266.2 million in the first six months of
 
2019.
 
The
increase in COGS of 63% was primarily due to the inclusion
 
of Houghton and Norman Hay sales and associated COGS, as
 
well as
$0.8 million of accelerated depreciation charges
 
and $0.2 million of an inventory fair value step up charge
 
described in the Non-
GAAP Measures section of this Item above, partially
 
offset by lower COGS on the decline in legacy Quaker
 
net sales, described
above.
Gross profit in the first six months of 2020 increased $80.3
 
million or 53% from the first six months of 2019, due
 
primarily to the
added Houghton and Norman Hay net sales.
 
The Company’s reported
 
gross margin in the current year was 34.8% compared
 
to 36.2%
in the first six months of 2019.
 
The decrease in gross margin quarter-over-quarter
 
was primarily the result of the same drivers
described in the second quarter description above.
 
SG&A in the first six months of 2020 increased $83.9
 
million compared to the first six months of 2019 due
 
primarily to additional
SG&A from Houghton and Norman Hay,
 
partially offset by the same decreases in SG&A described
 
in the second quarter description
above.
 
During the first six months of 2020, the Company incurred
 
$15.9 million of Combination, integration and other acquisition-
related expenses, primarily for professional fees related
 
to Houghton integration activities.
 
Comparatively,
 
the Company incurred
$9.1 million of expenses in the prior year,
 
primarily for integration planning and regulatory approval
 
for the Combination.
 
See the
Non-GAAP Measures section of this Item, above.
As described above,
 
the Company initiated
 
a restructuring program
 
during the third
 
quarter of 2019
 
as part of
 
its global plan
 
to
realize cost synergies
 
associated with
 
the Combination.
 
The Company recorded
 
additional restructuring
 
and related charges
 
of $2.2
million related to this
 
program during the first
 
six months of 2020
 
and there were no similar
 
restructuring charges recorded
 
during the
first six months of 2019.
 
See the Non-GAAP Measures section of this Item, above.
During the first quarter of 2020, the Company recorded
 
a $38.0 million non-cash impairment charge to write
 
down the value of
certain indefinite-lived intangible assets associated with the
 
Combination.
 
This non-cash impairment charge is related to certain
acquired Houghton trademarks and tradenames and
 
is primarily the result of the current year negative impacts of
 
COVID-19 on their
estimated fair values.
 
There were no impairment charges in the second quarter
 
of 2020 or in the prior year.
 
See the Critical
Accounting Policies and Estimates section as well as the Non
 
-GAAP Measures section, of this Item, above.
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
43
Operating loss in the first six months of 2020 was $10.2
 
million compared to operating income of $40.4 million in the
 
first six
months of 2019.
 
Excluding the Combination, integration and other acquisition-related
 
charges, restructuring and related charges, the
non-cash indefinite-lived intangible asset impairment charge
 
,
 
and other non-core items, the Company’s
 
current year non-GAAP
operating income of $47.2 million decreased compared to
 
$49.8 million in the prior year, primarily
 
due to the negative impact on
volumes due to the impact of COVID-19, which more
 
than offset the added net sales and operating
 
income from Houghton and
Norman Hay and the benefits from cost savings related
 
to the Combination.
The Company’s other
 
expense, net, was $22.2 million in the first six months of 2020 compared
 
to $0.6 million in the prior year.
 
The year-over-year increase in other expense,
 
net was primarily due to the first quarter of 2020 non-cash pension
 
plan settlement
charge of $22.7 million associated with the
 
termination of the Legacy Quaker U.S. Pension Plan, described
 
in the Non-GAAP
Measures section of this Item, above.
Interest expense, net, increased $13.8 million in the first six months
 
of 2020 compared to the first six months of 2019 primarily
due to additional borrowings under the Company’s
 
term loans and revolving credit facility to finance the closing
 
of the Combination
on August 1, 2019.
The Company’s effective
 
tax rates for the first six months of 2020 and 2019 were a benefit
 
of 20.7% and an expense of 25.4%,
respectively.
 
The Company’s current year
 
effective tax rate was impacted by the tax effect
 
of certain one-time pre-tax costs as well as
certain one-time tax
 
charges and benefits in the current period including
 
those related to changes in foreign tax credit valuation
allowances, tax law changes, additional charges
 
taken for uncertain tax positions taken resulting from certain
 
foreign tax audits, and
the impact of the Company’s
 
termination of its Legacy Quaker U.S. Pension Plan.
 
Comparatively, the prior
 
year effective tax rate was
primarily impacted by certain non-deductible costs associated
 
with the Combination, partially offset by a favorable
 
shift in earnings to
entities with lower tax rates.
 
Excluding the impact of these items as well as all other non-core
 
items in each year, described in the
Non-GAAP Measures section of this Item, above,
 
the Company estimates that its first six months of 2020 and 2019
 
effective tax rates
would have been approximately 21% and 23%, respectively.
 
Equity in net income of associated companies increased $0.7 million
 
in the first six months of 2020 compared to the first six
months of 2019, primarily due to additional earnings
 
from Houghton’s 50% interest
 
in a joint venture in Korea partially offset by
lower earnings as compared to the prior year period from
 
the Company’s interest in
 
a captive insurance company.
 
See the Non-GAAP
Measures section of this Item, above.
Net income attributable to non-controlling interest was consistent
 
in both the first six months of 2020 and 2019.
 
Foreign exchange negatively impacted the Company’s
 
first six months of 2020 results by approximately $0.11
 
per diluted share,
primarily due to approximately $0.8 million higher foreign
 
exchange transaction losses year-over-year
 
as well as the negative impact
from foreign currency translation due to the strengthening
 
of the U.S. dollar in the current year period.
Reportable Segments Review - Comparison of the Second
 
Quarter of 2020 with the Second Quarter of 2019
The Company’s reportable
 
segments reflect the structure of the Company’s
 
internal organization, the method by which the
Company’s resources are
 
allocated and the manner by which the chief operating decision
 
maker of the Company assesses its
performance.
 
During the third quarter of 2019 and in connection with the Combination,
 
the Company reorganized its executive
management team to align with its new business structure
 
which reflects the method by which the Company assesses its
 
performance
and allocates its resources.
 
The Company’s current
 
reportable segment structure includes four segments: (i)
 
Americas; (ii) EMEA;
(iii) Asia/Pacific; and (iv) Global Specialty Businesses.
 
The three geographic segments are composed of the net
 
sales and operations
in each respective region, excluding net sales and operations managed
 
globally by the Global Specialty Businesses segment, which
includes
 
the Company’s container,
 
metal finishing, mining, offshore, specialty coatings,
 
specialty grease and Norman Hay businesses.
 
Segment operating earnings for the Company’s
 
reportable segments are comprised of net sales less COGS and SG&A directly
related to the respective segment’s
 
product sales.
 
Operating expenses not directly attributable to the net
 
sales of each respective
segment are not included in segment operating earnings,
 
such as certain corporate and administrative costs, Combination, integration
and other acquisition-related expenses, and Restructuring
 
and related charges.
 
Other items not specifically identified with the
Company’s reportable
 
segments include interest expense, net and other (expense) income,
 
net.
All prior period information has been recast to reflect
 
these four segments as the Company’s
 
new reportable segments.
 
See Note
4 of Notes to Condensed Consolidated Financial Statements,
 
which appears in Item 1 of this Report.
Americas
Americas represented approximately 28%
 
of the Company’s consolidated
 
net sales in the second quarter of 2020.
 
The segment’s
net sales were $80.6 million, an increase of $8.8 million
 
or 12% compared to the second quarter of 2019.
 
The increase in net sales
reflects the inclusion of Houghton net sales of $38.5
 
million.
 
Excluding Houghton net sales, the segment’s
 
net sales decrease quarter-
over-quarter of 41% was due to lower volumes of 38
 
%
 
and a negative impact of foreign currency translation of 5%, partially
 
offset by
increases in selling price and product mix of 2%.
 
The current quarter volume decline was driven by the economic slowdown
 
that
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
44
began in late March and continued throughout the second
 
quarter due to the impacts of COVID-19.
 
The foreign exchange impact was
primarily due to the weakening of the Brazilian real and
 
the Mexican peso against the U.S. dollar,
 
as these exchange rates averaged
5.37 and 23.32, respectively,
 
in the second quarter of 2020 compared to 3.92 and 19.11,
 
respectively in the second quarter of 2019.
 
This segment’s operating
 
earnings were $10.3 million, a decrease of $3.7 million
 
or 26%
 
compared to the second quarter of 2019.
 
The decrease in segment operating earnings reflects the significant
 
decline in volumes due to the negative impact of COVID-19
 
which
also resulted in lower gross margins quarter
 
-over-quarter driven by certain fixed manufacturing
 
costs coupled with the lower volumes,
which more than offset the operating earnings from
 
Houghton in the current year quarter.
EMEA
EMEA represented approximately 27%
 
of the Company’s consolidated
 
net sales in the second quarter of 2020.
 
The segment’s
net sales were $77.7 million, an increase of $28.7 million
 
or 59%
 
compared to the second quarter of 2019.
 
The increase in net sales
reflects the inclusion of Houghton net sales of $40.2
 
million.
 
Excluding Houghton net sales, the segment’s
 
net sales decrease quarter-
over-quarter of 23% was due to lower volumes of 25
 
%
 
and a negative impact of foreign currency translation of approximately
 
1%,
partially offset by increases in selling price and
 
product mix of 3%.
 
The current quarter volume decline was driven by the economic
slowdown that began in late March and continued throughout
 
the second quarter due to the impacts of COVID-19.
 
The foreign
exchange impact was primarily due to the weakening
 
of the euro against the U.S. dollar as this exchange rate
 
averaged 1.10 in the
second quarter of 2020 compared to 1.12 in the second
 
quarter of 2019.
 
This segment’s operating earnings
 
were $10.2 million, an
increase of $1.3 million or 15% compared to the second
 
quarter of 2019,
 
which reflects the inclusion of Houghton net sales, partially
offset by lower gross margins quarter
 
-over-quarter as a result of fixed manufacturing costs coupled
 
with lower volumes, as well as
higher SG&A, including Houghton SG&A.
Asia/Pacific
Asia/Pacific represented approximately 24%
 
of the Company’s consolidated
 
net sales in the second quarter of 2020.
 
The
segment’s net sales were $68.4
 
million, an increase of $23.6 million or 53%
 
compared to the second quarter of 2019.
 
The increase in
net sales reflects the inclusion of Houghton net sales of
 
$32.9 million.
 
Excluding Houghton net sales, the segment’s
 
net sales decrease
of 21%
 
quarter-over-quarter was driven by lower volumes of 20
 
%
 
and a negative impact of foreign currency translation of 3%,
partially offset by increases in selling price and
 
product mix of 2%.
 
The current quarter volume decline was driven by the economic
slowdown that began in the first quarter in China and
 
in late March throughout the region due to the impacts of COVID-19.
 
The
foreign exchange impact was primarily due to the weakening
 
of the Chinese renminbi against the U.S. dollar as this exchange
 
rate
averaged 7.09 in the second quarter of 2020 compared to
 
6.82 in the second quarter of 2019.
 
This segment’s operating earnings
 
were
$19.3 million, an increase of $7.1 million or 58% compared
 
to the second quarter of 2019.
 
The increase in segment operating earnings
reflects the inclusion of Houghton net sales and
 
relatively consistent gross margins,
 
partially offset by higher SG&A, including
Houghton SG&A.
Global Specialty Businesses
Global Specialty Businesses represented approximately
 
21% of the Company’s consolidated
 
net sales in the second quarter of
2020.
 
The segment’s net sales were $59.3
 
million, an increase of $19.0 million or 47%
 
compared to the second quarter of 2019.
 
The
increase in net sales reflects the inclusion of Houghton
 
and Norman Hay net sales of $30.9 million.
 
Excluding Houghton and Norman
Hay net sales, the segment’s
 
net sales would have decreased 29%
 
quarter-over-quarter driven by lower volumes of
 
21%, decreases in
selling price and product mix of 5% and a negative
 
impact from foreign currency translation of 3%.
 
The current quarter volume
decline was primarily due to a decrease in the Company’s
 
specialty coatings business driven by Boeing’s
 
decision to temporarily stop
production of the 737 Max aircraft and continued volume
 
declines due to the economic slowdown that began in
 
late March
and
continued throughout the second quarter
due to the impacts of COVID-
19
.
 
The foreign exchange impact was primarily due to the
weakening of the Brazilian real against the U.S. dollar
 
described in the Americas section, above.
 
This segment’s operating
 
earnings
were $16.4 million, an increase of $5.4 million or 49%
 
compared to the second quarter of 2019.
 
The increase in segment operating
earnings reflects the inclusion of Houghton and Norman
 
Hay net sales, as well as slightly higher gross margin
 
due to price and product
mix, including higher Houghton and Norman Hay
 
gross margin compared to Legacy Quaker,
 
partially offset by higher SG&A,
including Houghton and Norman Hay.
 
Reportable Segments Review - Comparison of the First Six
 
Months of 2020 with the First Six Months of 2019
Americas
Americas represented approximately 32%
 
of the Company’s consolidated
 
net sales in the first six months of 2020.
 
The segment’s
net sales were $210.5 million, an increase of $66.5
 
million or 46%
 
compared to the first six months of 2019.
 
The increase in net sales
reflects the inclusion of Houghton net sales of $101.3
 
million.
 
Excluding Houghton net sales, the segment’s
 
net sales decrease year-
over-year of 24%
 
was due to lower volumes of 21% and a negative impact of foreign
 
currency translation of 4%, partially offset by
increases in selling price and product mix of 1%.
 
The current year volume decline was driven by the economic slowdown
 
that began
in late March and continued throughout the second
 
quarter due to the impacts of COVID-19.
 
The foreign exchange impact was
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
45
primarily due to the weakening of the Brazilian real and
 
the Mexican peso against the U.S. dollar,
 
as these exchange rates averaged
4.85 and 21.41, respectively,
 
in the first six months of 2020 compared to 3.84 and 19.16, respectively
 
in the first six months of 2019.
 
This segment’s operating
 
earnings were $39.5 million, an increase of $11.2
 
million or 40% compared to the first six months of 2019.
 
The increase in segment operating earnings reflects the
 
including of Houghton net sales, partially offset by
 
lower gross margins and
higher SG&A, including Houghton SG&A.
EMEA
EMEA represented approximately 27% of the Company’s
 
consolidated net sales in the first six months of 2020.
 
The segment’s
net sales were $182.5 million, an increase of $81.1
 
million or 80%
 
compared to the first six months of 2019.
 
The increase in net sales
reflects the inclusion of Houghton net sales of $98.1
 
million.
 
Excluding Houghton net sales, the segment’s
 
net sales decrease year-
over-year of 17%
 
was due to lower volumes of 15% and a negative impact of foreign
 
currency translation of 2%, partially offset by
increases in selling price and product mix of less than
 
1%.
 
The current year volume decline was driven by the
 
economic slowdown
that began in late March due to the impacts of COVID-19
 
and an overall reduced production in certain EMEA countries that
 
began in
the second half of 2019 and continued into 2020.
 
The foreign exchange impact was primarily due to the weakening
 
of the euro against
the U.S. dollar as this exchange rate averaged 1.10 in the
 
first six months of 2020 compared to 1.13 in the first six months of
 
2019.
 
This segment’s operating
 
earnings were $28.6 million, an increase of $10.9
 
million or 61% compared to the first six months of 2019.
 
The increase in segment operating earnings reflects the
 
including of Houghton net sales, partially offset by
 
lower gross margins and
higher SG&A, including Houghton SG&A.
Asia/Pacific
Asia/Pacific represented approximately 21% of the
 
Company’s consolidated net
 
sales in the first six months of 2020.
 
The
segment’s net sales were $142.0
 
million, an increase of $51 million or 56% compared to
 
the first six months of 2019.
 
The increase in
net sales reflects the inclusion of Houghton net sales of
 
$66.6 million.
 
Excluding Houghton net sales, the segment’s
 
net sales decrease
of 17%
 
year-over-year was driven by lower volumes
 
of 15%
 
and a negative impact of foreign currency translation of 3%, partially
offset by increases in selling price and product
 
mix of 1%.
 
The current quarter volume decline was driven by
 
the economic slowdown
that began in the first quarter in China and in late March
 
throughout the region due to the impacts of COVID-19.
 
The foreign
exchange impact was primarily due to the weakening
 
of the Chinese renminbi against the U.S. dollar as this exchange
 
rate averaged
7.03 in the first six months of 2020 compared to
 
6.78 in the first six months of 2019.
 
This segment’s operating earnings
 
were $38.8
million, an increase of $13.8 million or 55% compared
 
to the first six months of 2019.
 
The increase in segment operating earnings
reflects the including of Houghton net sales, partially
 
offset by lower gross margins and higher SG&A,
 
including Houghton SG&A.
Global Specialty Businesses
Global Specialty Businesses represented approximately
 
20% of the Company’s consolidated
 
net sales in the first six months of
2020.
 
The segment’s net sales were $129.6
 
million, an increase of $48.9 million or 61% compared to the
 
first six months of 2019.
 
The increase in net sales reflects the inclusion of Houghton
 
and Norman Hay net sales of $66.8 million.
 
Excluding Houghton and
Norman Hay net sales, the segment’s
 
net sales would have decreased 22% year-over-year
 
driven by lower volumes of 7%, decreases
in selling price and product mix of 12% and a negative
 
impact from foreign currency translation of 3%.
 
The current year volume
decline was primarily due to a decrease in the Company’s
 
specialty coatings business driven by Boeing’s
 
decision to temporarily stop
production of the 737 Max aircraft and continued volume
 
declines due to the economic slowdown that began in
 
late March due to the
impacts of COVID-19.
 
Partially offsetting these volume declines, and contributing
 
to the
decrease in selling price and product mix
were higher shipments of a lower priced product in the
 
Company’s mining business compared
 
to the prior year.
 
The foreign exchange
impact was primarily due to the weakening of the
 
Brazilian real against the U.S. dollar described in the Americas
 
section, above.
 
This
segment’s operating earnings
 
were $37.0 million, an increase of $15.4 million or 71%
 
compared to the first six months of 2019.
 
The
increase in segment operating earnings reflects the
 
inclusion of Houghton and Norman Hay net sales, as well as slightly higher
 
gross
margin due to price and product mix, including
 
higher Houghton and Norman Hay gross margin
 
compared to Legacy Quaker, partially
offset by higher SG&A, including Houghton and
 
Norman Hay
.
Factors That May Affect Our Future Results
(Cautionary Statements Under the Private Securities Litigation
 
Reform Act of 1995)
Certain information included in this Report and other
 
materials filed or to be filed by Quaker Chemical Corporation
 
with the
Securities and Exchange Commission (“SEC”) (as well as information
 
included in oral statements or other written statements made
 
or
to be made by us) contain or may contain forward-looking
 
statements within the meaning of Section 27A of the Securities Act
 
of
1933, as amended, and Section 21E of the Securities Exchange
 
Act of 1934, as amended.
 
These statements can be identified by the
fact that they do not relate strictly to historical or
 
current facts.
 
We have based
 
these forward-looking statements, including statements
regarding the potential effects of the COVID-19
 
pandemic on the Company’s
 
business, results of operations, or financial condition
and our expectations to maintain sufficient
 
liquidity and remain compliant with the terms of the Company’s
 
credit facility on our
current expectations about future events.
 
 
 
Quaker Chemical Corporation
Management’s Discussion and Analysis
 
 
46
These forward-looking statements include statements with respect
 
to our beliefs, plans, objectives, goals, expectations,
anticipations, intentions, financial condition, results of operations,
 
future performance, and business, including:
 
 
the potential benefits of the Combination;
 
 
the impacts on our business as a result of the COVID-19
 
pandemic and any projected global economic rebound
 
or
anticipated positive results due to Company actions taken
 
in response to the pandemic;
 
our current and future results and plans; and
 
 
statements that include the words “may,”
 
“could,” “should,” “would,” “believe,” “expect,” “anticipate,” “estimate,”
“intend,” “plan” or similar expressions.
Such statements include information relating to current and
 
future business activities, operational matters, capital spending,
 
and
financing sources.
 
From time to time, forward-looking statements are also included in
 
the Company’s other periodic
 
reports on Forms
10-K, 10-Q and 8-K, press releases, and other materials released
 
to, or statements made to, the public.
Any or all of the forward-looking statements in this Report,
 
in the Company’s 2019
 
Form 10-K and in any other public statements
we make may turn out to be wrong.
 
This can occur as a result of inaccurate assumptions or as a consequence
 
of known or unknown
risks and uncertainties.
 
Many factors discussed in this Report will be important in
 
determining our future performance.
 
Consequently,
 
actual results may differ materially from those that might
 
be anticipated from our forward-looking statements.
We undertake
 
no obligation to publicly update any forward-looking statements,
 
whether as a result of new information, future
events or otherwise.
 
However, any further disclosures made
 
on related subjects in the Company’s
 
subsequent reports on Forms 10-K,
10-Q, 8-K and other related filings should be consulted.
 
A major risk is that demand for the Company’s
 
products and services is
largely derived from the demand for our customers’
 
products, which subjects the Company to uncertainties related
 
to downturns in a
customer’s business and unanticipated customer
 
production shutdowns.
 
Other major risks and uncertainties include, but are not
limited to, the primary and secondary impacts of the COVID-19
 
pandemic, including actions taken in response to the pandemic by
various governments, which could exacerbate some
 
or all of the other risks and uncertainties faced by the Company,
 
including the
potential for significant increases in raw material costs, supply
 
chain disruptions, customer financial stability,
 
worldwide economic
and political conditions, foreign currency fluctuations,
 
significant changes in applicable tax rates and regulations, future
 
terrorist
attacks and other acts of violence.
 
Furthermore, the Company is subject to the same business cycles as those
 
experienced by steel,
automobile, aircraft, industrial equipment, and durable
 
goods manufacturers.
 
The ultimate significance of COVID-19 on our business
will depend on, among other things, the extent and
 
duration of the pandemic, the severity of the disease and
 
the number of people
infected with the virus, the effects on the economy
 
by the pandemic, including the resulting market volatility,
 
and by the measures
taken by governmental authorities and other third
 
parties restricting day-to-day life and business operations and
 
the length of time that
such measures remain in place, and governmental programs
 
implemented to assist businesses impacted by the COVID-19 pandemic.
 
Other factors could also adversely affect us, including
 
those related to the Combination and other acquisitions and
 
the integration of
the combined company as well as other acquired businesses.
 
Our forward-looking statements are subject to risks, uncertainties
 
and
assumptions about the Company and its operations that
 
are subject to change based on various important factors, some
 
of which are
beyond our control.
 
These risks, uncertainties, and possible inaccurate assumptions relevant
 
to our business could cause our actual
results to differ materially from expected
 
and historical results.
 
Therefore, we caution you not to place undue reliance
 
on our forward-looking statements.
 
For more information regarding these
risks and uncertainties as well as certain additional
 
risks that we face, refer to the Risk Factors section, which appears
 
in Item 1A of
this Report, as well as Item 1A in our 2019 Form
 
10-K and in our quarterly and other reports filed from
 
time to time with the SEC.
 
This discussion is provided as permitted by the Private
 
Securities Litigation Reform Act of 1995.
Quaker Houghton on the Internet
 
Financial results, news and other information about
 
Quaker Houghton can be accessed from the Company’s
 
website at
https://www.quakerhoughton.com
. This site includes important information on the Company’s
 
locations, products and services,
financial reports, news releases and career opportunities.
 
The Company’s periodic
 
and current reports on Forms 10-K, 10-Q, 8-K, and
other filings, including exhibits and supplemental
 
schedules filed therewith, and amendments to those reports, filed with
 
the SEC are
available on the Company’s
 
website, free of charge, as soon as reasonably
 
practicable after they are electronically filed with or
furnished to the SEC.
 
Information contained on, or that may be accessed through,
 
the Company’s website is not
 
incorporated by
reference in this Report and, accordingly,
 
you should not consider that information part of this Report.
 
47
Item 3.
 
Quantitative and Qualitative Disclosures About Market
 
Risk.
 
Quaker Houghton is exposed to the impact of interest
 
rates, foreign currency fluctuations, changes in commodity prices
 
and credit
risk.
 
The current economic environment associated with COVID-19
 
has led to significant volatility and uncertainty with each of
 
these
market risks.
 
Other than the impact of the COVID-19 pandemic on market
 
risks generally, we believe
 
there has been no other
material change to the information disclosed in Part II,
 
Item 7A, of our 2019 Form 10-K.
 
See Item 1A, “Risk Factors”, of this Report
for additional discussion of the current and potential risks associated
 
with the COVID-19 pandemic.
 
48
Item 4.
 
Controls and Procedures.
 
Evaluation of disclosure controls
 
and procedures.
 
As required by Rule 13a-15(b) under the Securities Exchange
 
Act of 1934, as
amended (the “Exchange Act”), our management,
 
including our principal executive officer and principal financial
 
officer, has
evaluated the effectiveness of our disclosure
 
controls and procedures (as defined in Rule 13a-15(e) under the
 
Exchange Act ) as of the
end of the period covered by this Report.
 
Based on that evaluation, our principal executive officer
 
and our principal financial officer
have concluded that, as of the end of the period covered by
 
this Report, our disclosure controls and procedures (as defined
 
in Rule
13a-15(e) under the Exchange Act) were not effective
 
as of June 30, 2020 because of the material weaknesses in our
 
internal control
over financial reporting, as described below.
As previously disclosed in “Item 9A. Controls and Procedures.”
 
in the Company’s 2019
 
Form 10-K, through the process of
evaluating risks and corresponding changes to the
 
design of existing or the implementation of new controls
 
in light of the significant
non-recurring transactions that occurred during 2019,
 
including the Combination, the Company identified certain deficiencies in
 
its
application of the principles associated with the Committee
 
of Sponsoring Organization of the Treadway
 
Commission in Internal
Control – Integrated Framework (2013) that management
 
has concluded in the aggregate constitute a material weakness.
 
A material
weakness is a deficiency,
 
or combination of deficiencies, in internal control over financial reporting,
 
such that there is a reasonable
possibility that a material misstatement of annual or interim
 
financial statements will not be prevented or detected on
 
a timely basis.
 
Specifically, management
 
concluded that changes to existing controls or the implementation
 
of new controls were not sufficient to
respond to changes to the risks of material misstatement to
 
financial reporting.
 
As a result of this deficiency in the design and
implementation of an effective risk assessment, this material
 
weakness contributed to certain control deficiencies that
 
management
concluded result in the following additional material weaknesses: (i)
 
we did not design and maintain effective
 
controls over the review
of pricing, quantity and customer data to verify that revenue
 
recognized at certain locations was complete and
 
accurate, and (ii) we did
not design and maintain effective controls
 
over the reliability of data used to support the reasonableness of
 
certain assumptions in the
accounting for business combinations.
 
Notwithstanding these material weaknesses, the Company
 
has concluded that the unaudited condensed consolidated financial
statements included in this Report present fairly,
 
in all material respects, the financial position of the Company as of
 
June 30, 2020
and December 31, 2019, and the results of its operations and
 
its cash flows and changes in equity for both the three and six
 
month
periods ended June 30, 2020 and 2019, are in conformity
 
with accounting principles generally accepted in the United States of
America.
 
However, these control deficiencies
 
could have resulted in misstatements of interim condensed consolidated
 
financial
statements and disclosures that could have resulted
 
in a material misstatement that would
 
not be prevented or detected.
Remediation Plan Activities.
As previously disclosed in “Item 9A. Controls and Procedures.”
 
in the Company’s 2019
 
Form 10-K,
the Company and its Board of Directors are committed
 
to maintaining a strong internal control environment.
 
During the first six
months of 2020, management began developing its full remediation
 
plan and executing what will be a multi-step remediation process
to completely and fully remediate the material weaknesses identified
 
and described above.
 
The initial steps the Company has taken
include identifying dedicated internal resources supplemented
 
with third-party specialists to assist with formalizing a robust and
detailed remediation plan and specifically completing
 
an updated risk assessment, including identifying and assessing
 
those risks
attendant to the significant changes within the Company
 
as a result of becoming a larger,
 
more complex global organization as a result
of the Combination.
 
The Company is conducting a comprehensive review,
 
and, as appropriate, is updating its existing internal control
framework to ensure that it has identified, developed
 
and deployed the appropriate business process and information
 
technology
general controls to meet the objectives and address the risks
 
identified through the updated risk assessment process.
 
In undertaking
this process, the Company is identifying and will be
 
implementing further modifications to strengthen its internal
 
control environment.
 
It is the Company’s
 
goal to remediate all of the previously identified material weaknesses as
 
quickly and effectively as possible,
however, the impact of COVID-19,
 
including travel restrictions and remote work arrangements has
 
presented and is expected to
continue to present challenges with regards to the timing
 
of the Company’s remediation
 
plan activities.
 
Changes in internal control over financial
 
reporting.
 
As required by Rule 13a-15(d) under the Exchange Act,
 
our management,
including our principal executive officer
 
and principal financial officer,
 
has evaluated our internal control over financial reporting to
determine whether any changes to our internal control over
 
financial reporting occurred during the quarter ended June 30, 2020
 
that
have materially affected, or are reasonably
 
likely to materially affect, our internal control over financial
 
reporting.
 
Based on that
evaluation, there were no changes that have materially
 
affected, or are reasonably likely to materially affect,
 
our internal control over
financial reporting during the quarter ended June 30,
 
2020.
 
49
PART
 
II.
 
OTHER INFORMATION
Items 3, 4 and 5 of Part II are inapplicable and have been
 
omitted.
Item 1.
 
Legal Proceedings.
 
Incorporated by reference is the information in Note
 
19 of the Notes to the Condensed Consolidated Financial
 
Statements in Part
I, Item 1, of this Report.
Item 1A. Risk Factors.
In addition to the other information set forth in this Report,
 
you should carefully consider the risk set forth below,
 
which updates
the risk factors previously disclosed in Part I, Item 1A
 
of our 2019 Form 10-K, as well as the other risk factors
 
described in the 2019
Form 10-K, which could materially affect
 
our business, financial condition or future results.
 
The risk described below,
 
and the risks
described in our 2019 Form 10-K are not the only risks we
 
face.
 
Additional risks and uncertainties not currently known
 
to us or that
we currently deem to be immaterial also may materially
 
and adversely affect our business, financial condition
 
or operating results.
The outbreak of COVID-19 and its impact on business and
 
economic conditions have negatively affected
 
our business, results of
operations and financial condition and the extent and
 
duration of those effects is uncertain.
Beginning in early 2020, there has been an outbreak
 
of COVID-19, initially in China and which has spread
 
globally, including
generally all locations where the Company does business.
 
In March 2020, the World
 
Health Organization formally identified the
COVID-19 outbreak as a pandemic.
 
The COVID-19 pandemic, including the fear of exposure
 
to and the actual effects of the illness,
together with the measures implemented to reduce its spread,
 
including travel restrictions, shutdowns of businesses deemed
nonessential, and large gatherings and shelter
 
-in-place or similar orders, have significantly impacted the global
 
economy.
 
The
pandemic has disrupted global supply chains, lowered
 
equity market valuations, created significant volatility and disruption
 
in
financial markets, and increased unemployment levels.
 
In addition, it has resulted in temporary closures of many businesses, and
although many of the businesses have subsequently re-opened,
 
they may be operating at reduced capacity,
 
while other closures may be
prolonged or become permanent.
The scale and scope of the COVID-19 outbreak, the resulting
 
pandemic, and the primary and secondary impacts on
 
the economy
and financial markets have had a significant disruption
 
on the operations of the Company and its suppliers and
 
customers and have
adversely affected the Company’s
 
results of operations and financial condition during the first six months
 
of 2020 as further described
in Management’s Discussion and
 
Analysis of Financial Condition and Results of Operations included
 
in this Report.
 
The Company
has experienced disruptions as a result of COVID-19,
 
first at its China subsidiaries in the first quarter of 2020
 
and subsequently,
particularly beginning late March and continuing into the
 
second quarter of 2020, throughout the rest of the business due
 
to the global
economic slowdown.
 
We have experienced,
 
and may experience in the future, temporary site or facility closures
 
at our own facilities
or those of our customers in response to government mandates
 
in certain jurisdictions in which we operate.
 
We may also be required
to close certain of our facilities for the safety of our
 
employees in response to positive diagnoses for COVID-19.
 
Even in facilities that
are not closed, we could be affected by reductions
 
in employee availability and productivity,
 
changes in operating procedures, and
increased costs
.
 
The Company anticipates that its future results of operations,
 
including the results for the remainder of 2020 may
continue to be adversely impacted by COVID-19.
 
In particular, the spread of COVID-19
 
and efforts to contain the virus have had the
following additional effects, which are likely
 
to increase or become exacerbated the longer the crisis continues:
 
reduced the demand for our products and services as many
 
customers have reduced production levels;
 
driven declines in volume and net sales across all reportable
 
segments;
 
required us to adjust certain of our facility operating procedures
 
and to take steps to reduce costs and preserve liquidity;
 
and
 
negatively affected the estimated fair value of
 
certain of the Company’s reporting
 
units or other indefinite-lived or long-lived
assets, namely the Company’s
 
Houghton and Fluidcare trademark and tradename indefinite-lived
 
intangible assets, such that
their estimated fair values were less than their carrying
 
values and required adjustments.
The spread of COVID-19, a prolonged outbreak,
 
and efforts to contain the virus in some cases have already
 
or could in the future
also:
 
limit the availability and reduce the productivity of our
 
employees;
 
impact our financial reporting systems and processes, internal control
 
over financial reporting, and disclosure controls and
procedures, including our ability to ensure information
 
required to be disclosed in our reports under the Exchange Act
 
is
recorded, processed, summarized and reported within the
 
time periods specified in the SEC’s rules
 
and forms and that such
information is accumulated and communicated to our
 
management, including our chief executive officer
 
and chief financial
officer, as appropriate,
 
to allow for timely decisions regarding required disclosure;
 
present challenges as a result of travel restrictions and remote work
 
arrangements, including the timing of our ERP system
implementations which are an integral part of our integration
 
activities; the timing of the Company’s
 
remediation plan
activities as described in Item 4 Controls and Procedures, of
 
this Report; and the Company’s
 
first year assessment of internal
control over financial reporting for Houghton and Norman
 
Hay, including the
 
implementation of new or enhanced business
 
50
process and information technology general controls,
 
as necessary, to meet the
 
objectives and address the risks identified
once the Company completes its initial design assessment;
 
increase our costs as a result of emergency
 
measures that we may take or that may be imposed on us by regulatory
authorities;
 
cause a delay in customer payments or cause a deterioration
 
of the credit quality of other counterparties that could
 
result in
credit losses or force both customer and supplier bankruptcies;
 
cause delays and disruptions in the availability of and timely
 
delivery of materials and components used in our operations;
 
 
result in our inability to meet the requirements of the covenants
 
in our existing credit facility,
 
including covenants regarding
our consolidated interest coverage ratio and consolidated
 
net leverage ratio, or increase our cost of capital or make additional
capital, including the refinancing of our credit facility,
 
more difficult or available only on terms less favorable
 
to us;
 
impact our liquidity position and cost of and ability to access funds
 
from financial institutions and capital markets;
 
negatively affect the estimated fair values of the
 
Company’s reporting units or other
 
indefinite-lived or long-lived assets; and
 
cause other risks to impact us, including the risks described
 
in the “Risk Factors” section of the 2019 Form 10-K.
While the Company has implemented business continuity
 
and emergency response plans to permit it to continue
 
to provide
services and products to customers and support the
 
Company’s operations, while also taking
 
health and safety measures such as
implementing worker distancing measures, enhancing
 
on-site hygiene measures, and using a remote workforce where
 
possible, there
can be no assurance that the continued spread of COVID-19 and
 
efforts to contain the virus (including, but not limited
 
to, voluntary
and mandatory quarantines, restrictions on travel, limiting
 
gatherings of people, and reduced operations and extended
 
closures of
many businesses and institutions) will not further impact
 
our business, results of operations and financial condition.
 
However, given
the unprecedented and continually evolving developments
 
with respect to this pandemic, the Company cannot, as of the
 
date of this
Report, reasonably estimate the magnitude or full extent
 
of the impact to its future results of operations or to the
 
ability of it or its
customers to resume more normal operations.
 
A further prolonged outbreak or resurgence and period
 
of continued restrictions on day-
to-day life and business operations would likely result in
 
volume declines and lower net sales for later periods in 2020
 
as well, when
compared to the prior year.
The ultimate significance of COVID-19 on our business
 
will depend on, among other things, the extent and duration
 
of the
pandemic, the severity of the disease and the number
 
of people infected with the virus, the ultimate geographic
 
spread of the virus, the
effects on the economy by the pandemic,
 
including market volatility, and
 
by the measures taken by governmental authorities and other
third parties restricting day-to-day life and the length
 
of time that such measures remain in place, and laws or government
 
al programs
implemented to assist businesses impacted by the COVID-19
 
pandemic, such as fiscal stimulus and other legislation designed
 
to
deliver monetary aid and other relief.
 
The likelihood of a further impact on the Company that could
 
be material increases the longer
the virus impacts economic activity levels in the United
 
States and across the world.
Item 2.
 
Unregistered Sales of Equity Securities and Use of
 
Proceeds.
Recent Sales of Unregistered
 
Securities
On May 7, 2020, the Company acquired Tel
 
Nordic ApS (“TEL”), a company that specializes in lubricants and
 
engineering
primarily in high pressure aluminum die casting for
 
its EMEA reportable segment.
 
Consideration paid was in the form of a
convertible promissory note in the amount of 20
 
.0 million DKK, or approximately $2.9 million, that was subsequently
 
converted on
May 20, 2020 into 17,894 shares of the Company’s
 
common stock based on the closing market price of the common
 
stock on May 19,
2020, as reported on the New York
 
Stock Exchange, and the conversion rate of Danish Kroner into
 
U.S. dollars as reported on that
day in the Wall
 
Street Journal.
 
The issuance of the convertible promissory note and the
 
shares issued thereunder were made in a
private placement transaction in reliance upon Regulation
 
D promulgated under the Securities Act of 1933, as amended,
 
based on the
written representations from TEL regarding its “accredited
 
investor” status as defined in Rule 501 of Regulation D.
 
The Company
subsequently registered the resale by the holder of these
 
shares under the Securities Act of 1933, as amended.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51
Purchases of Equity Securities by
 
the Company
The following table sets forth information concerning
 
shares of the Company’s
 
common stock acquired by the Company during
the period covered by this Report:
(c)
(d)
Total
 
Number of
Approximate Dollar
(a)
(b)
Shares Purchased
 
Value of
 
Shares that
Total
 
Number
Average
as part of
May Yet
 
be
of Shares
Price Paid
Publicly Announced
Purchased Under the
Period
Purchased (1)
Per Share (2)
Plans or Programs
Plans or Programs (3)
April 1 - April 30
$
$
86,865,026
 
May 1 - May 31
72
 
$
159.15
 
$
86,865,026
 
June 1 - June 30
3,858
 
$
189.73
 
$
86,865,026
 
Total
3,930
 
$
189.17
 
$
86,865,026
 
 
(1)
 
All of these shares were acquired from employees upon
 
their surrender of Quaker Chemical Corporation shares in payment
 
of
the exercise price of employee stock options exercised or
 
for the payment of taxes upon exercise of employee stock
 
options
or the vesting of restricted stock.
 
(2)
 
The price paid for shares acquired from employees pursuant
 
to employee benefit and share-based compensation
 
plans is, in
each case, based on the closing price of the Company’s
 
common stock on the date of exercise or vesting as specified by the
plan pursuant to which the applicable option or restricted
 
stock was granted.
 
(3)
 
On May 6, 2015, the Board of Directors of the Company
 
approved, and the Company announced, a share repurchase
program, pursuant to which the Company is authorized
 
to repurchase up to $100,000,000 of Quaker Chemical Corporation
common stock (the “2015 Share Repurchase Program”)
 
and has no expiration date.
 
There were no shares acquired by the
Company pursuant to the 2015 Share Repurchase Program
 
during the quarter ended June 30, 2020.
Limitation on the Payment of Dividends
The New Credit Facility has limitations on the payment
 
of dividends and other so-called restricted payments.
 
See Note 15 of
Notes to Condensed Consolidated Financial Statements, in
 
Part I, Item I, of this Report.
 
 
 
 
52
Item 6.
 
Exhibits.
 
(a) Exhibits
3.1
3.2
4.1
10.1
10.2
31.1
31.2
32.1
.**
32.2
.**
101.INS
Inline XBRL Instance Document*
101.SCH
Inline XBRL Taxonomy
 
Extension Schema Document*
101.CAL
Inline XBRL Taxonomy
 
Extension Calculation Linkbase Document*
101.DEF
Inline XBRL Taxonomy
 
Extension Definition Linkbase Document*
101.LAB
Inline XBRL Taxonomy
 
Extension Label Linkbase Document*
101.PRE
Inline XBRL Taxonomy
 
Extension Presentation Linkbase Document*
104
Cover Page Interactive Data File (formatted as Inline XBRL and
 
contained in Exhibit 101.INS)*
* Filed herewith.
** Furnished herewith.
† Management contract or compensatory plan.
 
 
*********
 
Pursuant to the requirements of the Securities Exchange Act
 
of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
QUAKER CHEMICAL CORPORATION
 
(Registrant)
 
 
 
 
 
 
 
/s/ Mary Dean Hall
Date: August 5, 2020
 
 
 
Mary Dean Hall, Senior Vice President,
 
Chief Financial
Officer and Treasurer
 
(officer duly authorized on behalf
of, and principal financial officer of, the Registrant)
 
exhibit101
 
 
 
 
 
 
1
EXHIBIT 10.1
AMENDMENT NO. 2 TO THE
QUAKER HOUGHTON
 
RETIREMENT SAVINGS
 
PLAN
 
(As Amended and Restated January 1, 2020)
 
WHEREAS
, Quaker Chemical Corporation d/b/a Quaker Houghton (the “Company”) adopted the
Quaker Houghton Retirement Savings Plan, as amended and restated
 
effective January 1, 2020, and as
 
amended
on one occasion thereafter (the “Plan”);
 
 
WHEREAS
, the Company
 
desires to amend
 
the Plan to
 
clarify eligibility for
 
nonelective contributions
for certain collectively bargained employees; and
 
WHEREAS
, pursuant to
 
Section 8.1 of
 
the Plan, the
 
Retirement Savings Plan
 
Committee has the
 
right
to amend the Plan at any time, subject to certain inapplicable limitations.
 
NOW,
 
THEREFORE
, effective as
 
of February 10,
 
2020, the Plan
 
shall be, and
 
hereby is, amended
 
as
follows:
 
Effective as
 
of February
 
10, 2020,
 
a sentence
 
is hereby
 
added to
 
the end
 
of Section
 
4.5(a) to
 
read as
follows:
“Notwithstanding the foregoing, Employees hired on or after February 10,
 
2020 who are covered
by a
 
collective bargaining
 
agreement between
 
the Employer
 
and the
 
International Chemical
 
Workers
Union Council
 
of the
 
United Food
 
and Commercial
 
Workers Union
 
and its
 
Local No.
 
125C, shall
 
be
eligible to
 
receive Nonelective
 
Contributions provided
 
they have
 
met the
 
conditions of
 
eligibility set
forth in Section 3.1(b).”
 
IN WITNESS WHEREOF
, Quaker Chemical Corporation d/b/a Quaker Houghton has caused these
presents to be duly executed on this __30____ day of ______April_________, 2020.
 
 
 
QUAKER CHEMICAL CORPORATION
 
 
D/B/A QUAKER HOUGHTON
 
 
Attest:
 
____/s/ Victoria K. Gehris__________________ By:
 
_______/s/_Robert T. Traub
 
_______________
 
exhibit102
 
 
 
 
1
EXHIBIT 10.2
AMENDMENT NO. 3 TO THE
QUAKER HOUGHTON
 
RETIREMENT SAVINGS
 
PLAN
 
(As Amended and Restated January 1, 2020)
 
WHEREAS
, Quaker Chemical Corporation d/b/a Quaker Houghton (the “Company”) adopted the
Quaker Houghton Retirement Savings Plan, as amended and restated
 
effective January 1, 2020, and as
 
amended
on two occasions thereafter (the “Plan”);
 
 
WHEREAS
, the
 
Company desires
 
to amend
 
the Plan
 
to change
 
the investment
 
direction of
 
matching
contributions and nonelective contributions, and to make certain other clarifying changes; and
 
WHEREAS
, pursuant to
 
Section 8.1 of
 
the Plan, the
 
Retirement Savings Plan
 
Committee has the
 
right
to amend the Plan at any time, subject to certain inapplicable limitations.
 
NOW,
 
THEREFORE
, effective
 
as of
 
April 17,
 
2020, the
 
Plan shall
 
be, and
 
hereby is,
 
amended as
follows:
 
1.
 
The last paragraph of Section 4.4(a) (“Matching Contributions”) is amended to read as follows:
“Effective with
 
the Elective
 
Contributions taken
 
from the
 
paycheck for the
 
first pay
 
date on
 
or
after April 17,
 
2020, the Matching
 
Contribution may be
 
made in cash
 
or in Company
 
Securities in the
sole discretion of the Administrator.
 
Matching Contributions made in cash will be invested according
 
to
the direction
 
of the
 
Participant, Beneficiary,
 
or alternate
 
payee under
 
Section 4.13(a).
 
To the
 
extent a
Matching Contribution is
 
made in Company
 
Securities, the contribution
 
shall be invested
 
in the Quaker
Stock Fund,
 
subject to
 
any subsequent
 
reapportionment direction
 
of the
 
Participant, Beneficiary,
 
or
alternate payee under Section 4.13(e).”
2.
 
Section 4.5(c) (“Employer Nonelective Contributions”) is amended to read
 
as follows:
(c) Investment.
 
Effective
 
with
 
the first
 
pay date
 
on or
 
after
 
April
 
17, 2020,
 
the
Nonelective
 
Contribution
 
may be made in cash or in Company Securities in the sole discretion of the
Administrator.
 
Nonelective Contributions made in cash will be invested according to the direction of
the Participant, Beneficiary, or alternate payee under Section 4.13(a).
 
To the extent Nonelective
Contributions are made in Company Securities, the contribution shall be invested in the Quaker Stock
Fund, subject to any subsequent reapportionment direction of the Participant, Beneficiary, or alternate
payee under Section 4.13(e).
3.
 
Section 4.13(a) (“Investment of Aggregate Accounts”) is amended to read as follows:
(a) Participant
 
Directed.
 
Every
 
Participant,
 
Beneficiary,
 
and alternate
 
payee
 
shall
 
have
the right
 
to designate
 
the investment
 
category
 
or categories
 
in which
 
the Trustee
 
is to invest
 
his or
her Aggregate
 
Account
 
including,
 
pursuant
 
to Section
 
4.13(e),
 
any contributions
 
that are
 
initially
invested
 
in the Quaker
 
Stock
 
Fund
 
at the time of
 
contribution
 
pursuant
 
to Section
 
4.4(a)
 
or Section
4.5(c).
4.
 
Section 4.13(e) (“Investment of Aggregate Accounts”) is amended to read as follows:
(e) Investment
 
Direction – Reapportionment of Aggregate Account.
 
A Participant,
 
 
 
 
 
 
2
Beneficiary,
 
or alternate
 
payee
 
may,
 
subject
 
to the
 
Company’s
 
insider
 
trading
 
policy
 
or other
restriction(s)
 
imposed
 
by the
 
Company
 
pursuant
 
to Sections
 
4.13(m)
 
or 4.13(n),
 
on any
 
business
day,
 
by giving
 
notice
 
in the manner
 
prescribed
 
by the Trustee,
 
transfer
 
all or any portion
 
of the
 
assets
held on
 
his or
 
her behalf
 
in any
 
investment
 
category
 
or categories
 
to any
 
other
 
category
 
or
categories
 
then
 
provided,
 
including
 
any contributions
 
that are
 
initially
 
invested
 
in the
 
Quaker
 
Stock
Fund
 
at the
 
time
 
of contribution
 
pursuant
 
to Section
 
4.4(a)
 
or Section
 
4.5(c).
 
IN WITNESS WHEREOF
, Quaker Chemical Corporation d/b/a Quaker Houghton has caused these
presents to be duly executed on this __30____ day of _____April_________, 2020.
 
 
 
QUAKER CHEMICAL CORPORATION
 
 
D/B/A QUAKER HOUGHTON
 
 
Attest:
 
____/s/ Victoria K. Gehris__________________ By:
 
_______/s/_Robert T. Traub
 
_______________
exhibit311
 
 
1
EXHIBIT 31.1
 
 
CERTIFICATION
 
OF CHIEF EXECUTIVE OFFICER OF THE COMPANY
 
PURSUANT TO RULE 13a-14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
I, Michael F.
 
Barry, certify that:
 
1.
I have reviewed this quarterly report on Form 10
 
-Q of Quaker Chemical Corporation;
 
2.
Based on my knowledge, this report does not contain
 
any untrue statement of a material fact or omit to state a material
 
fact
necessary to make the statements made, in light of
 
the circumstances under which such statements were made,
 
not misleading with
respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and
 
other financial information included in this report, fairly
 
present in all
material respects the financial condition, results of operations
 
and cash flows of the registrant as of, and for,
 
the periods presented
in this report;
 
4.
The registrant’s other certifying
 
officer and I are responsible for establishing and
 
maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and
 
15d-15(e)) and internal control over financial reporting (as defined
 
in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant
 
and have:
 
 
(a)
Designed such disclosure controls and procedures, or
 
caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information
 
relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those
 
entities, particularly during the period in which this report
 
is
being prepared;
 
 
(b)
Designed such internal control over financial reporting,
 
or caused such internal control over financial reporting
 
to be
designed under our supervision, to provide reasonable
 
assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes
 
in accordance with generally accepted accounting
principles;
 
 
(c)
Evaluated the effectiveness of the registrant’s
 
disclosure controls and procedures and presented in this report
 
our
conclusions about the effectiveness of the disclosure
 
controls and procedures, as of the end of the period covered
 
by
this report based on such evaluation; and
 
 
(d)
Disclosed in this report any change in the registrant’s
 
internal control over financial reporting that occurred during
the registrant’s most recent
 
fiscal quarter (the registrant’s
 
fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely
 
to materially affect, the registrant’s
 
internal control over financial
reporting; and
 
5.
The registrant’s other certifying
 
officer and I have disclosed, based on our most recent
 
evaluation of internal control over financial
reporting, to the registrant’s
 
auditors and the audit committee of the registrant’s
 
board of directors (or persons performing the
equivalent functions):
 
 
(a)
All significant deficiencies and material weaknesses in the
 
design or operation of internal control over financial
reporting which are reasonably likely to adversely affect
 
the registrant’s ability to record,
 
process, summarize and
report financial information; and
 
 
(b)
Any fraud, whether or not material, that involves management
 
or other employees who have a significant role in the
registrant’s internal control
 
over financial reporting.
Date: August 5, 2020
 
/s/ Michael F. Barry
Michael F. Barry
Chief Executive Officer
 
exhibit312
 
 
1
EXHIBIT 31.2
 
 
CERTIFICATION
 
OF CHIEF FINANCIAL OFFICER OF THE COMPANY
 
PURSUANT TO RULE 13a-14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
I, Mary Dean Hall, certify that:
 
1.
I have reviewed this quarterly report on Form 10
 
-Q of Quaker Chemical Corporation;
 
2.
Based on my knowledge, this report does not contain
 
any untrue statement of a material fact or omit to state a material
 
fact
necessary to make the statements made, in light of
 
the circumstances under which such statements were made,
 
not misleading with
respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and
 
other financial information included in this report, fairly
 
present in all
material respects the financial condition, results of operations
 
and cash flows of the registrant as of, and for,
 
the periods presented
in this report;
 
4.
The registrant’s other certifying
 
officer and I are responsible for establishing and
 
maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and
 
15d-15(e)) and internal control over financial reporting (as defined
 
in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant
 
and have:
 
 
(a)
Designed such disclosure controls and procedures, or
 
caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information
 
relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those
 
entities, particularly during the period in which this report
 
is
being prepared;
 
 
(b)
Designed such internal control over financial reporting,
 
or caused such internal control over financial reporting
 
to be
designed under our supervision, to provide reasonable
 
assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes
 
in accordance with generally accepted accounting
principles;
 
 
(c)
Evaluated the effectiveness of the registrant’s
 
disclosure controls and procedures and presented in this report
 
our
conclusions about the effectiveness of the disclosure
 
controls and procedures, as of the end of the period covered
 
by
this report based on such evaluation; and
 
 
(d)
Disclosed in this report any change in the registrant’s
 
internal control over financial reporting that occurred during
the registrant’s most recent
 
fiscal quarter (the registrant’s
 
fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely
 
to materially affect, the registrant’s
 
internal control over financial
reporting; and
 
5.
The registrant’s other certifying
 
officer and I have disclosed, based on our most recent
 
evaluation of internal control over financial
reporting, to the registrant’s
 
auditors and the audit committee of the registrant’s
 
board of directors (or persons performing the
equivalent functions):
 
 
(a)
All significant deficiencies and material weaknesses in the
 
design or operation of internal control over financial
reporting which are reasonably likely to adversely affect
 
the registrant’s ability to record,
 
process, summarize and
report financial information; and
 
 
(b)
Any fraud, whether or not material, that involves management
 
or other employees who have a significant role in the
registrant’s internal control
 
over financial reporting.
Date: August 5, 2020
 
/s/ Mary Dean Hall
Mary Dean Hall
Chief Financial Officer
 
exhibit321
 
 
1
EXHIBIT 32.1
 
CERTIFICATION
 
PURSUANT TO 18 U.S.C. SECTION 1350
 
The undersigned hereby certifies that the Form 10-Q Quarterly
 
Report of Quaker Chemical Corporation (the “Company”)
 
for the
quarterly period ended June 30, 2020 filed with the Securities and
 
Exchange Commission (the “Report”) fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange
 
Act of 1934 and that the information contained
 
in the Report fairly
presents, in all material respects, the financial condition
 
and results of operations of the Company.
 
 
Dated: August 5, 2020
 
 
/s/ Michael F. Barry
 
 
Michael F. Barry
 
 
Chief Executive Officer of Quaker Chemical
 
Corporation
 
exhibit322
 
 
1
EXHIBIT 32.2
 
CERTIFICATION
 
PURSUANT TO 18 U.S.C. SECTION 1350
 
The undersigned hereby certifies that the Form 10-Q Quarterly
 
Report of Quaker Chemical Corporation (the “Company”)
 
for the
quarterly period ended June 30, 2020 filed with the Securities and
 
Exchange Commission (the “Report”) fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange
 
Act of 1934 and that the information contained
 
in the Report fairly
presents, in all material respects, the financial condition
 
and results of operations of the Company.
 
 
Dated: August 5, 2020
 
 
/s/ Mary Dean Hall
 
 
Mary Dean Hall
 
 
Chief Financial Officer of Quaker Chemical Corporation